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Summary 
 
Human papillomavirus infection is regulated by multiple factors including 
methylation, viral integration and aberrations in host and viral gene expression. In 
most patients, the infection is transient and cleared effectively by the host’s immune 
system but in a minority of cases, the Human papillomavirus infection progresses to 
neoplasia and cancer if not detected and treated. Assays that detect the presence of 
Human Papillomavirus infection alone are not good prognostic markers of clinical 
outcome. Alternative clinical biomarkers that can measure other regulatory factors of 
Human Papillomavirus infection are required to more accurately predict patient 
outcome and help direct treatment options specifically to patients at risk of neoplasia 
and cancer progression.  
This study aimed to examine several Human Papillomavirus regulatory factors 
to determine if they would be suitable as clinical biomarkers and explore further the 
link between molecular changes and associated pathology. This involved 
development of assays, application to samples obtained from different cohorts of 
women to ascertain prognostic validity and development of an in vitro system to 
model the in vivo pathology. 
Initial work focused on investigating Human Papillomavirus 31, 33, 35 and 51 
integration and methylation assays as prognostic biomarkers in young women 
attending their first routine cervical smear. Results indicated that Human 
Papillomavirus E2 gene disruption and methylation were not common events and the 
assays investigated were not suitable biomarkers for predicting clinical outcome in 
xx 
 
young women. The assays were then applied to clinical samples taken from patients 
with varying grades of cervical disease and high levels of viral methylation were 
present in women with high grade disease (Cervical Intraepithelial Neoplasia II+) and 
a correlation between methylation and HPV gene disruption was shown. 
Novel in vitro organotypic raft cultures of cells from Vulval Intraepithelial 
Neoplasia and Vaginal Intraepithelial Neoplasia were employed to understand how 
molecular changes in viral methylation and gene expression correlated with 
observed pathology. The organotypic raft cultures showed diverse differentiation 
patterns. No correlation of pathology with viral integration status was detected. 
However, organotypic raft cultures with high-grade disease morphology all had a 
higher level of methylation and expression of regulatory genes p16, Ki-67 and Sonic 
Hedgehog in comparison cultures displaying a histology consistent with low-grade 
disease. p16 and Ki-67 are already being examined as part of cervical screening 
triage.  
The findings presented in this thesis, highlight a need for further research into 
Human Papillomavirus infection and the molecular changes associated with Sonic 
Hedgehog gene expression and viral methylation as these show promise as 
prognostic biomarkers. 
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1 Chapter 1 
 Background 
 
Human Papillomavirus (HPV) is a non-enveloped deoxyribonucleic acid (DNA) 
virus; approximately 8 kilo base (kb), which commonly infects epithelial cells. Most 
infections resolve spontaneously following the induction of an effective host immune 
response. Occasionally persistent infection with a High-Risk HPV (HR-HPV) type 
can lead to invasive disease. HPV causes almost half a million cancers each year 
worldwide, most of these in the cervix. Progress in understanding of the molecular 
biology of HPV has led to the development of a highly effective prophylactic vaccine 
that will reduce the incidence of anogenital cancer further. The optimal model of 
cervical screening in this vaccinated population still needs to be refined. Molecular 
biomarkers of disease presence and progression are a potential feature of future 
cervical screening programmes. More work is needed to define at which stage in 
anogenital disease these biomarkers can be used either discretely or independently. 
 
 
 Molecular biology of HPV 1.1
 
Viruses in the Papillomaviridae family have been detected in a wide variety of 
species and are host specific. 170 HPV types have been identified and are 
organised into genera, Alpha-, Beta-, Gamma-, Mu-, Nu-Papillomavirus primarily 
2 
 
based on the sequence of the L1 gene (de Villiers et al., 2004). Alpha-HPV types are 
responsible for a range of benign warts (e.g. HPV 6 and 11) and 15 Alpha-HPV 
types have been classified as HR-HPV that have the potential to cause neoplastic 
changes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82) (Muñoz  
et al., 2003). This thesis will focus almost exclusively on HR-HPV types. 
 
The Alpha-HPV types have circular ~8 kb double stranded DNA genomes that 
encode eight major proteins designated as either early (E) or late (L) according to 
when they are expressed in the viral lifecycle. The circular genome contains a non-
coding regulatory region (NCR), also known as the upstream regulatory region 
(URR) or long-control region (LCR). The early proteins; E1, E2, E4, E5, E6 and E7, 
have regulatory functions and the late proteins, L1 and L2, are major and minor 
structural proteins respectively (Figure 1.1). 
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Figure 1.1. A schematic of the linearized HPV genome. The functions of the early 
and late viral proteins are highlighted and their location in the HPV genome. E = 
early protein; L = late protein; NCR = non-coding region. 
 
 
1.1.1 Late gene expression: L1 and L2 
 
L1 and L2 are the major and minor capsid proteins that form the outer surface 
of the virus. New virus particles are made from 72 pentamers of L1 protein in a T = 7 
icosahedral lattice (Conway and Meyers, 2009). The protein is folded with variable 
regions on the outer surface and the highly-conserved regions on the inside. L2 
protein is located on the inner surface of the viral capsid and is much less abundant 
than L1. When L1 is produced in isolation it spontaneously forms an icosahedral 
lattice thus forming a virus like particle (VLP) (Joyce et al., 1999). VLPs consisting of 
pure L1 protein constitute the antigen in the HPV prophylactic vaccine that is proving 
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highly effective at reducing the incidence of HPV infection around the world in the 
cervical cancer prevention programmes (Kemp et al., 2011). 
 
 
1.1.2 Functional Genes: E1, E2 and E4 
 
E1 encodes the only virally encoded enzyme, DNA helicase, which allows the 
HPV DNA to unwind and transcription of the viral genome to occur (Wilson et al., 
2002). 
E2 protein has many important functions in the HPV lifecycle, with four 
binding sites for E2 located in conserved regions of the NCR. Through interactions 
with these binding sites E2 can promote or repress viral gene expression. When E2 
is expressed in low quantities the protein only binds to the first binding site. This 
promotes transcription and E6 and E7 oncogenes are expressed. When high levels 
of E2 are present, the protein binds to all four promoters and transcription from the 
early promoter is suppressed (Figure 1.2) (Demeret et al., 1995, Thierry, 2009, 
Thierry and Yaniv, 1987). 
 
E2 has a variety of additional functions that ensure the virus lifecycle is 
correctly maintained and prevents over-expression of the viral oncogenes (Blachon 
et al., 2005, Gammoh et al., 2009, McPhillips et al., 2005). This includes increasing 
the binding affinity of the E1 protein to the origin of replication.  
5 
 
 
The HPV E4 protein is produced from an E1^E4 spliced messenger 
ribonucleic acid (mRNA) (Doorbar et al., 2015). In productive infections, high levels 
of this protein are found and E4 expression can be used to establish an active HPV 
infection in which late HPV genes are expressed (Griffin et al., 2012). HR-HPV 
E1^E4 contains a leucine cluster (LLKLL) at the N-terminus region which is essential 
for interaction between E1^E4 and keratin (Wang et al., 2003). Keratin is a structural 
protein, which is part of the cellular cytoskeleton that contributes to the stability of the 
cell (Moll et al., 2008). This binding of E1^E4 to keratin causes destabilisation of the 
keratin network. Although not fully understood it is thought that this interaction 
between E1^E4 and keratin assists with virion release and subsequent spread of the 
virus (Doorbar et al., 2015). 
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Figure 1.2. The E2 negative feedback loop controlling HPV genome expression. 
(A) When low levels of E2 are produced, transcription can occur and early genes can 
be expressed from the p97 early promoter. (B) When high levels of E2 are 
expressed E2 proteins bind to all four E2 binding sites which blocks transcription 
from the early promoter. This acts as a negative feedback loop to control 
unregulated expression of the HPV genome. 
 
 
1.1.3 Viral Oncogenes: E5, E6 and E7 
 
7 
 
The virus produces three proteins which contribute to the malignant 
transformation of the host cell: E5, E6 and E7. Changes in their levels of expression 
may lead to modifications to the normal cell cycle and subsequent DNA damage 
(Moody and Laimins, 2010). E6 and E7 proteins are responsible for oncogenic 
transformation and immortalisation of host cells (Hawley-Nelson et al., 1989, Münger 
et al., 1989). E6 protein contributes to cell transformation and immortalisation by 
coupling with and degrading the tumour suppressor protein p53, via an ubiquitin-
proteasome pathway. p53 protein is an important factor involved in cell cycle repair 
and can subsequently induce apoptosis of damaged cells. The loss of p53 allows 
damaged DNA to accumulate without apoptosis (Scheffner et al., 1990, Howie et al., 
2009). E6 also contributes to cell immortalisation by interacting and increasing 
activity of the human telomerase reverse transcriptase (hTERT) protein and 
inhibition of Bcl-2 homologous antagonist/killer (BAK) proteins (Liu et al., 2009, 
Thomas et al., 1999, Thomas and Banks, 1998).  
 
The predominant oncogenic property of E7 is to bind and degrade pocket 
proteins, mainly pRB, which is involved in the regulation of the cell cycle. Disruption 
of this protein allows the cell to continue though the G1/S cell check point and 
contributes to the immortalisation of the infected cell (McLaughlin-Drubin and 
Munger, 2009a, Munger et al., 2001). E7 also has several secondary functions 
contributing to cell immortalization. These include decreasing levels of the Claspin 
protein leading to defective DNA repair and increasing levels of the gene enhancer 
of zeste homologue 2 (EZH2) which inhibits apoptosis (Holland et al., 2008, Spardy 
et al., 2009) (Figure 1.3). 
8 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. DNA damage and immortalization mechanisms employed by HPV 
E6 and E7 oncoproteins. E6 couples with E6 adaptor protein (E6AP) to degrade 
p53 tumour suppressor protein and increases levels of hTERT and BAK. E7 couples 
with and degrades pocket protein pRB. E7 also decreases levels of Claspin and 
increases EZH2 levels. 
 
A large percentage of cervical cancers have been shown to have increased 
epithelial growth factor (EGF) receptor expression and research has shown that E5 
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expression contributes to this increase. There have been many studies to assess the 
mechanism by which E5 protein alters the normal activity of EGF receptors, the most 
widely accepted method being that E5 interacts with a 16 K subunit of the vacuolar 
ATPase (Müller et al., 2015), however the development of a 16 K antibody has cast 
this theory into question as the amount of E5 bound to 16 K appears to be too low to 
account for the increase in observed EGF reception expression (Suprynowicz et al., 
2010). Regardless of method of action the E5 protein increases EGF-receptor 
expression which leads to an increase in DNA synthesis and maintains active cell 
division in the upper layers of the stratified epithelium (Fehrmann et al., 2003). 
 
E5 also couples with E6 and E7 to promote transformation of the cell (DiMaio 
and Mattoon, 2001). It has been demonstrated that with prolonged oestrogen 
treatment, E5 caused oncogenic transformation in transgenic mice in the absence of 
E6 and E7. The same study also showed that mice expressing all three oncoproteins 
had only a marginal difference in number of tumours and tumour size compared with 
mice only expressing E6 and E7. These results suggest E5 is a minor oncoprotein 
compared with E6 and E7 (Maufort et al., 2010). Although E5 protein contributes to 
the oncogenic transformation of virus infected cells, this gene is often lost when the 
virus integrates into the host genome. It has therefore been suggested that E5 is a 
factor in cellular transformation rather than maintenance of the malignant phenotype 
(McLaughlin-Drubin and Munger, 2009b). 
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 Immunoregulation of HPV Infection 1.2
 
In a transient infection, the virus remains below detectable levels from the host 
immune system, which allows the productive lifecycle to be complete before viral 
clearance occurs. HPV avoids the host immune system effectively by not infecting 
antigen presenting cells, not lysing cells, tightly controlling host gene expression and 
innate immune signalling and only producing new virus particles in the upper layers 
of the epithelium (Tindle, 2002, Westrich et al., 2017). It has been shown that HPV 
16 E5 reduced MHC-I expression on the surface of the cells by accumulating them in 
the Golgi Apparatus (Campo et al., 2010). Women with multiple HPV infections were 
shown to be less likely to clear a HPV 16 infection; and it has been suggested this 
susceptibility may be due to failings in the host’s immune system (Schmeink et al., 
2013). 
 
Although HPV is successful at evading the immune system the induction of the 
host immune system plays an important role in limiting spread and promoting viral 
clearance. Studies have shown that a localised increase in mononuclear cells, 
CD4+, CD8+ CD56+ and macrophages, and the expression of TH1 cytokines are 
signs of viral regression (Stanley, 2015). Also, HPV 16 clearance has been 
correlated with the presence of intraepithelial granzyme B+, CD8+ and CD 56+ cells 
(Westrich et al., 2017) 
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 Productive HPV lifecycle 1.3
 
The HPV productive lifecycle leads to the production of new virus particles 
that can go on to infect other individuals. It is estimated that by the age of 50, 80% of 
women will have been infected with at least one type of HPV (CDC, 2013). However, 
the majority these infections are cleared by the host. 
 
HPV transmission requires entry into basal epithelial cells and it does so via 
small micro abrasions in the skin or through the squamocolumnar junction that 
allows access to basal cells without micro abrasions. Most HPV induced cervical 
lesions occur in the transformation zone of the squamocolumnar epithelial junction. 
The transformation zone is a small region of differentiating squamous cells between 
the endocervix and ectocervix. The cells of the transformation zone are a single layer 
of differentiating cells, making them an ideal location for HPV entry to occur (Herfs et 
al., 2013, Herfs et al., 2012). 
 
The productive HPV lifecycle leads to the release of new virus particles that 
can go on to infect new host cells. For a productive infection to take place the 
following stages must occur. These stages must all occur whilst evading the host’s 
immune system to ensure the productive infection persists for as long as possible: 
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● Viral entry 
● Replication of the viral genome 
● Packaging and release of new virions 
 
Although the receptor(s) involved in HPV have yet to be determined 
conclusively, there is evidence that glycosaminoglycans – more specifically heparin 
sulphate proteoglycans and syndecan-1 are involved in the uptake of HPV into host 
cells (Giroglou et al., 2001, Joyce et al., 1999, Patterson et al., 2005, Shafti-Keramat 
et al., 2003). Irrespective of receptor usage the virus is taken up by basal cells by 
means of endocytosis, this is a slow process taking up to 12 hours. The L1 protein 
on the cell surface attaches to the heparin sulphate proteoglycans which leads to a 
conformational change to the L2 protein. The L2 protein is then cleaved by furin on 
the cell surface (Aksoy et al., 2016). HPV 16 has been shown to enter the cells via 
clathrin-dependent, receptor-mediated endocytosis (Day et al., 2003), however it 
has been suggested that HPV 31 enters via caveola-mediated endocytosis 
(Bousarghin et al., 2003). 
 
Once within the basal cells, the virus enters into the host nucleus via nucleus 
envelope breaks (Senapati et al., 2016). Once inside the nucleus of the cell the virus 
genome is maintained as an episome at low copy numbers, with the E2 protein 
regulating E6 and E7 transcription levels (as described in section 1.1.2). Two 
promoters control viral gene expression. The early promoter is located in the NCR 
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(P97 in HPV 16 and 31, P105 in HPV 18) and the late promoter is located in the E7 
open reading frame (ORF) (P742 in HPV16 and 31) (Graham, 2010). Expression of 
E6 and E7 ensures that replication of viral DNA continues in terminally differentiated 
cells. In the upper epidermis, the structural proteins L1 and L2 are produced 
alongside E4 protein (Doorbar, 2005, Longworth and Laimins, 2004). E4 protein is 
important at this stage as it helps disrupt the cytokeratin structure of the host cell 
assisting virion release (Doorbar et al., 1991, Wang et al., 2003) from the epithelium. 
The virus is said to be cleared when HPV DNA can no longer be detected, however 
HPV may still be present but just at a level which cannot be detected by current DNA 
testing technology (Fernandes et al., 2013). 
 
 
 Transforming infection and neoplastic progression in HPV infected 1.4
cells 
 
Most individuals infected with HPV will naturally clear the infection, however a 
small percentage of individuals will not. This is due to the viruses’ ability to evade the 
host immune system and down regulation of the host’s innate immune signalling 
(Westrich et al., 2017). The failure of the immune system to clear the HPV virus 
leads to a persistent infection that can remain for many years; during the productive 
infection, the viral proteins E1, E2, E5, E6 and E7 are expressed. E4 is expressed 
further up in the epithelium and L1 and L2 are expressed in the upper layers of the 
epithelium and new viral particles are produced. Over time the infection can lead to 
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genetic instability and mutations within the viral genome, which can contribute to 
cancer. 
 
The transition from a productive infection to a transforming infection is driven by 
the deregulation of the viral oncogenes. Prolonged infection leads to genetic 
instability; neoplastic changes and the virus lifecycle cannot be completed. This turns 
the infection from a productive infection into a transforming infection; oncoproteins 
E5, E6 and E7 are expressed throughout the epithelium and E4 is expressed in the 
upper-layers of the epithelium. Viral proteins E1, E2 and L1 and L2 are no longer 
expressed in the transformed epithelium and therefore the viral particles are no 
longer produced (Figure 1.4). This deregulation of HPV gene expression and 
neoplastic progression is ascribed to various factors including alterations in host 
gene expression, integration of the HPV DNA into the host genome or hyper- and/or 
hypo-methylation of the HPV genome. These mechanisms of viral genome 
deregulation and their by-products being considered as potential biomarker(s) for 
disease progression to either support or replace cervical cytology. 
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Figure 1.4. Representation of HPV gene expression in a productive and a 
transformed infection. (A) HPV gene expression in a productive infection. (B) 
HPV gene expression in a transformed infection. 
 
 
1.4.1 Aberrant expression of host gene molecules in HPV infection 
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Aberrant expression of host genes, proteins and micro-ribonucleic acids 
(miRNA) is present in a transformed HPV infection. These include (but are not 
limited to) over expression of cell cycle regulators p16 and Ki-67, over expression of 
Hedgehog proteins, specifically Sonic Hedgehog protein (SHH), and suppression of 
tumour suppressor proteins p21 and p27. P16 is a tumour suppressor protein which 
inhibits cell cycle progression (Alcorta et al., 1996, Romagosa et al., 2011). In HPV 
infection p16 expression is increased in relation to an increase in cervical neoplasia 
(Benevolo et al., 2006, Romagosa et al., 2011). Ki-67 is a marker of cellular 
proliferation which in the normal epithelium is confined to the proliferating cells in the 
parabasal layer of the epithelium. In cervical intraepithelial neoplasia (CIN) Ki-67 
expression is seen in the higher layers of the epithelium (Dwivedi et al., 2013, Sari 
Aslani et al., 2013). Both p16 and Ki-67 have been extensively studied as 
biomarkers for HPV infection and are now used as a clinical marker for HPV infection 
(Wentzensen et al., 2017, Ikenberg et al., 2013, Petry et al., 2011). 
 
The Hedgehog proteins are key factors in embryo development, and 
inappropriate expression has been linked to cancer development. Hedgehog 
proteins are divided into three subgroups, Desert Hedgehog, Indian Hedgehog and 
SHH (Varjosalo and Taipale, 2008). SHH is the most studied of the three subgroups 
and aberrant expression has been shown to lead to several cancers including basal 
cell carcinoma, medulloblastoma and bladder cancer (Varjosalo and Taipale, 2008, 
Hahn et al., 1996, Gupta et al., 2010, Hanna and Shevde, 2016a, Hanna and 
Shevde, 2016b). SHH is aberrantly activated in vulval cancer and 8/10 solitary Vulval 
Intraepithelial Neoplasia (VIN) cases have shown over expression of SHH and its 
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downstream effector Zinc Finger Protein GLI-1 (GLI-1) (Dr C Dawson, personal 
communication). The expression of SHH is controlled by different factors of which 
GLI-1 is key to its regulation. GLI-1 expression is induced by Hedgehog ligands, and 
it provides a positive feedback and prolongs the effects of SHH (Ruiz i Altaba, 1999, 
Kasper et al., 2006).  
 
miRNA is non-coding ribonucleic acid (RNA) which regulates the expression 
of mRNA. The over or under expression of miRNAs can influence the regulation of 
cell proliferation, apoptotic pathways and cell adhesion (Calin and Croce, 2006, 
Peng and Croce, 2016). In HPV infections it has been shown that HPV oncogenes 
E6 and E7 affect the miRNAs which regulate p53, leading to the degradation of p53 
(Zheng and Wang, 2011). 
 
 
1.4.2 Viral integration 
 
Often in cervical cancer the HPV genome is integrated into the human 
genome with no remaining viral episomes. This results in the loss of several genes, 
including those that are essential for new virion production. HPV integration is a by-
product of HPV infection rather than a step in the virus lifecycle; however it is a 
significant step in the process of viral transformation of the host cell (Pett and 
Coleman, 2007, McBride and Warburton, 2017). The virus integrates randomly into 
the host genome and this has been shown to occur in multiple chromosomes 
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(Wentzensen et al., 2004, Hu et al., 2015). Stages in the transition from episomal 
infection to integration are not well defined. 
 
DNA damage and genomic instability are important prerequisites for HPV 
integration. In normal cells, various mechanisms are used to repair DNA damage 
and cell death is induced if the damage cannot be repaired. This is not always the 
case in HPV infected cells. HPV has been shown to induce DNA damage and disrupt 
normal cellular damage response mechanisms. This can lead to genomic instability 
and double stranded breaks (DSBs) forming. DSBs allow DNA recombination to 
occur via homologous recombination. High levels of DSB are seen in common fragile 
sites (CFS), and there DSB occur spontaneously or can be induced by 
environmental factors (Dmitrieva et al., 2011, Matovina et al., 2009). Research has 
shown that HPV DNA integrates into CFS at a higher frequency than in other 
locations (Gao et al., 2017, Dall et al., 2008). DNA plasmids also integrate into CFS 
at a higher frequency (Matzner et al., 2003) and the unstable nature of CFS make 
them an ideal location for HPV integration to occur. 
 
When HPV integrates into the host genome it is common that the viral 
genome is only partially integrated. The E6 and E7 ORF are almost always fully 
intact; however other viral genes important in the production of new virus particles 
are frequently lost. The loss of the E2 regulatory gene is a predominant finding in 
viral integrants (Pett, 2004, Cricca et al., 2009, Choo et al., 1987). Loss of E2 
through viral integration has been shown to increase the levels and stability of E6 
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and E7 proteins in the cell, thus contributing to cell transformation (Choo et al., 1987, 
Jeon et al., 1995). Not all evidence agrees that integration leads to heightened levels 
of viral oncogenes. A study by Häfner and colleagues compared the level of viral 
transcripts against the physical state of the virus genome. Their results showed that 
the level of E6 transcribed was similar in all samples with no marked increase in cells 
with only integrated HPV (Hafner et al., 2008). 
 
 
1.4.3 Viral Genomic DNA Methylation 
 
Methylation is a post-translational modification which is associated with 
cancer development. Methylation is also a normal consequence of aging with well 
characterised and reproducible changes occurring at specific sites of the human 
genome (Weidner and Wagner, 2014). Methylation occurs in cytosine located in a 
CpG dinucleotide where are methyl group is added to cytosines at the 5’ position. 
The addition of the methyl group can alter chromatin conformation and DNA 
topology, leading to changes in gene expression (Stein, 2011, Deaton and Bird, 
2011). DNA methylation is associated with a range of functions within the host that 
contribute to normal gene expression and foetal development. However methylation 
can also have an impact on malignant cells associated with the progression of 
cancers (Robertson, 2005). 
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Viral genomic DNA methylation in cancer cells has been shown prominently in 
HPV 16 infected cells with an increase in viral DNA methylation in the E2, L1 and L2 
genes (Bryant et al., 2015, Bhattacharjee and Sengupta, 2006, Mirabello et al., 
2012). Methylation of HPV DNA has also been shown to occur in cells infected with 
different HPV types such as HPV 18, 31 and 45, although this has not been 
extensively studied (Wentzensen et al., 2012). Several studies have shown a 
positive correlation between viral methylation and CIN that make it a potential 
biomarker for CIN presence or progression (Bhat et al., 2016, Chapman et al., 2016, 
Clarke et al., 2012, Shridhar et al., 2016). Following HPV vaccination, work is 
needed to identify where viral genomic DNA methylation testing would fit in a future 
screening programme and the cost benefit of introducing viral genomic DNA 
methylation as a screening test. 
 
There are several methods of assessing DNA methylation. These can be 
broadly split into methods which detect global methylation within a sample, and can 
either profile whole genome methylation level or identify specific genes or regions 
which may have differential methylation expression levels (Kurdyukov and Bullock, 
2016). Methods which can be employed to profile whole genome methylation 
patterns include HPLC-UV (Armstrong et al., 2011), LC-MS (Hu et al., 2013) and 
LINE-1 plus Pyrosequencing (Iwagami et al., 2012). These methods provide an 
overall picture of methylation in the sample without identifying exact regions of 
hyper-/hypo-methylation within the sample. These methods can be used to detect 
changes in the brain that occur during aging and learning (Gaglio et al., 2014) as 
well as looking at global patterns of methylation in disease such as cancer. 
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To directly identify genes or regions of the DNA which have been methylated 
bisulphide sequencing and array systems can be employed. Bisulphide sequencing 
involves firstly converting all unmethylation cytosines into uracil via treatment with 
sodium bisulphite, the methylated cytosine molecules are resistant to this change 
and are left unconverted. Therefore, when sequenced, unmethylated cytosine will be 
read as thyamine and methylated cytosines will be read as guanine (Figure 1.5). 
Bisulphite conversion is considered to be the gold standard in the identification of 
methylation changes (Patterson et al., 2011).  
 
After bisulfide conversion, the DNA is sequenced to analyse the level of 
methylation at each CpG site. Different sequencing methods can be employed such 
as Sanger sequencing, Pyrosequencing and DNA microarrays. Sanger sequencing 
is the most traditional method however the results are not quantitative. The results of 
Sanger sequencing the DNA can be semi-quantitative by cloning the polymerase 
chain reaction (PCR) product into a bacterial population, plating out colonies and 
then sequencing individual colonies to assess the percentage methylation in each 
CpG site. Pyro sequencing is a fast method of DNA sequencing. The results 
achieved are quantitative giving a percentage methylated for each CpG site in the 
region of interest (Tost and Gut, 2007). DNA microarrays give a vast quantity of 
quantitative information that is not specific to the area of interest. DNA microarray 
analysis is also expensive particularly when working with a large number of samples 
(Deatherage et al., 2009). 
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With advances in next generation sequencing several commercial kits are 
now available to carry out whole genome bisulphide sequencing (such as the 
Illumina Whole Genome Bisulphide Sequencing WGBS) however these are still 
prohibitively expensive ($6000/samples) (Johnson et al., 2012b). 
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Figure 1.5. The process of bisulphite conversion of DNA with sodium 
bisulphite. A. Unmethylated cytosines are converted to uracil with the addition of 
sodium bisulphate. However methylated cytosine is resistant to bisulphide 
conversion and remains as methylated cytosine. B. In a sequence with methylation 
and unmethylated ‘CG’ sites bisulphide conversion converts unmethylated CG into 
UG (highlighted in green). Then after PCR UG is converted to TG. The methylated 
CG remains unchanged throughout (highlighted in red). This change can then be 
measured by Pyrosequencing, PCR with high resolution melt analysis or via 
methylation specific PCR.  
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Bisulphide conversion is also used to assess methylation in specific genes 
and regions of DNA. This can be does by Pyrosequencing, methylation specific 
PCR, PCR with high resolution melt or bead arrays. Pyrosequencing, methylation 
specific PCR and PCR with high resolution melt analysis all involve specific primers 
which amplify the region of interest and can be particularly useful for small cohort 
studies, where a small number of known points of interest have already been 
identified (Wojdacz et al., 2008). Bead arrays are similar to those used to identify 
genes of interest and multiple locations of interest can be tested using a single array 
(Bibikova et al., 2006). 
 
 
 Epidemiology of HPV in Women 1.5
 
80% of women will be infected with at least one type of HPV in their lifetime 
and only a small percentage of infections go on to cause any neoplastic changes 
(CDC, 2013). HPV is associated with neoplastic progression in the cervix, vulva and 
vagina as well as genital warts. Neoplastic changes can regress back to normal or 
can progress and lead to cancer. Factors such as age, number of sexual partners, 
pregnancy and smoking can all contribute to disease progression from a transient 
infection to neoplastic changes and disease. Low-risk HPV (LR-HPV) types such as 
HPV 6 and HPV 11 are responsible for 90% of genital warts (Pineros et al., 2013). 
The rest of this section will concentrate on HR-HPV infections and associated 
disease. 
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Intraepithelial neoplasia is spilt into three phases, I, II and III, which is 
characterised by increasing neoplastic changes to the cells. Individuals with 
intraepithelial neoplasia can regress back to normal naturally over time or can 
progress to a higher grade of neoplasia or cancer if left untreated (Sellors and 
Sankaranarayanan, 2003) (Figure 1.6). 
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Figure 1.6. The progression of HPV infection to cancer and the key features of 
the cervical epithelium as seen using histological analysis. The red arrow 
represents disease progression. Around 90% of HPV infections will be cleared by the 
immune system of the host. The green arrows represent intraepithelial neoplasia 
regressing back to normal over time. Images of epithelium in the progression are 
from Robbins and Cotran Pathologic Basis of Disease.(Kumar et al., 2015).  
 
Cervical cancer is the 4th most common female cancer worldwide (Figure 1.7) 
and the second most common cancer in women aged 15 to 44. Worldwide cervical 
cancer mortality is substantially lower than incidence with a ratio of mortality to 
incidence of 50.3% (Bruni et al., 2017). Less is known about HPVs role in other 
anogenital cancers. Vulva cancer represents 4% of all gynaecological cancers with 
27,000 new cases in 2008, and vaginal cancer represents 2% of all gynaecological 
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cancers with 13,000 newly diagnosed cases in 2008 (de Martel et al., 2012). Both 
cervical and vaginal cancers occur more commonly in developing countries, however 
most vulvar cancers (60%) occur in more developed countries (Bruni et al., 2010). 
 
 
Figure 1.7. Cancer incidence and mortality in women in less developed and 
more developed regions. Incidence is shown in blue and mortality is shown in red. 
Figure adapted from Globocan 2012 (Ferlay et al., 2013). 
 
 
 Cervical cancer prevention models 1.6
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Cervical screening has decreased the incidence of cervical cancer as 
precancerous lesions are treated before they progress to invasive carcinoma. 
Prevention strategies can be spilt into primary prevention with vaccination of young 
people and secondary prevention with cervical cytology, HPV DNA testing and future 
biomarker screening. 
 
HPV prophylactic vaccinations are based on late proteins of the virus, cloned 
into vectors that spontaneously form VLPs in culture (Garland and Smith, 2010, 
Hagensee et al., 1993). The UK national HPV vaccine programme began in 2008 for 
girls aged 12-13 years and a catch-up program was introduced for older girls using 
the bivalent vaccine Cervarix™ (Jit et al., 2008). Initially two prophylactic vaccines 
were licensed against HPV; A quadrivalent vaccine, Gardasil® (Merck Sharp & 
Dohme), which protects against two HR-HPV types (HPV 16 and 18) and two LR-
HPV types (HPV 6 and 11) and Cervarix™ (GlaxoSmithKline), a bivalent vaccine 
offering protection against HR-HPV types 16 and 18 (Keam and Harper, 2008). 
Approximately 70-76% cases of invasive cervical carcinoma (ICC) are caused by 
HPV types 16 and 18 (Li et al., 2011) and these vaccines are projected to offer 
significant protection against cervical cancer. Clinical trials have shown the bivalent 
and quadrivalent HPV vaccine offer partial cross-protection against other HR-HPV 
including types 31, 33 and 45 (Harari et al., 2016). 
 
Recently a 9-valent HPV (9v-HPV) prophylactic vaccine (Gardasil 9, Merck 
and Co., Inc.) has been introduced which will offer prolonged protection against nine 
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HPV types including HR- HPV types 16,18, 31, 33, 45, 52 and 58 plus LR-HPV types 
6 and 11 (Joura et al., 2015, Cuzick, 2015) and the level of protection offered against 
HPV 6, 11, 16 and 18 is non-inferior to the first generation HPV vaccine (Zhai and 
Tumban, 2016, Lopalco, 2017) This 9-valent vaccine have been approved by the 
Food and Drug Administration for females aged 9 – 26 years and males aged 9 – 15 
years (Bonanni et al., 2010). With the addition of HPV 31, 34, 45, 52 and 58 this 
vaccine will potentially prevent almost 90% of cervical cancer cases (Zhai and 
Tumban, 2016).  
 
Since the UK national cervical screening programme began testing women 
20 to 64 years every 3-5 years in 1988, the number of cases of cervical cancer has 
significantly decreased (Levi et al., 2000, Michalas, 2000, Peto et al., 2004b). 
Screening costs around £150 million in England and prevents around 4,500 deaths 
(Peto et al., 2004b). This is a considerable cost to the National Health Service 
(NHS); however, this is offset by ICC treatment costs which equate to approximately 
£10,464 per person in their first year of treatment. Identifying individuals before they 
require invasive treatment has the dual benefit of increasing quality of life and 
providing a cost saving to the NHS (Brown et al., 2006). 
 
There is an on-going debate about HPV testing as a suitable alternative to 
cytology. HPV DNA testing is more sensitive, less specific and has a higher negative 
predictive value than current cervical cytology (Waxman, 2008, Bulkmans et al., 
2007). The sensitivity of HPV DNA testing appears to be equally high in a spectrum 
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of age ranges and geographical locations; this contrasts with cytology which varies in 
sensitivity (Cuzick et al., 2006). HPV testing was implemented in the UK in 2014, 
alongside cervical cytology with a view to reducing the number of ICC cases further 
(DH/NHS Finance, 2010).  
 
 
 Laboratory based research tools to investigate HPV infection 1.7
 
This section details the various molecular and cellular research tools available 
to investigate HPV infection. 
 
1.7.1 Collection of clinical samples to investigate of HPV infection 
 
Collection and preservation of clinical samples is important in cervical screening 
and residual material can be used for scientific research such as the development 
and optimisation of novel biomarkers. The use of cellular cytology as a screening 
method to predict neoplastic changes in the cervix was first described by Dr George 
N. Papanicolaou in 1941 (Michalas, 2000, Papanicolaou and Traut, 1997). This 
involved exfoliating cells from the surface of the cervix and transferring them to a 
microscope slide at the bedside. Slides were then processed and stained for 
microscopic examination to identify neoplastic changes. This enabled treatment of 
women with neoplastic changes and reduced risk of subsequent cervical cancer 
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development. Incorporating this into a systematic screening programme led to a 
reduction in cervical cancer associated mortality. 
 
In recent years, there has been a move from the conventional cervical cytology to 
liquid based cytology (LBC). LBC involves storing cells in a protective media, 
transporting to a laboratory and transferring to a slide for automated analysis. LBC 
has a higher sensitivity in detecting cellular changes and residual cellular material 
can be used for molecular HPV testing (Bernstein et al., 2001, Zhu et al., 2007). LBC 
media such as SurepathTM (Source BioScience, Nottingham, UK) and PreservCyt 
(Cytyc Corporation, Boxborough, Mass.) are commercial cellular preservatives used 
for collection of cervical smear tests. However, LBC media is designed for the 
preservation of cellular morphology, not for preservation of nucleic acid. LBC media 
has a detrimental effect on the nucleic acid preservation, degrading nucleic acid and 
cross-linking DNA due to the presence of formalin (BectonDickinson, 2017, 
Huijsmans et al., 2010). With the incorporation of HPV DNA testing into the cervical 
screening programme, the preservation of nucleic acid is as important as the 
preservation of cellular morphology structures within the cells. Cervical biopsies are 
used for the diagnosis of disease and can be cultured to generate cell lines for use in 
research. 
 
Other types of material have been assessed for clinical HPV analysis 
including urine (Piyathilake et al., 2016), blood (Patel et al., 2011) and saliva (Turner 
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et al., 2011, Wimardhani et al., 2015), however these do not reliably detect HPV and 
are not used as part of screening. 
 
 
1.7.2 Nucleic Acid Extraction and Purification 
 
Proteinase K enzyme is used to break down cellular glycoproteins, DNase 
and RNase to release nucleic acid with limited denaturation (Roche, 2010, Ebeling et 
al., 1974). Cellular debris can subsequently be pelleted and purified nucleic acid in 
the aqueous phase can be collected. This is a crude method of extraction, but 
provides a high quantity of nucleic acid from clinical samples. 
 
Many commercial nucleic acid extraction kits use Proteinase K to lyse cells, 
however the samples are then purified using a solid phase extraction (Janecka et al., 
2015, Tan and Yiap, 2009, Bonin and Stanta, 2013). This involves binding nucleic 
acid to a solid membrane or beads. Centrifugal force is then used to wash the 
membrane or beads to remove contaminants including salt and cellular residue. The 
nucleic acid can then be eluted using a sterile buffer. A solid phase extraction 
reduces the chance of contamination that may occur in a normal proteinase K 
extraction. 
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1.7.3 Methods of HPV identification and typing 
 
HPV identification and typing can be categorised into three broad categories; 
(i) nucleic acid hybridisation (ii) nucleic acid amplification, and (iii) signal 
amplification. 
 
Southern blotting and in-situ hybridisation (ISH) both provide high quality 
information on the presence of HPV as well as the state of the viral genome. 
However, both methods are time consuming, suffer from low sensitivity and require a 
large quantity of purified DNA. Also, nucleic acid hybridisation requires well 
preserved DNA which can be difficult to achieve from clinical material which has 
been stored in a cellular preservative (Abreu et al., 2012, Villa and Denny, 2006). 
 
The amplification of HPV DNA or RNA can identify the presence and 
genotype of HPV in a sample. DNA amplification identifies the presence of the viral 
genome and RNA amplification provides information of viral gene expression. RNA is 
sensitive to degradation and pure, intact RNA can be difficult to extract from clinical 
samples collected in LBC (Houseley and Tollervey, 2009). However, there are 
several commercially available assays for HPV mRNA available such as Aptima 
HPV Assay (Hologic, 2017) and the QuantiVirusTM HPV Cervical and Oral Tests 
(DiaCarta, 2017). Both of which have shown higher specificity and fewer false-
positive results when compared to DNA based assays (Munson et al., 2014, Clad et 
al., 2011, Benevolo et al., 2011). 
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DNA is less sensitive to degradation and adequate purification can be 
achieved from clinical samples stored in LBC. Nucleic acid amplification can be 
achieved using consensus or type-specific HPV primers. Consensus primers target 
highly conserved regions of the HPV genome and can identify many HPV genotypes 
simultaneously. These include GP5+/6+ and MY09/MY11 consensus primers 
(Venceslau et al., 2014). Type specific primers are designed to only target a single 
HPV type; thus, the specific HPV type of infection can be identified. Many type-
specific primers have been published and they can also be easily developed in-
house. A range of commercial HPV nucleic acid amplification assays are available. 
These include INNO-LiPA® HPV test (Innogenetics, 2013), COBAS® (Roche 
Molecular Diagnostics, 2017) and PapilloCheck® (Greiner Bio-One, 2006, Vieira and 
Almeida, 2013). DNA-array technology can also be used to identify and type HPV 
from clinical samples. This involves amplification of a portion of the HPV genome, 
the PCR product is fluorescently labelled and hybridised to the DNAchip. The DNA 
chip can then be analysed and show the HPV types present in the sample. 
PapilloCheck® is a simple commercial assay which uses type-specific E1 primers 
and DNA-array technology to simultaneously identify 24 different HPV types. HPV 
types present at a low copy number and multiple infections may not be identified if 
one genotype has a low copy number compared to other HPV types in the sample. A 
low viral copy number may represent a transient infection and not have a major 
impact on the clinical treatment of the patient (Depuydt et al., 2012). 
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HPV signal amplification involves hybridisation of HPV-DNA to labelled 
probes that produce a non-radioactive signal, which can then be assessed. These 
tests can differentiate between HR-HPV and LR-HPV infections but cannot 
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signal amplification assays are Hybrid Capture 2 (HC2)(QIAGEN, 2017a) and 
Cervista (Hologic, 2010). 
 
 
1.7.4 Detection of genetic changes in HPV infection 
 
HPV gene expression is closely linked to the stratification of the epithelium 
and alters between transient and transforming infections, as described in section 
1.3. HPV gene expression can be measured using various methods such as 
Northern Blotting, quantitative real-time polymerase chain reaction (qRT-PCR) and 
RNA sequencing. Northern Blotting is a classic technique however it does not 
provide sufficient information compared to qRT-PCR and RNA sequencing. qRT-
PCR uses fluorescence to amplify and detect PCR targets in a single step and 
increasingly multiple targets can be detected in a single reaction. Further qRT-PCR 
can achieve greater accuracy than northern blotting, detecting small differences in 
gene expression between samples (Wong and Medrano, 2005). RNAseq is a 
relatively new method which provides in-depth quantitative detail of the whole 
transcriptome of the sample (Wang et al., 2009b).This involves parallel sequencing 
of either RNA or complementary DNA (cDNA) using next generation sequencing 
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technologies. These sequences can then be compared to a known reference 
genome to assess levels of transcript expression or De novo, in which a 
transcriptome can be assembled without a reference genome which may identify 
novel splice patterns (Surget-Groba & Montoya-Burgos, 2010) 
 
Detecting HR-HPV infections identifies individuals at risk of precancerous 
lesions or who have already developed lesions. However many HR-HPV infections 
are transient and will be cleared naturally by the body’s immune system (Fernandes 
et al., 2013). There is a need to develop molecular tests that can differentiate 
between transient infections and productive infections likely to progress to high-
grade disease. Detecting genetic changes in HPV methylation of HPV DNA into the 
host genome may give an insight into which infections are transient and which are 
transforming (Clarke et al., 2012). Several methods of viral genomic DNA 
methylation analysis have been developed including bisulfide conversion, 
methylation sensitive restriction enzyme digestion and affinity purification of 
methylated DNA. As standard sequencing techniques cannot differentiate between 
cytosine and methylated cytosine an additional step is therefore necessary to identify 
methylated cytosines. Sodium bisulphite converts unmethylated cytosine into uracil, 
but not methylated cytosine (Clark et al., 1994). This is described in detail in section 
1.4.3. 
 
Integration is a random event in cervical neoplasia progression, which has 
been shown to occur frequently in CFS (described in section 1.3.1) (Thorland et al., 
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2003). Various methods have been developed to identify viral integration events that 
may be useful in detecting HPV infections likely to progress to high grade CIN. 
Methods of detecting viral integration can be categorised as: 
 
 Gene lost as a substitute marker of viral integration. 
 Fusion transcripts that determine the viral integration event are 
transcriptionally active. 
 Viral DNA integration events that may or may not be transcriptionally active. 
 
As the E2 gene is commonly disrupted in cervical cancer; the absence of the 
E2 gene in the presence of HPV oncogenes E6 and/or E7 can be a potential marker 
for viral integration. This can be assessed by a tiling PCR which amplifies the E2 and 
E6 genes, assessing the absence (all or partial loss) of the E2 gene in samples with 
detectable viral oncogenes. This test is less laborious than identification of individual 
integrants and is a good indicator of integration (Collins et al., 2009). This assay 
however is limited as E2 gene presence could be a false positive indicator for 3 
reasons: (1) Integrants and episomes can exist as a “mixed infection”; (2) Viral 
integration sites in the HPV genome can occur outside the E2 region; (3) The stage 
at which the E2 gene is lost is undetermined and variable between patients (Boulet 
et al., 2009). 
 
The E2 tiling PCR uses type specific primers to amplify overlapping regions 
across the E2 gene. When all reactions are positive, the E2 gene is considered intact 
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in the test sample, however if one or more portions of the E2 gene are missing then 
the sample is indicative of integration (Collins et al., 2009). E6 viral oncogene 
relative to the E2 gene is another substitute marker determined by qRT-PCR. The 
E6 gene is typically maintained in viral integration and the E2 gene is generally lost, 
therefore the ratio should decrease upon viral integration (Chang et al., 2013). 
 
The identification of fusion transcripts can determine if the integration event is 
transcriptionally active. Methods involve the identification of the sequence and state 
of the RNA. Traditional methods of fusion transcript identification include RNA ISH 
and Amplification of Papillomavirus transcripts (APOT) (Klaes et al., 1999). However, 
technological advancements have increased the prominence of RNA sequencing as 
a method of identifying HPV-human fusion transcripts. There are several methods to 
identify viral integrants that may or may not be transcriptionally active, these include 
Southern Blotting (Villa and Denny, 2006), Restriction site Polymerase Chain 
Reaction (RS-PCR) (Sarkar et al., 1993), Fluorescent in situ-hybridisation (FISH) 
(Hopman et al., 2005) and Detection of Integrated of Papillomavirus Sequences 
(DIPS) (Luft et al., 2001) (Table 1.1). 
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1.7.5 Laboratory models for HPV study 
 
Primary cells that have migrated from a piece of tissue grown under 
favourable conditions are a useful tool for the study of HPV infection. 
Primary cells have a limited life span, however with extended culture they 
can become immortalised, this may be due to chemical or viral stimulation, 
or a spontaneous process due to cellular stress during cell culture. 
Immortalised cells lines can be grown continually in the lab if suitable 
culture conditions are met and the cells are split at regular intervals. Over 
time cells with a growth advance are naturally selected for and cells can 
become different from the tissue of origin. This genetic drift is a significant 
problem in the development and culture of new models for disease 
research. 
 
When developing novel cell lines, procedures need to be put in 
place to identify the genotype of the cells at the time of propagation and 
then cell lines can be tested to ensure that cells have not drifted away from 
the original patient phenotype (Gulliksen et al., 2012). If suitable controls 
are in place to check cells remain true to the original patient samples then 
cells lines can provide an invaluable tool in HPV research. 
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Another issue which affects cell line development is the 
misidentification of cell lines which can lead to questionable research 
results (Masters, 2002). This misidentification can be avoided with good 
laboratory practice and by limiting the number of laboratories the cells 
pass through from the origin. The production of in-house cell lines is an 
asset. Regardless, cell lines are an important cornerstone to the 
development of drug therapies and research into genetic changes driving 
disease progression. Some commonly used cell lines for HPV study are 
listed in Table 1.2. 
 
Table 1.2 Description of origin and HPV genome status of 
immortalised cell lines that are commonly used in HPV research  
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One way of studying HPV biology in the lab is to grow cell lines in a 
monolayer culture. In a monolayer culture the cells are attached to a solid 
surface, such as a flask or a petri dish and then allowed to grow and 
colonise the surface. To assist cell growth, feeder cells such as irradiated 
J2 3t3 fibroblast cells (Stanley, 2002, Eiselleova et al., 2008) are used to 
support growth. 
 
Cells grown in monolayer culture can provide information about how 
HPV infection influences cellular morphology and how cells respond to 
adverse conditions such as chemicals and radiation. However, as the HPV 
lifecycle is closely linked to the stratification of cells (as described in 
section 1.2) there are limitations to research carried out in monolayers. To 
overcome the limitations of cells grown in monolayer, organotypic raft 
culture was established as a model of the typical HPV life cycle. Some 
benefits of employing the raft culture include: 
 
1. Cellular differentiation and inappropriate mitosis can be measured. 
2. Changes in HPV gene expression linked with cellular stratification 
can be measured 
3. Cell cycling markers can be assessed as to when they are 
expressed in a differentiated culture. 
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Cell lines are seeded on to a collagen matrix containing live J2 3t3 
fibroblast cells. Cells are then grown to confluence and lifted onto a metal 
grid. Cells are fed from beneath with a liquid air interface for 13 days 
before being harvested and sent for pathological analysis (Anacker and 
Moody, 2012, Andrei et al., 2010, Delvenne et al., 2001). This model 
allows the entire viral life cycle to be produced and viral particles can be 
produced if the viral genome is intact (Anacker and Moody, 2012). This 
can be used to assess the cellular phenotype and levels of cellular 
differentiation, cell cycle markers and mitotic activity can also be 
measured. In normal skin, it would be expected that cells in the upper 
levels of the epithelium would stop all mitotic activity; however cells with a 
persistent HPV infection may still have mitotic activity high in the 
epithelium. 
 
In normal morphology, cells differentiate from the basal cells at the 
bottom of the epithelium, to the elongated terminally differentiated cells at 
the surface. In low-grade disease, the viral particles have entered the 
basal cells and the viral lifecycle progresses normally during cell 
differentiation, with viral particle production and release. In high-grade 
disease, virus particles are not released and cells become less 
differentiated in the upper levels of the epithelium. Cell lines are seeded 
onto a collagen plug, placed upon a metal grid creating a liquid air 
interface with E media. After 14 days, the cells are stratified on top of the 
  
44 
 
collagen plug and the cells are fixed and sent for histological analysis 
(Figure 1.8). 
 
Figure 1.8. Process of cell growth in an organotypic raft culture. Cells 
were seeded onto collagen plugs and grown for 13 days. On the 14th day 
the collagen plugs (with the cells on top) were lifted onto a sterilised metal 
grid in a 10 cm petri dish using a metal spatula. E media was added below 
the culture until the top of the media touched the base of the collagen plug 
on top of the metal grid. Media was changed every day for 10 days until 
the cells had grown into a stratified layer, a white later can be seen on top 
of the collagen plug. At this point the cells were removed from the collagen 
and either placed into PBS for nuclear acid extraction or the collagen plug 
was lifted with the metal spatula and placed into formalin to fix the cells 
and allow downstream immunohistochemistry (IHC) analysis.  
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 Biomarker development 1.8
 
Biomarkers are biological changes which can be measured to 
indicate the presence, progression or prognosis of disease. A suitable 
biomarker must show a specified and specific correlation between the 
biomarker and clinical outcome. The use of a biomarker must also show 
improved clinical outcome e.g. earlier treatment or more targeted 
treatment which will lead to a reduction of unnecessary treatment.  
 
Biomarkers have already been employed in screening (BRCA1 in 
breast cancer), predicting response to therapy (KRAS mutation in 
colorectal cancer) and monitoring disease recurrence (AFP and LDH in 
germ cell tumours) (Henry and Hayes, 2012). Cancer Research UKs 
Biomarkers and Imaging Discovery and Development Committee (BIDD) 
has defined stages of biomarker research (Cancer Research UK, 2016) 
from initial basic research and rational to biomarker discovery and assay 
development and quantification (as shown in appendix 1). Biomarker 
discovery assay development is divided into three stages.  
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Stage 1: The development of accurate and reproducible assays.  The 
distribution of the biomarker is defined in samples which are 
representative of the target patient population.  
 
Stage 2: Biomarker distribution indicates a potential clinical utility. 
Standard operating procedures and performance of assays are 
defined. At this stage, the relationship between the biomarkers and 
clinical outcome is studied retrospectively. 
 
Stage 3: Biomarkers in this stage have shown a correlation between 
distribution and clinical outcome and appropriate assay standards 
are met. At this stage, the assay should be fit for purpose.  
 
If the potential biomarker fulfils the criteria at each stage the assay 
can then be quantified for clinical application. If a potential assay fails at 
any stage further basic research may be required or the research may be 
redirected. 
 
Research in this thesis followed the Prognostic/Predictive Biomarker 
Roadmap for biomarker discovery, development and quantification. All 
results presented in this thesis will be considered within the framework set 
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up in the Prognostic/Predictive Biomarker Roadmap and next stages of 
biomarker discovery and development will be considered.  
 
 
 Hypothesis 1.9
 
This study aimed to examine several HPV regulatory factors to 
determine their suitability as clinical biomarkers. This involved 
development of assays, application to samples obtained from different 
cohorts of women to ascertain prognostic validity and development of an in 
vitro system to model the in vivo pathology. Table 1.3 outlines the 
hypothesis addressed by this PhD thesis. 
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Table 1.3 Hypothesis addressed by this PhD thesis 
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2 Chapter 2  
Materials and Methods 
 
 Study Cohorts and Cell Lines 2.1
 
Two study cohorts were evaluated in this thesis: (1) The ‘Baseline’ 
cohort, which consisted of samples taken from young women attending 
their first cervical smear in Wales (Hibbitts et al., 2014); (2) The ‘HPV 
Integration as a biomarker for cervical disease (HI-BCD)’ cohort, 
representing a pilot study of potential biomarkers of disease in women 
attending colposcopy due to CIN. Study protocols for both studies are 
shown in Appendix 1, including inclusion and exclusion criteria for each 
research study respectively. 
 
 
2.1.1 Study 1: Young women attending their first cervical smear 
 
This study was conducted in April 2009 - July 2010 and involved 
taking pseudo-anonymous residual LBC (BD SurePathTM, Source 
Bioscience) samples from women aged 20-22 attending their first cervical 
smear test. This was done in conjunction with Cervical Screening Wales 
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(CSW) who confirmed eligibility of samples and provided clinical data to 
link with the anonymous case ID of each sample. Participating cervical 
screening laboratories included Welsh laboratories in: Llandough, 
Singleton, Royal Gwent Hospital, Wrexham Maelor, Ysbyty Glan Clwyd, 
Withybush, Royal Glamorgan, Princess of Wales, Prince Charles and 
West Wales General, and Hereford, Chester and Shrewsbury laboratories 
which lie on the England-Wales border. Ethical approval was obtained 
from the Dyfed Powys Local Research Ethics Committee (08/WMW01/69).  
 
 
2.1.1.1 Sample Collection, Storage and Processing 
 
In total 14,128 LBC samples were collected and processed by CSW 
according to CSW guidelines (Cervical Screening Wales, 2005). These 
cases were managed according to standard guidelines and data collected 
from this study did not impact routine patient treatment or management. 
Samples that met all the study inclusion criteria were flagged and 
transported to the HPV Research laboratory in the University Hospital 
Wales, Cardiff. 
 
Residual material from cervical smear samples were transferred 
from the SurePathTM pot to a 15 ml falcon tube. The falcons were spun for 
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10 minutes at 2,100 x g at 4oC and the supernatant was aspirated, leaving 
the cells pelleted at the bottom. These were then re-suspended in 2 ml of 
10 mM Tris (pH 7.4) and 1 ml of the cell suspension was transferred into 
two 1.5 ml eppendorfs for each LBC sample 4 tubes were stored for 
further analysis: 1 x 1.5 ml tube containing the cell pellet, 1 x 1.5 ml tube 
containing 300 μl of cell suspension; and 2 x 0.5 ml tubes containing 100 
μl of cell suspension each. Samples from this study were then used to 
evaluate the genome status of women attending their first routine cervical 
smear. Samples were included in subsequent analysis if they were HPV 
positive by type specific PCR for the HPV type under investigation (Figure 
2.1). 
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Figure 2.1 Flow diagram of samples included in a study of young 
women attending their first cervical smear. Samples included in this 
study had a single HPV infection and were HPV positive by type specific 
PCR (HPV 31, 33, 35 and 51 respectively). 
 
 
2.1.2 Study 2: HI-BCD Study Cohort 
 
The HI-BCD study ran from March 2011 to April 2014 and consisted 
of 200 women who attended colposcopy at a single site within the Cardiff 
and Vale Health Board. Eligible women were identified by Cervical 
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Screening Administration Department of CSW and were invited to donate 
a smear sample of convenience when attending colposcopy following an 
abnormal cervical smear result. An amendment to the study protocol 
allowed for the collection of smear samples from women who had cancer. 
Ethical approval was obtained from the Dyfed Powys Local Research 
Ethics Committee/National Institute for Social Care and Health Research 
Permission Co-ordinating Unit. The Cardiff and Vale R&D committee also 
approved this study. 
 
 
2.1.2.1 Sample Collection, Storage and Processing 
 
Cervical smear samples were collected at Llandough Hospital, Cardiff by 
colposcopy nurses and colposcopy gynaecologists. During the patients’ 
visit a smear sample was taken with a standard cytology brush. This was 
then placed into 2 ml of RNA Protect® (QIAGEN Ltd, Manchester, UK) in a 
sterile 30 ml universal container. The tip of the brush was agitated in the 
media and then detached. Samples were electronically anonymised and 
then transported to the HPV Research Group, Cardiff University at room 
temperature, stored at −80oC. HPV type was assessed by Papillocheck® 
and by HPV 16 type specific E6 PCR. Confirmed HPV 16 positive samples 
were used to assess viral integration, methylation and gene expression 
(Figure 2.2) 
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Figure 2.2. Flow diagram of samples included in HI-BCD study. Thirty 
two samples included in this study had a HPV 16 infection (single or 
multiple infections) as assessed by Papillocheck® and/or HPV 16 E6 type 
specific PCR. 
 
 
 
 
 Cell Lines 2.2
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Several cell lines were employed in this study as a model of HPV 16 
disease. Cell lines used in this thesis along with their origin and growth 
conditions are detailed in Table 2.1. 
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Table 2.1 Origin, growth conditions and source/reference of cell lines 
used in this research. All cell lines used in this work were grown at 37oC 
with 5% CO2. 
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 Molecular Cloning of Plasmid DNA 2.3
 
Reagents used in the molecular cloning of the plasmid DNA are 
listed with their supplier in Table 2.2.- 
 
Table 2.2 Reagents used in the molecular cloning of the plasmid DNA 
and their supplier. 
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2.3.1 HPV Plasmids 
 
Information on positive control HPV plasmids obtained from 
Professor Dr Ethel-Michele de Villiers from the HPV Reference lab, 
Heidelberg, Germany and the plasmids that were kindly donated are 
detailed in Table 2.3 
Table 2.3 Detail of Positive Control Plasmids used in this study 
 
 
2.3.2 Agar Plate Production 
 
Lysogeny broth (LB) Agar was produced by adding 250 ml of 
deionized water to 8.75 g of LB Agar powder. The LB agar was autoclaved 
and 500 μl of ampicillin was added to the agar solution. Plates were 
poured, set and inverted in the cold room until they were required. Plates 
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for HPV 51 cloning had 40 μl of 5-bromo-4-chloro-indolyl-β-D-
galactopyranoside (X-gal) and isopropyl β-D-1-thiogalactopyranoside 
(IPTG) added to the surface of each plate. These were then allowed to dry 
in the incubator at 37oC for 30 minutes before use. All plates were stored 
in the incubator at 37oC prior to Escherichia coli (E. coli) plating. 
 
 
2.3.3 E. coli Transformation with Plasmid DNA 
 
E. coli cells were thawed on ice and 50 μl was pipetted into two 1.5 
ml eppendorf tubes. Plasmid DNA (2 μl) was added to one eppendorf and 
2 μl of water was added to the negative control. The tubes were mixed and 
placed on ice for 30 minutes. The E. coli was then heat-shocked at 42oC 
for 30 seconds and subsequently placed on ice for a further 5 minutes. 
Room temperature super optimal broth with catabolite repression (SOC) 
media (950 μl) was added and placed in an incubator at 37oC for 60 
minutes while shaking at approximately 0.35 x g. A serial dilution of E. coli 
cultures was performed and 50 μl of each dilution was plated onto an 
agarose gel and incubated for 16-18 hours at 37oC. 
 
A single colony was picked from the transformed plate and placed 
into 2 ml of LB Broth and left overnight in a shaking incubator at 37oC 
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(approx. 0.35 x g). The following day a glycerol stock was produced from 
the culture and DNA was extracted from the culture. 
 
To produce a glycerol stock 50 μl of the culture was diluted in 5 ml 
of LB broth and incubated at 37oC with 0.5 x g shaking for 75 minutes. 
Then 800 μl of the growing E. coli was added to a 1.5 ml eppendorf with 
200 μl of autoclaved glycerol. This was briefly mixed and stored at -80oC 
for future use. 
 
 
 Nucleic Acid Extraction from Clinical Samples and Cell 2.4
Culture 
 
The nucleic acid extracted in this study was assessed for quality 
and quantity using a Thermo Scientific Nanodrop® 1000 
Spectrophotometer. As nucleic acids have absorbance maxima at 260 nm 
and proteins at 280 nm, the ratio between 260 nm and 280 nm is used as 
a measure of sample purity. For DNA an A260/A280 ratio of ~1.8 is 
considered pure and an A260/A280 ratio of ~2.0 is considered pure for 
RNA. A low 260/280 ratio may be indicative of residual reagent being 
carried over from the extraction protocol (Thermo Scientific, 2012). 
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2.4.1 Plasmid DNA Extraction 
 
Plasmid DNA extraction was carried out using a QIAamp® DNA 
Mini and Blood Mini Kit. In brief, 1 ml of E. coli culture was centrifuged for 
5 minutes at 4,600 x g. The supernatant was removed leaving the cell 
pelleted. DNA was extracted from the cell pellet using the bacteria protocol 
and the sample was eluted with AE buffer and stored at -20oC. 
 
 
2.4.2 DNA Extraction from Baseline Study Cohort 
 
Baseline samples were previously pelleted and stored at -80oC. 
C33a cell pellets and transformed E. coli containing the HPV type of 
interest were used as positive controls. Samples were re-suspended using 
500 μl of Tris and 250 μl was used for DNA extraction. Sterile water was 
used as a negative extraction control. 
 
To each sample 50 μl of Proteinase K was added and samples 
were placed in an incubator at 56oC with shaking for 16-18 hours. 
Samples were then placed into a dry heating bath at 80oC for 10 minutes 
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then transferred to a chilled rack and placed in the fridge (4oC) for a further 
10 minutes. Samples were then spun in a chilled microfuge at 4oC for 10 
minutes at 14,200 x g. The supernatant containing DNA was recovered 
and the pellet was discarded. 
 
 
2.4.3 DNA and RNA Extraction from HI-BCD Study Cohort and 
cultured cells 
 
All Prep DNA/RNA Mini Kit (QIAGEN Inc, Gaithersburg, USA) was 
used to extract DNA and RNA from both clinical samples in the HI-BCD 
cohort and cell lines grown in vitro. 
 
Cells grown in vitro were trypsinised, resuspended in growth media 
and counted using a haemocytometer. For this extraction kit it was 
recommended that no more than 1 x 107 cells were used per spin column. 
If the column was overloaded then it would lead to the co-purification of 
DNA and RNA. Both HI-BCD samples and cell lines DNA and RNA were 
then extracted using the protocol for ‘Simultaneous Purification of 
Genomic DNA and total RNA from Animal Cells’ according to 
manufacturer’s instructions. In brief, RNA was eluted using 40 μl of 
RNase-free water and the DNA was eluted in two steps using 50 μl of EB 
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buffer in each step to total 100 μl of eluted DNA. DNA and RNA were then 
stored at -20oC until they were required for downstream analysis. 
 
 
 Identification of HPV Genes and Gene Expression by 2.5
Molecular Analysis 
 
The identification of HPV genes and gene expression in this thesis 
relied on PCR to amplify HPV genes of interest. PCR is a key molecular 
biology technique which involves cycles of denaturing DNA, annealing 
primers and the synthesis of a new DNA strand. The numerous cycles 
produce a large quantity of the specific DNA region of interest. This can 
then be sequenced or run on an agarose gel to visualise the size and 
quantity of DNA (Mullis et al., 1986, Bartlett and Stirling, 2003). 
 
Reagents used in the molecular analysis are listed in Table 2.4. 
Table 2.5 shows the reagents and quantities used in each assay 
Mastermix and the PCR conditions are listed in Table 2.6. For BetaGlobin 
PCR, E2 tiling PCR, E1/E2 PCR, DIPS and methylation analysis the PCR 
Mastermix was produced in a PCR UV sterile hood. Mastermix was made 
for the appropriate number of samples plus one to account for pipetting 
loss and loaded into each well of the PCR plate and DNA was added to 
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the assigned location on the PCR plate. The plate was sealed using 
adhesive lids and placed in a thermocycler. Once the PCR cycle was 
complete the samples were run on a 2% agarose gel and viewed under 
UV using a transilluminator. All molecular tests presented in this thesis 
were carried out in triplicate. 
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Table 2.4 Reagents and their suppliers used in the identification of 
HPV genes and gene expression by molecular analysis 
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Table 2.5 (part 1) Mastermix used in the identification of HPV genes 
and gene expression assays 
 
 
  
67 
 
Table 2.5 (part 2) Mastermix used in the identification of HPV genes 
and gene expression assays 
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Table 2.6 Thermocycler conditions used in the identification of HPV 
genes and gene expression by molecular analysis 
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2.5.1 PCR Primer Design for E6, E7, E2 tiling PCR and DIPS Assays 
 
Software and archives used for primer design is shown in Table 2.7 
 
Table 2.7 Software and archives used in primer design and analysis. 
 
 
Genome files of the HPV types of interest were obtained from the 
European Nucleotide Archive (ENA) (Hinxton, Cambridgeshire) and 
opened in Artemis (Sanger Institute) (Rutherford et al., 2000), this allowed 
for the genome to be annotated with restriction sites and the location of 
viral genes. A FASTA file was also downloaded and this was used to 
design the primers using National Institute of Biotechnology Information 
(NCBI) Primer Basic Local Alignment Search Tool (BLAST) (Ye et al., 
2012). The NCBI Primer BLAST options were kept on the default setting 
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and the preferred primer location was selected. Appropriate primer 
information was saved and the primer sites were annotated on the Artimis 
file. 
 
The primers that appeared to be suitable were input into Net Primer 
(PREMIER Biosoft International, Palo Alto, CA) to check for unwanted 
secondary structure formation. Primers, which formed secondary 
structures with a very low ΔG, were excluded. The suitable primers were 
also checked for unwanted secondary structure formation with the adapter 
primer as well as the corresponding linear/nested primer. Finally the 
primers were loaded onto BioEdit software (Ibis Bioscience) which 
checked the primer sequences against 13 of the most common HR-HPV 
types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) to ensure 
that primers were specific to the HPV type of interest. 
 
 
2.5.2 Agarose Gel Electrophoresis of PCR Products 
 
Agarose gel electrophoresis was used to visualise DNA 
amplification and provide a semi-quantitative analysis. The agarose 
powder was weighed out according to the required gel concentration. Tris-
acetate-EDTA (TAE) buffer was added and placed into a 500 ml Duran 
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Bottle. This was placed into a standard microwave and heated for several 
minutes with occasional swirling to ensure the agarose and TAE were well 
mixed. Once the agarose was fully dissolved and the solution was clear 
and viscous the Duran was placed into cold water and allowed to chill to 
approximately 60oC at which point 3% ethidium bromide was added; the 
solution was mixed well and poured into the gel tray. Combs were added 
and the gel allowed to set for 15 to 20 minutes. 
 
Once fully set the gel was placed into a suitably sized tank. 1% TAE 
buffer was added to the tank until the gel was covered with a thin layer of 
buffer. The PCR samples were then added to the gel with 20% Orange G 
and at least one DNA ladder (100 base pairs (bp) or 1 kb) was added per 
row of samples. Electrophoresis was carried out until the sample had 
almost reached the bottom of the gel. The gel was then transferred to the 
transilluminator and visualised. 
 
 
2.5.3 E2 and E1/E2 tiling PCR 
 
The E2 PCR assay uses multiple PCRs spanning the E2 gene 
(Collins et al., 2009) (Figure 2.3). This assay is a primary indicator of 
whether the virus has integrated into the host genome. 
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Figure 2.3. Principle of the E2 PCR assay. P1-P7 represents the 
individual PCRs that span the E2 gene of the HPV genome. (A) The 
genome is intact and all PCRs produced the expected product. (B) 
Integration of HPV into the human DNA. Here the E2 gene is disrupted 
and three of the PCRs will fail, indicating integration. 
 
To produce E2/E1 tiling PCR Mastermix reagents were mixed as 
noted in Table 2.4. One master mix was made for each primer set (details 
can be found in Appendix 3). The Mastermix was aliquoted into 96 well 
PCR plates. DNA from clinical samples (2 μl) was added to the individual 
wells. Positive (type specific plasmid DNA) and negative controls (PCR 
grade water) was added into the remaining well. The PCR plate was 
sealed and placed in a thermocycler and E2/E1 PCR protocol was carried 
out (as detailed in Table 2.5) 
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Once the thermocycler programme was complete five microliters of 
PCR product was then run on a 2% agarose gel. PCR products from 
clinical samples were compared to positive control to assess if the E2/E1 
gene was intact.  
 
 
2.5.4 Detection of Integrated Papillomavirus Sequences PCR 
 
The DIPS assay involves digesting clinical samples with restriction 
enzymes and ligating nucleotide adapters to the ends of the digested 
DNA. A HPV specific linear PCR is carried out followed by a nested PCR 
with primers specific for HPV and the adapter primer (Luft et al., 2001). 
PCR products are then run on an agarose gel and bands which deviate 
from the expected size can be sequenced to identify the sequence of the 
HPV-human viral junction (Figure 2.4). 
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Figure 2.4 Principle of the DIPS assay. The sample is digested with 
digestion enzyme Sau3AI. DNA adapters are then ligated onto the DNA 
sample before a linear PCR is carried followed by a nested PCR with 
primers for HPV and the adapter sequence. The PCR products can then 
be visualised and sequenced.  
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To produce DIPS adapter’s reagents were mixed as noted in Table 
2.4. The mix was aliquoted into PCR tubes and placed in a thermocycler 
and gradually cooled from 90oC to 4oC overnight. 
 
The genomic DNA was digested using Sau3AI enzyme by mixing 
reagents listed in table 2.4 and then incubated at 37oC for 2 hours followed 
by heat inactivation at 80oC for 20 minutes. The adapter was then ligated 
onto the digested PCR product and incubated as detailed in table 2.5. The 
linear PCR was then carried out using type specific primers, followed by a 
nested PCR using HPV 16 specific primers and AL1 primer which 
corresponds to the DNA sequence of the adapter. 
 
PCR product (5 μl) was then run on a 2% agarose gel. If the sample 
produced dissimilar bands from those produced by the plasmid control the 
rest of the PCR product (20 μl) was run on a fresh 2% agarose gel and the 
band extracted from the gel for further sequencing. 
 
 
2.5.5 PCR Gel Extraction 
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The PCR product was run on a gel and photographed using a low 
UV light intensity on the transilluminator. Individual wells were processed 
on to the table top UV transilluminator. Using a sterile scalpel, the bands of 
interest were cut from the gel and placed into individual tubes. 
 
The DNA from each band was then purified using the Illustra GFX 
PCR DNA and Gel Band Purification Kit (GE Healthcare Life Sciences, 
Buckinghamshire, UK). In brief, 300 μl of Capture buffer type 3 was added 
to each gel slice and placed into a 60oC water bath for 15-30 minutes to 
allow the gel to dissolve. Once the gel was fully dissolved, if the solution 
was pink then ~10 μl of sodium acetate was added to bring the solution to 
a yellow/pale orange colour. The content of the eppendorf was placed into 
a GFX MicroSpin column in a 2 ml collection tube. This was incubated at 
room temperature for 1 minute and then spun at 16,000 x g for 30 
seconds. The flow-through was discarded and the column was returned to 
the collection tube. The sample was then washed using 500 μl of wash 
buffer type 1. This step was carried out twice followed by a third spin 
(16,000 x g) to ensure the column was completely dry. The column was 
then transferred to a fresh 1.5 ml eppendorf and the sample was eluted 
using 25 μl of elution buffer type 6. This was incubated for 1 minute at 
room temperature and then spun at full speed for 1 minute. From the 25 μl 
of purified DNA, 5 μl was run on a new agarose gel to ensure the 
purification was successful and to estimate the concentration of DNA in 
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the sample. The remaining 20 μl was sent for sequencing, if the 
purification was successful. 
 
 
2.5.6 DNA Sequencing and Analysis 
 
PCR bands were sent to Source Bioscience (Nottingham, UK) and 
sequenced using Sanger sequencing. Sequencing results were then 
assessed using NCBI nucleotide BLAST to identify the location of virus-
host integration site for the HPV genome and the host (Figure 2.5). 
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Figure 2.5 Example of NCBI nucleotide blast used to identify the 
location of virus-host integration site for the HPV genome and the 
host. 
 
 
2.5.7 qRT PCR 
 
A two-step qRT-PCR assay was used in this study to assess the 
level of mRNA from clinical samples. The first step involved converting 
mRNA into complementary DNA by a reverse transcriptase reaction. In 
this reaction the retroviral enzyme M-MLV reverse transcriptase enzyme is 
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used along with random primers to produce cDNA (Invitrogen, 2004). This 
is then used as a template for the second step. 
 
The qRT-PCR reactions involves a PCR reaction like conventional 
PCR (section 2.5), however a fluorescent dye or probe is used to take a 
reading after each amplification cycle. This allows the amount of DNA 
produced after each PCR cycle to be measured and normalised against 
stable reference genes. In this work, SYBR Green I dye was used to 
quantify the mRNA expression. SYBR green I preferentially binds to 
double stranded DNA and in the qRT-PCR reaction the level of 
fluorescence increases relating to PCR production and subsequent 
fluorescence is measured. The level of expression of genes of interest is 
then reported compared to the expression levels of reference genes, in 
this thesis reference genes TATA-binding protein 2 (TBP2) and 
Hypoxanthine Phosphoribosyltransferase (HPRT) were used.  
 
 
2.5.7.1 Reverse Transcription 
 
Firstly, DNase treatment was carried out to remove any DNA that 
has been carried over in the extraction procedure. RNaseZap (Sigma 
Aldrich) was used in the PCR hood to remove any RNase contamination 
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from the hood and equipment which could degrade the RNA of interest. 
Reagents detailed in Table 2.4 were mixed on ice, incubated at room 
temperature for 10 minutes and then DNaseI was inactivated with 25 mM 
EDTA. Finally, samples were heated at 65oC for 10 minutes. 
 
To synthesise cDNA reagents in Table 2.4 (Reverse Transcription 
part 1) were utilised. This was heated at 65oC for 5 minutes before being 
placed on ice for at least 1 minute. Mastermix Reverse Transcription part 2 
was then produced and 7 μl was added to each sample from Reverse 
Transcription part 1. Samples were then placed on a thermocycler as 
detailed in Table 2.5 and then diluted 1/10 with H2O before being stored at 
-80oC. 
 
 
2.5.7.2 qRT-PCR 
 
qRT master mixes were prepared as detailed in table 2.4 and 18 μl 
of each Mastermix was placed in each capillary tube with 2 μl of cDNA. 
Glass capillaries were centrifuged at 750 x g for 5 seconds to transfer the 
PCR mix to the capillary tube. Glass capillaries were then placed in the 
light cycler carousel, which was set to the optimum PCR condition for the 
gene of interest (detailed in Table 2.5). 
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2.5.7.3 qRT-PCR analysis 
 
qRT-PCR analysis was carried out using LightCycler® software and 
qBasePLUS (Hellemans et al., 2007). LightCycler® software automatically 
calculated the Ct value (the number of cycles required for the fluorescent 
signal to exceed background) using second derivative maximum. 
LightCycler® software was also used to identify samples which failed to 
amplify the specific target; these samples were excluded from further 
analysis.  
 
The data was then transferred into qBasePLUS software which was 
used to calculate the ratio between the genes of interest (HPV E2 and E6) 
compared to the reference genes (HPRT and TBP2). To reduce errors due 
to sample quality and quantity the PCR efficiency was calculated for each 
target by using a dilution series of CaSki cDNA (Bryant, 2012). This data 
was uploaded to qBasePLUS and used to quantify PCR efficiency and 
compensate for sample variability (Hellemans et al., 2007). Expression 
levels were reported as calibrated normalised relative quantities (CNRQ) 
Expression levels were calculated relative to expression in the HPV 16 cell 
line CaSki. This allowed for the data to be comparable between studies.  
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2.5.8 DNA Methylation Study 
 
HPV DNA methylation was assessed in this work by bisulphide 
conversion of sample DNA followed by PCR and Pyrosequencing. As 
described in Section 1.4.3. The bisulfide converted DNA is then used as 
the PCR template with primers designed specifically to not anneal to any 
cytosine bases which may have been converted to uracil. For the 
downstream Pyrosequencing reaction one of the primers used in this PCR 
reaction is biotinylated.  
 
The PCR product is denatured; this allows the sequencing primer to 
bind to a single strand of DNA. To this is added DNA Polymerase, ATP 
sulfurylase, luciferase, apyrase and the substrates 
5’phosphosulphate(APS) and luciferin. deoxiribose nucleotide 
triphosphates (dNTPs) are then added in sequential order; the DNA 
polymerase catalyses the addition of the dNTP to the sequencing 
primer/template. The incorporation of the dNTP is accompanied by a 
release of phosphate (PPi). ATP sulphurylase converts PPI into ATP in the 
presence of APS. This drives the luciferase –mediated conversion of 
luciferin to oxyluciferin which generated visible light. This intensity of the 
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light is proportional to the amount of ATP and therefore the amount of 
dNTPs incorporated. The addition of dNTPs is set to occur in sequential 
order and the level of signal with each dNTP addition can be measured. 
This can then be used to calculate the percentage of DNA methylation at 
each CpG site. To ensure there is no cross talk between nucleotide 
additions Apyrase degrades unincorporated dNTPs and ATP, when the 
degradation is complete the next nucleotide in sequence is added 
(QIAGEN, 2017b) 
 
2.5.8.1 Bisulfide Conversion 
 
All the reagents were prepared as specified in the kit protocol, in 
brief, CT conversion reagents were prepared by adding 750 μl of H2O and 
185 μl of M-Dilution buffer into a tube of CT conversion reagents and 
vortexed at a low speed until required. 7.5 μl of M-Dilution buffer was 
added to 500 ng of DNA and the volume was adjusted to 50 μl with PCR 
grade H2O. Samples were mixed by repeat pipetting then incubated at 
42oC for 30 minutes on a hot block. Pre-prepared CT conversion reagents 
(97.5 μl) were added to each DNA sample and mixed. Samples were then 
incubated on the heating block at 50oC for 12 – 16 hours covered with a 
black box to reduce the exposure to light. 12 – 16 hours later the samples 
were incubated on ice for 10 minutes. M-Binding Buffer (400 μl) was 
added to a Zymo-Spin column in a 2 ml collection tube. The sample were 
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then added to a spin column and mixed by inverting several times. The 
column and collection tube was then centrifuged at 14,200 x g for 30 
seconds. 100 μl of M-Binding Buffer was added to each column and the 
sample was again spun at 14,200 x g for 30 seconds. M-Desulphonation 
Buffer (200 μl) was added to each sample and incubated at room 
temperature for 20 minutes. The samples were spun again at 14,200 x g 
for 30 seconds. Finally, 20 μl of M-Wash Buffer was added to the column, 
which was again spun at 14,200 x g for 30 seconds. 10 μl of M-Elution 
buffer was added to each tube and spun at 14,200 x g for 30 seconds to 
elute the sample. 90 μl of PCR grade H2O was added to each sample to 
dilute to 1/10. These samples were then used in the pyro sequencing PCR 
or stored at −20oC until required. 
 
 
2.5.8.2 Pyro sequencing PCR 
 
Pyro sequencing PCR reactions were carried out using ZymoTaq 
PCR reagents (Zymo Research Corporation, California, USA). Samples 
were diluted 1/100 by adding 90 μl to 10 μl of the bisulphide conversion 
product and 2 μl was added to the master mix in each well. PCR grade 
H2O was added into a well as a negative control. The PCR was carried at 
the conditions shown in Table 2.5. Once complete 10 μl of PCR product 
was run on an agarose gel to ensure the PCR was successful. 
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2.5.8.3 Pyrosequencing Reaction 
 
The workstation was set up according to the manufacturers’ 
instructions with the wash buffer, 70% ethanol, water and denaturation 
buffer (QIAGEN, 2012). The details of the sample and the reaction were 
selected on the PyroMark CpG Software. Into each reaction well 1.75 μl of 
streptavidin sepharose bead suspension and PyroMark Binding Buffer 
(38.25 μl) were added. This was then placed onto a shaking hot plate at 
10 x g at 22oC until required. The sequencing primer was diluted by adding 
1.5 μl of 10 μM to 43.5 μl of PyroMark Annealing Buffer for each reaction. 
45 μl of sequencing primer was placed the PSQ plate and the plate was 
securely placed on the correct position on the workstation.
 
The DNA and sepharose bead mix was taken off the hot plate and 
placed into the position on the workstation. The vacuum was dried and the 
vacuum prep tool captured the beads with the PCR product. The vacuum 
prep tool was then placed into the ethanol for 5 seconds, the denaturation 
solution for 5 seconds and the wash buffer for 5 seconds. All the fluid was 
aspirated and the vacuum switched off and the prep tool was lowered into 
the PSQ plate. The PSQ plate was then heated at 80oC for two minutes 
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and allowed to cool to room temperature. The PyroMark Gold Q96 
reagents were prepared as specified in the kit and reagents were then 
placed into the correct location in the PSQ96 Reagent Cartridge. The 
PyroMark CpG Software calculated the volume of reagents required. The 
PSQ plate and cartridge were both placed into the PyroMark Q96 ID 
instrument and the run began. 
 
 
2.5.8.4 Methylation Analysis 
 
All samples included in this analysis were repeated in duplicate 
within a run to improve the reliability of the data. Analysis was performed 
using PyroMark CpG Software. Samples were categorised as either pass 
‘blue’, check ‘yellow’ or fail ‘red’. Samples which failed were repeated to 
ensure this was not a false-negative result and were excluded from the 
study after a second failed run. Samples which were categorised as 
‘check’ were manually checked to assess the acceptability of the data, 
some of these had failed results at CpG sites CpG 3461 and CpG 3471, 
thus the first 6 CpG sites were included in the analysis and sites CpG 
3461 and CpG 3471 were excluded.  
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 Growth Medium and Optimal Conditions for Cell Growth 2.6
 
Information on cell lines used in this study is shown in Table 2.1 in 
section 2.2. All cells used in this project were incubated during growth at 
37oC with 5% CO2. Reagents used for the growth of cells are listed in 
Table 2.8 and the media components are listed in Table 2.9.  
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Table 2.8. Reagents used in the growth of cells and their suppliers 
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Table 2.9. Components of media used to culture cells 
 
 
 
2.6.1 Vulval and Vaginal Cell Lines 
 
The vulva and vaginal cell lines were cultured using E media plus 2 
x 106 J2 3T3 and passaged when they reached ~80% confluence. The 
components for this E media are listed in Table 2.10 and 2.11. All 
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components were filter sterilized and EGF was only added for growing the 
cells in a monolayer. 
 
 
 
 
Table 2.10. Components for 200 ml of E Media Cocktail 
 
 
 
2.6.2 J2 3T3 Cells 
 
J2 3T3 cells were grown in Dulbecco's Modified Eagle's Medium 
(DMEM) media made up as described in Table 2.8 and passaged every 3 
days. After passage cells that were not re-plated were irradiated for use as 
feeder cells, losing the ability to replicate but still producing extracellular 
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matrix protein. Cells were irradiated for 22 minutes, absorbing 60 gray 
(Gy) radiation in a Caesium-137 irradiator. 
 
 
2.6.3 Freezing and Thawing of Cell Lines 
 
Cells were frozen down to preserve a stock of cells in case of 
infection and to preserve earlier passages of cell stocks in case of 
changes in composition through further passage. Cells were trypsanised 
and resuspended in 10 ml of normal growth media and centrifuged for 5 
minutes at 160 x g and the supernatant removed. Cells were resuspended 
in (foetal bovine serum) FBS supplemented with 10% dimethyl sulfoxide 
(DMSO) to the desired concentration (from 5 x 105 cells/ml to 2 x 106 
cells/ml). The resuspended cells were transferred to appropriately labelled 
cryovials in 1 ml aliquots. Vials were then placed in a Mr Frosty Freezing 
Container overnight, and placed in the -80oC freezer. After 24 hours, cells 
were stored in liquid nitrogen and their location recorded for future use. 
 
To thaw cell lines, cryovials were removed from the liquid nitrogen 
and defrosted. The cells were pipetted to ensure they were in single 
suspension and placed in the centre of a petri dish. If required, 1 x 106 J2 
3T3 cells were added to the top of the defrosted cell suspension. Finally, 
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normal growth media was added. Cells were then incubated at 37oC with 
5% CO2. 
 
 
 Keratinocyte Differentiation Using Organotypic Raft 2.7
Culture 
 
Organotypic raft culture (as described in section 1.7.5) was carried 
out to assess the differentiation level of cells and relative gene expression, 
methylation and integration status. In brief this involves seeding cells on a 
collagen matrix, with subsequent growth to confluence. Once cells reach 
confluence the collagen matrix is then lifted onto a metal grid above 
growth media (so the base of the collagen is touching the top of the 
media). The media is then replaced ever two days and the collagen matrix 
and cells are left untouched. After 13 days, the collagen matrixes along 
with the cells were lifted from the metal grid and were either placed into a 
cellular preservative or cells were removed from the collagen matrix and 
placed into saline for DNA/RNA extraction. Reagents used in organotypic 
raft culture are shown in Table 2.11. 
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Table 2.11. Reagents used in the organotypic raft culture and their 
suppliers. 
 
 
 
2.7.1 Production of Collagen Plugs 
 
Reconstitution buffer (10x) was prepared by adding 2.2 g of sodium 
bicarbonate to 4.77 g of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES). This was the dissolved in 100 ml of 0.05 M Sodium 
hydroxide. This was then filter sterilized, as was the DMEM and stored at -
2oC until required. Once the plugs were ready to be produced J2 3T3 cells 
were harvested at 80% confluence and 1-2 x 106 cells were pelleted for 
each collagen plug. 0.3 ml of 10x DMEM and 0.3 ml of 10x reconstitution 
buffer was added to the cell pellet for each collagen gel. 2.4 ml of rat-tail 
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collagen at 4 mg/ml per collagen gel was then added using pipette tips that 
had previously been stored at -20oC and solution mixed by pipetting up 
and down. Sodium hydroxide was then added using a Pasteur pipette until 
the solution reached the correct pH range (pH 6 – 8). 
 
Once the solution was prepared, 3 ml was pipetted slowly onto a 3 
cm petri dish again using chilled pipette tips. The plugs were then stored in 
10 cm petri dishes to ensure they were stable and transferred to an 
incubator at 37oC for 30 minutes. After 30 minutes 2 ml of complete E 
media was placed on top of the collagen plug. Collagen plugs must remain 
in the incubator for 1 day after it preparation and can be kept for up to 4 
days before being used to grow the differentiated cells on. For optimum 
results the collagen gels were used within two days’ storage. 
 
 
2.7.2 Growing Differentiated Cells on Raft 
 
Firstly, the stainless-steel metal grids were treated with 
chromic/sulphuric acid for an hour and rinsed overnight in tap water. After 
24 hours they were rinsed with double distilled water for a further 3 – 5 
hours and then autoclaved. Metal grids were then placed in a 10 cm petri 
dish using sterile forceps (autoclaved). Media was removed from the top of 
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the collagen gel and sides of the gel loosened from the edges of the petri 
dish using an autoclaved, sterile spatula. Carefully placing a spatula under 
the collagen gel, it was lifted away from the 3 cm petri dish. The collagen 
gel was then laid on to the metal grid ensuring no air bubbles formed. The 
liquid interface was then created by adding E media (without EGF) to the 
plate until it touched the bottom of the metal grid but did not touch the 
collagen, again this had to be done slowly to ensure no bubbles formed at 
the interface, this could lead to non-uniform growth. Rafts were then 
incubated at 37oC and the media changed every two days. On the 
thirteenth day the cells could be harvested. 
 
 
2.7.3 Analysis of Organotypic Raft Culture 
 
IHC results were quantified by grading the positive pixels in the 
selected raft cultures as a marker of the amount of stain the cells have 
taken in. Figure 2.3 shows the process by which the rafts were graded. 
The total number of pixels were counted and scored as either high-
positive, positive, low positive or negative. IHC results were also quantified 
by measuring the depth of the culture that has taken in the IHC stains 
using ImageJ (Fiji) software (Jensen 2013; Varghese et al. 2014). The 
total depth of the culture was measured, and then the length from the base 
of the culture to the top of the stained area was measured and the 
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percentage was calculated. Each culture was measured three times and 
the average percentage of depth of IHC stain recorded. SHH and GLI-1 
protein expression was also quantified using ImageJ. Each image had the 
colour adjusted to display the fluorescent stain as red and the proportion of 
the epithelium that stained red was measured. Results for SHH and GLI-1 
expression were compared to the 4’, 6’-diamidino-2-phenylindole (DAPI) 
nuclear control stain to produce a relative percentage stain compared to 
the control. 
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2.7.4 HPV IHC 
 
IHC raft culture analysis was kindly performed by Dr Sally Roberts 
(HPV E4) and by Dr Christopher Dawson (SHH and GLI-1) at the 
University of Birmingham, table 2.11 shows the antibodies used in this 
IHC. p16 and Ki-67 IHC were performed by Contract Research 
Organisation Propath Laboratories (Hereford, UK).  
Table 2.12 Details of Antibodies used in IHC including concentration 
used and details or supplier/reference 
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2.7.4.1  HPV 16 E4 IHC 
 
In brief the raft sections were deparaffinised in Histoclear and low 
temperature antigen retrieval performed in 1 mM EDTA (pH 8.0), Tween 
20 (0.1%) on a hot hotplate-stirrer at 65oC overnight (Watson et al., 
Carcinogenesis 2002 23:1791). Slides were blocked in a humidified 
chamber at room temperature in PBS containing 20% heat inactivated 
normal goat serum and 0.1% (w/v) bovine serum albumin (fraction V) for 
90 min. The blocking buffer was removed and replaced with primary 
antibody solution prepared in blocking buffer and incubated at 4oC 
overnight.  Primary antibodies used were 1D11, a mouse monoclonal E4 
antibody (1:10 dilution) (Roberts et al., 2003) and a rabbit anti-HPV18 E4 
polyclonal antibody r424 (1 in 1000 dilution) (Wilson et al., 2007).  The 
slides were washed in PBS twice for 15 minutes and secondary antibodies 
applied (mouse and rabbit IgG – specific Alexa 488 and 594 antibodies 
(Molecular Probes; each diluted 1 in 500). Nuclei were counterstained with 
DAPI (4’, 6’-diamidino-2-phenylindole), prior to mounting in ProFade 
(Molecular Probes Inc). 
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 Statistical Analysis 2.8
 
Guidance on statistical analysis was kindly provided by Professor 
Robert Hills. Statistical analysis reported in this thesis was carried out 
using Microsoft Excel (Microsoft, Washington, USA) and IBM SPSS 
Statistics (IBM Corporation, New York, USA).  
 
 
2.8.1 Chi-square Test of Independence 
 
In this thesis categorical data was assessed using the Chi-square 
Test for Independence. This test assesses the association between two 
independent variables and demonstrates how likely the distribution of the 
data is due to chance. This is done by comparing the observed values ‘O’ 
to the expected ‘E’ (Laerd Statistics, 2016). 
 
  
 
The significance of this Chi-square value was then determined by 
comparing the degrees of freedom in the data to the Chi-square value 
using a Chi-square distribution table, a result is considered statistically 
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significant if p<0.5. Chi-square test can also use Cramer’s V as a 
measurement of the strength of the association between the two variables. 
Guidelines for interpreting the Cramer’s V were established by Cohen 
(1988) (Table 2.13) 
 
Table 2.13. The strength of association guidelines for Cramer’s V as 
established by Cohen (1988). 
 
 
 
 
 
2.8.2 Spearmans Correlation coefficient 
 
The Spearmans Correlation coefficient can be employed to 
measure both the strength of a correlation as well as the direction of the 
correlation. This test was used over the Pearsons Correlation Coefficient 
as Spearmans Correlation coefficient is less sensitive to data skewing by 
outliers (Mukaka, 2012). As sample sizes in this study were small this 
allowed for a robust statistical analysis without removing samples from the 
analysis.  
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In this equation, the total sample size = n and the two groups to be 
tested are separated into two groups, x and y. and Sx and Sy are the 
standard deviation of x and y respectively: 
 
 
 
The resulting value (r) is between -1 and +1, where a r = +1 is a 
perfect positive association of ranks, r = -1 is a perfect negative 
association of ranks and r = 0 is no correlation. Unlike the Pearsons 
correlation there is no set guidelines on how to determine the strength of 
the relationship. In this thesis the results will be interpreted using the 
following criteria (Table 2.14) (Hinkle et al., 2003): 
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Table 2.14. Interpretation of Spearman Correlation Coefficient 
reported in this thesis. Table adapted from Hinkle et al,.(2003). 
 
 
2.8.3 Kruskal-Wallis H Test 
 
The Kruskal-Wallis H test is a nonparametric test like a one-way 
ANOVA, however it can be used when the data fails to meet the 
assumptions of a one-way ANOVA (e.g. non-normally distributed, ordinal 
data). The Kruskal-Wallis H test was used in this study when the data was 
not normally distributed to determine if there are statistically significant 
differences between two or more groups of independent variables (Kruskal 
and Wallis, 1952, Laerd Statistics, 2015).  
 
Firstly, the distributions of the data were compared for all groups by 
visual inspection of a box plot. If distributions were similarly shaped, 
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differences in the medians could be investigated. If the distribution of the 
independent variables were not similar then no inference about the median 
between groups could be made. In this case, the differences in distribution 
and mean ranks can still be assessed. The Kruskal-Wallis H test is 
reported as the value of the chi-squared distribution (X2) with the degrees 
of freedom (k-1, where k is the number of groups).  
 
In addition to the Kruskal-Wallis H test a pairwise comparison was 
carried out between individual groups to discover which groups were 
statistically different from each other. The pairwise comparison was 
interpreted using Dunn’s (1964) procedure with a Bonferroi adjustment. In 
the pairwise comparison when you make multiple comparisons there is an 
increase in type 1 error, where a result is incorrectly reported as 
statistically significant, this error increases with each pairwise comparison 
carried out. The Bonferroni correction is used to compensate for this error, 
and the significance of the pairwise comparisons (p) will be reported as the 
“adjusted-significance”. 
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3 Chapter 3  
HPV genome status in first routine smear sample from women 
aged 20-22 years 
 
Integration of episomal HPV DNA in to the host genome is not part of the 
normal virus replication cycle, and frequently results in loss of E2 gene (McBride, 
2013). E2 plays a pivotal role in regulating HPV transcription, including limiting 
expression of the HPV oncogenes E6 and E7. The disruption of the regulatory E2 
gene results in enhanced expression of E6 and E7. Although integration is now 
known not to be an absolute pre-requisite for the progression to cervical cancer, 
HPV E2 disruption could be used as a potential biomarker for predicting HPV 
malignant disease progression. E2 disruption can be most readily assessed using 
the E2 tiling PCR assay (discussed in sections 1.6.4).  
 
DNA methylation is generally indicative of transcriptionally repressed 
chromatin. Studies performed in the HPV laboratory, Cardiff University and 
elsewhere have correlated the methylation state of the HPV genome with 
chromosomal integration (Bryant et al., 2014, Marongiu et al., 2014). Thus work was 
carried out to assess if HPV E2 viral DNA methylation could be used as a potential 
biomarker for the prognosis of HPV related disease progression. 
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 DNA quality in clinical samples stored in SurePathTM LBC media 3.1
 
Reliable and reproducible purification of high quality nucleic acid is 
paramount in ensuring optimal results in HPV molecular assays. When working with 
clinical material it is therefore essential that the extraction and purification 
procedures be optimised. SurePathTM LBC media is an ethanol based media 
containing formalin that preserves the morphology of the cellular and subcellular 
components within the cytoplasm and nucleus. This improves the sample quality for 
cytological examination; however, DNA damage and cross-linking can result 
following exposure to chemical agents, especially formalin. Formalin fixes cellular 
material for storage and subsequent histological analysis; however, it can cross-link 
DNA, making subsequent molecular analysis difficult. To overcome the potential 
degradation from storage in SurePathTM five different extraction methods were 
assessed to determine the most effective method to extract DNA from clinical 
samples stored in SurepathTM LBC media, and the merits of each is summarised in 
Table 3.1. DNA yields and purity was assessed by measuring absorbance at 260 
and 280 nm (described in material and methods section 2.3) and semi-quantitative 
analysis of PCR product for the BetaGlobin gene. 
 
Consistent with previous published findings from the laboratory, Protocol 1 
resulted in relatively low yields of PCR products 0-2.750 µg DNA; (Hibbitts et al. 
2014). Although Protocol 2 improved yields to 5 – 7.5 µg DNA, the amplification of 
target DNA by PCR was still not optimal (Figure 3.1). A Kruskal-Wallis H test was 
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carried out to assess if there were differences in the DNA concentrations achieved 
for the two extraction methods. The mean ranks of the DNA concentration were 
statistically different between the two protocols X2(1) = 7.410, p = 0.006. There was 
no significant difference between protocol 1 and 2 when compared to the 260/280 
ratio, X2(1) = 0.315, p = 0.575. 
 
Three further extraction protocols were then assessed alongside Protocol 2 
(Table 3.1). Protocol 2 obtained the highest-level DNA yield (28619.9 ng) in this 
cohort (Figure 3.2). A Kruskal-Wallis H test was carried out to assess if there were 
differences in the DNA concentrations achieved for the four extraction methods. The 
distributions of the DNA concentration were not similar for all groups, as assessed by 
visual inspection of the boxplot. The mean ranks of the DNA concentration were 
statistically different between the four groups X2(3) = 19.15, p > 0.001. A pairwise 
comparison revealed statistically significant differences in DNA concentration 
between Protocol 2 (mean rank = 28.00), Protocol 4 (mean rank = 6.00) (p < 0.001) 
and Protocol 5 (mean rank = 13.29) (p = 0.046). The mean ranks of DNA purity (as 
measured by 260/280) were statistically different between the four extraction 
methods tested, X2(3) = 18.916, p < 0.001. When a pairwise comparison was carried 
out the only significant difference in DNA purity was between Protocol 2 (mean rank 
= 5.00) and Protocol 5 (mean rank = 23.86), (p < 0.001). While product quality was 
improved by Protocol 3 (mean rank = 13.00), compared to Protocol 2 (mean rank = 
5.00) this was not statistically significant (p = 0.413).  
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The enhanced Proteinase K extraction (protocol 2) was selected as the 
preferred method for this study as it was compatible with PCR amplification and 
significantly higher DNA yield compared to Protocols 1, 4 and 5. Protocol 2 resulted 
in the extraction of approximately 28691 ng of DNA from each sample, whereas 
Protocols 3, 4 and 5 yielded 2440 ng, 888 ng and 1779 ng DNA respectively. 
Although the samples extracted with Protocol 2 had reduced purity based upon the 
260/280 ratio and the purity was only significantly reduced compared to Protocol 5 
(which produced the lowest DNA yield). Subsequently the BetaGlobin PCR was 
applied to all samples extracted with a 95.3% success rate (n = 523/549).  
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Figure 3.1 Samples extracted by Protocol 1 and Protocol 2: Yield and purity of 
DNA and BetaGlobin PCR comparison (A) Comparison of protocol 1 and 2. (B) 
PCR product (110 bp) is highlighted with the yellow arrow and CaSki (positive) and 
water (negative) controls are labelled above. In samples extracted using protocol 1 
BetaGlobin gene was detected in half of the samples. In samples extracted using 
protocol 2 all the clinical samples produced a weak PCR product. (C) DNA yield and 
purity results of the samples extracted using protocol 1 and 2 as assessed using 
Thermo Scientific Nanodrop® 1000 Spectrophotometer. 
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Figure 3.2. Average DNA yield and purity for four extraction procedures. 
Comparison of DNA yield (ng) and sample purity (as measured by 260/280 ratio) for 
samples using four extraction procedures to assess which procedure produces the 
highest quality and quantity of DNA for subsequent analysis. Analysis was carried 
out on 6 clinical samples and extraction and extraction and analysis was performed 
in triplicate. DNA yield and purity (260/280 ratio) as measured by Thermo Scientific 
Nanodrop® 1000 Spectrophotometer. 
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 Identifying HPV E2 gene in clinical samples 3.2
 
A HPV 16 E2 tiling PCR assay is an established method to detect disruption of 
the E2 by performing multiple PCRs across the HPV genome spanning E2 (Collins et 
al., 2009). In this study, novel type-specific E2 tiling PCR assays were developed for 
HPV 31, 33, 35 and 51. The assays were developed based on the consensus, type-
specific, genome sequences extracted from the EMBL-EBI Database and primers 
were designed using NCBI Primer BLAST (Ye et al., 2012). A small PCR product 
was preferential (max 350 bp) due to the potential fragmented and cross-linked 
nature of the DNA stored in SurePathTM LBC media. Suitable primer pairs were 
checked in Net Primer (PREMIER Biosoft International, Palo Alto, CA) for potential, 
unwanted, secondary structures. Primers were also compared to the genome of 12 
of the most common HR-HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 
and 59) to ensure the primers were specific to only the HPV type of interest. Primer 
details can be found in Appendix 3.  
 
In touchdown PCR, the initial annealing temperature is around 5-10oC higher 
than the calculated Tm of the primers, it is then reduced every cycle until around 5oC 
below the calculated Tm of the primers. Initially a touchdown PCR was used for the 
E2 tiling PCR to reduce the time spent optimising assays as primer pairs with 
different optimal annealing temperatures could be run together (Hibbitts et al., 2014, 
Korbie and Mattick, 2008). The touchdown PCR resulted in faint bands with an 
average yield of 5.65 ng/µl DNA. The PCR bands remained faint even when the 
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cycle number was extended from 40 to 50 cycles. A standard PCR produced strong 
single bands with an average DNA concentration of 25 ng/µl of DNA, a greater than 
4-fold increase from the touchdown PCR (Figure 3.3). 
 
Assay sensitivity was established by means of a serial dilution from 50 ng to 5 
x 10-7 ng of type specific plasmid DNA. All assays were sensitive to 0.05ng of 
plasmid DNA with some primer sets being sensitive to 5 x 10-3 ng of DNA (Table 
3.2). E2 tiling PCRs were successfully applied to 89.55% (n = 429) clinical samples 
that had been extracted using protocol 2 (Figure 3.4). Assays were considered 
successful based upon positive E6/E7 PCR. These assays enable a quick and low 
cost assessment of the presence of the E2 gene. 
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 Disruption of HPV 16 E2 in cervical smear samples 3.3
 
Starting with 13,306 samples in women aged 20 – 22 years old attending their 
first cervical smear, 4,870 were PCR-positive for HPV, of which 3,545 were 
attributed to HR-HPV types. This study aimed to answer hypothesis 2 by evaluating 
disruption of E2 gene in a subset of less studied HPV types 31, 33, 35 and 51. 
Samples exhibiting single infections with HPV 31 (n = 122), 33 (n = 64), 35 (n = 17) 
or 51 (n = 139) were included in this analyses. This cohort included a higher 
prevalence of HPV 51 samples than expected, however analyses reported 
elsewhere has assessed that these are true HPV 51 infections (Bowden et al., 
2013). 
 
HPV 16 E2 disruption has previously been assessed in this cohort but only 
assessing individuals with high-grade cytology results (Raybould, 2013). To produce 
a comparable assessment, a subset of HPV 16 samples was included in this 
analyses (n = 93) and were chosen randomly to mirror the prevalence of cytology 
grades shown in the total cohort (Figure 3.5). Samples that were either E6/E7 
negative by PCR were excluded from further analyses. E6/E7 was chosen to 
evaluate sample eligibility as E6/E7 are small genes which are present and 
expressed even in high-grade infections (Origoni et al., 2015). 
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Figure 3.5. HPV 16 samples selection to reflect the proportion of cervical 
cytology in the total cohort. HPV 16 samples were separated by the cervical 
cytology and then samples were randomly selected to represent a similar proportion 
for each cervical cytology result (n = 93) compared to the total cohort (n = 724). 
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 Prevalence of E2 disruption in a cohort of young unvaccinated 3.4
women 
 
A systematic investigation of 412 clinical samples infected with a single HPV 
genotype identified E2 gene was disrupted in 5.12% of samples. The levels of viral 
disruption ranged from 1.08% to 12.5% depending on HPV genotype (HPV 16 – 
1.08% (n = 93), HPV31 – 8.26% (n = 121), HPV 33 – 6.25% (n = 64), HPV 35 – 
12.5% (n = 16), HPV 51 – 5.12% (n = 116)) (Figure 3.6). There was no significant 
association between any specific HPV type and E2 disruption (X2 = 8.292, p = 
0.081). All individuals with disrupted E2 had negative or borderline smear results and 
subsequently none of these individuals attended colposcopy because of their first 
smear test. 
 
The results suggested that E2 was disrupted in a lower percentage of HPV 16 
compared to the four high risk types not included in the vaccine (1.08% and 6.31% 
respectively) and when the results from the four non-vaccine types (HPV 31, 33, 35 
and 51) were combined and compared with the results from HPV 16 the HPV 16 
samples were significantly less likely to have disrupted E2 gene in this cohort of 
young women (Χ2 = 4.0533, p = 0.044). The hypothesis that the integrity of the E2 
locus (a biomarker of HPV genome integration) in HPV 16 infected samples would 
be equivalent to other HR-HPV types (HPV 31, 33, 35 and 51) was rejected. 
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Figure. 3.6 E2 gene disruption as detected by type specific E2 tiling PCR for 
HPV 16, 31, 33, 35 and 51. (A) Table of the percentage of disruption for each HPV 
type (B) the percentage of samples with E2 disruption (X2 = 8.292, p = 0.081).  
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 E2 status as a predictor of future HPV disease 3.5
 
A further study was carried out to determining whether individuals infected 
with HPV with a disrupted E2 were more likely to have developed CIN II+ in their first 
round of screening follow-up (≥ 36 months). Samples were included in this study if 
the individual had attended colposcopy in Wales from the date of their first smear 
until November 2013. Women who had not attended colposcopy and therefore had 
no reported histology, were excluded as it was not known if they had CIN II+. 
Samples were also excluded if they attended colposcopy and CIN was ungraded.  
 
From this cohort, 89 individuals attended colposcopy (HPV 16 n = 22, HPV 31 
n = 17, HPV 33 n = 20, HPV 51 n = 30). Only two samples in this cohort had E2 
disruption, one was HPV 31 positive and was diagnosed with CIN III and the other 
was HPV 16 positive and diagnosed with CIN I. The other 87 samples had an intact 
E2 gene (no-CIN = 12, CIN I = 23, CIN II = 24, CIN III = 28). Chi-squared test 
revealed that there was no significant association between intact E2 gene and follow 
up histology, X2(4) = 1.421, p = 0.841.  
 
The E2 tiling PCR is not a suitable biomarker for HPV related disease 
progression in young women attending their first cervical smear. High-grade disease 
(CIN II+) does not correlate with E2 disruption suggesting other viral/host factors are 
playing a role in disease progression. The E2 gene was intact in 54 samples that 
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went on to have CIN II+ disease during the follow up period (≥ 36 months). Also 19 
samples showed E2 gene disruption but to date have not attended colposcopy due 
to a suspicious smear result. 
 
In this cohort of young women attending their first smear 5.12% had complete 
or partial E2 disruption (n = 21/410). All samples with disrupted E2 had either a 
borderline or negative cervical cytology, thus E2 disruption, as measured by type 
specific tiling PCR alone, is not a suitable alternative for cervical cytology. This result 
may be due to the age of women in this cohort (20 – 22 years) as HPV related 
disease progression tends to result from persistent infection. (Molano, 2003, Bodily 
and Laimins, 2011) 
 
 
 HPV E2 viral DNA methylation as a potential biomarker for HPV 3.6
related disease 
 
Methylation of cytosine located in CpG dinucleotides is known to have a major 
impact on gene expression (as described in Introduction 1.4.3). Methylation can 
have an impact on malignant cells associated with the progression of cancers. Viral 
genomic DNA methylation in cancer cells has been shown prominently in HPV 16-
infected cells with an increase in viral genomic DNA methylation in the E2, L1 and L2 
genes (Introduction section 1.3.2). Therefore HPV E2 gene methylation was 
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investigated as a potential biomarker for disease presence in young women or an 
indicator of future disease progression. 
 
HPV 16 samples (n = 93) were tested for E2 methylation from those studied 
for E2 disruption, however viral genomic DNA methylation level was not identified in 
50% of samples. This result may have been due to the low copy number of HPV or 
due to sample disruption caused by cellular fixative. Samples that could not be 
sequenced were excluded from analyses. Therefore, further high-grade samples 
from the same cohort were sourced to increase the sample subset (Bryant et al. 
2015). Samples in this study were chosen based on available cytology and histology 
results, leading to this cohort having a greater proportion of high grade disease 
compared to the entire cohort. The final cohort included 194 samples: No CIN = 21, 
CIN I = 32, CIN II = 52, CIN III = 88, adenocarcinoma = 1. All assays were carried 
out in triplicate and the average percentage of E2 viral DNA methylation at each 
CpG site calculated for each sample. 
 
When E2 methylation was compared for samples with different histology 
results a trend can be seen with a decrease in viral DNA methylation from no-CIN to 
CIN III histology result, however the correlation between the average DNA 
methylation and histology was negligible, rs = -0.203, p = 0.004 (Figure 3.7). 
Similarly, when the average DNA methylation at each CpG site is assessed a trend 
can be seen with decreased viral DNA methylation from no-CIN to CIN III, however 
the correlation between viral methylation and histology at all CpG sites was 
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negligible (Figure 3.8). From these results, no significant correlation can be drawn 
between histology and viral E2 methylation in this cohort.  
 
 
Figure 3.7. Average E2 viral DNA methylation values for samples with different 
Histology. Results show a negligible negative correlation between increasing 
cervical cytology results and the average viral DNA methylation rs = -0.203, p = 
0.004. 
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Figure 3.8. Average E2 viral DNA methylation at each CpG site for samples 
with varying cervical histology. (A) Table of viral DNA methylation results for each 
cervical cytology result at each CpG site. (B) Average E2 viral DNA methylation at 
each CpG site (95% confidence interval is shown).  
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 Discussion 3.7
 
This section will highlight the key findings from this chapter and the strength and 
limitations of this study. Each of the key findings will then be considered in greater 
detail compared to the available literature and the broader implications. 
 
 
3.7.1 Key Findings 
 
1. Novel E2 primers were successfully applied to clinical samples stored in 
SurePathTM. 
2. Molecular tests to determine disruption and methylation of the HPV E2 
gene are not suitable biomarkers for CIN II+ in young women: 
a. The HPV E2 gene was disrupted in 5.12% of samples tested. 
b. Viral methylation of the E2 gene decreased with increased histology 
from no-CIN to CIN III, however this association was negligible. 
 
 
3.7.2 Study Strengths 
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This work benefitted from a large cohort of samples (13,306 in total) with 
follow up histology data (up to 36 months). This allowed for samples with a single 
HPV infection to be used in further analysis. This resulted in a large cohort of 
samples with a single detectable HPV infection (n = 410) in this study. Along with the 
HPV type of interest a subset of HPV 16 samples were also included in this analysis. 
Previous research with this cohort had assessed viral integration in samples with 
high-grade cytology results (Raybould, 2013). To produce comparable results 
between all HPV types a subset of HPV 16 positive samples were included. The 
number of samples with each baseline cytology result (negative, borderline, mild, 
moderate and severe cytology) was chosen to represent a similar proportion of 
samples from the entire cohort. The individual samples within each cytology group 
were chosen at random to ensure that this cohort was a true representation of the 
total cohort.  
 
 This study benefitted from optimisation of extraction protocols as well as 
optimising E2 tiling PCR assays. Extraction of DNA and assay optimisation was 
carried out specifically on samples generated from this study cohort which had 
undergone the exact same sampling storage and processing as the samples 
included in this study. This ensured that most samples were fit for analysis.  
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3.7.3 Study Limitations 
 
 This research aimed to investigate one potential measure of viral integration 
and methylation respectively, in four non-vaccine HPV types (HPV 31, 33, 35 and 
51). Although biomarkers for common HPV types play an increasingly important role 
in cervical screening the introduction of the 9-valent HPV vaccine (Cuzick, 2015, 
Joura et al., 2015) may reduce the necessity for bookmarks specifically targeted 
against HPV types discussed in this thesis.  
 
 Work in this study does not consider samples with multiple HPV infections. This 
choice was made as in an infection with multiple HPV types it cannot be determined 
which infection/s are driving disease progression. Thus, any results would have been 
confounded by multiple infections. This reduced the number of samples available to 
this study. 
 
 It also could not be determined within this study if a sample had mixed infection 
consisting of both integrated and episomal HPV infections. If an individual had a 
mixed infection the integration event may be masked by the DNA present from viral 
episomes which would also be present, generating a potential false positive result 
and only viral integration events with purely integrated HPV infections would be 
accurately measured. 
 
 
  
129 
 
3.7.4 Novel E2 primers were successfully applied to clinical samples stored in 
SurePathTM. 
 
This work has demonstrated that clinical samples stored in SurePathTM LBC 
media can be utilised in molecular assays to detect molecular changes in viral DNA. 
Four novel HPV E2 tiling PCR assays have been developed which are both sensitive 
and specific to four highly prevalent HR-HPV types (HPV 31, 33, 35 and 51) which 
until recently women were not vaccinated against. This was the first study of HPV 
31, 33, 35 and 51 E2 disruption in young women attending their first cervical smear 
and the novel assays were successfully applied to 410 samples. Therefore, findings 
in this thesis support Hypothesis 1: Novel HPV E2 tiling PCR assays specific for 
genotypes 31, 33, 35 and 51 will detect viral E2 gene disruption in DNA extracts from 
smears collected in SurePathTM LBC media.  
 
Two recent studies differed in the reported quality of nucleic acid after storage 
in SurePathTM LCB media. One study showed that 16% of samples were degraded 
and produced a false negative result after only three weeks storage in SurePathTM 
LBC media (Kubik et al., 2015) while another study by Gilbert et al, showed samples 
were viable up to 10 weeks of storage in SurePathTM LBC media at ambient room 
temperature (Gilbert et al., 2013). It has been shown that treating the clinical sample 
pre-extraction with a 1:1 alkaline solution and heating at 120oC for 20 minutes and 
improves the stability of the DNA while maintaining assay sensitivity (Tardif et al., 
2016), in future work this may be an option to further improve DNA extraction and 
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assay sensitivity. All of these studies assess HPV presence and stability using the 
Roche Cobas 4800 assay (Roche Applied Science, Mannheim, Germany) which 
identifies a ~200 bp size fragment of the HPV L1 gene (Rao et al., 2013). These 
studies do not address whether the HPV genome is intact in fragments > 200 bp. 
Work in this thesis restricted the size of DNA fragments amplified (< 352 bp) to 
account for potential DNA degradation. 
 
3.7.5  Tests for disruption of viral E2 gene and viral methylation are not 
suitable biomarkers for CIN II+ in young women. 
 
 This study has shown that both E2 tiling PCR and viral DNA methylation 
independently are unsuitable biomarkers in young women attending their first routine 
cervical smear test with as there was no distinct association with increased cervical 
histology (≥36 months), failing BIDD biomarker discovery stage 1. Following the 
prognostic and predictive biomarker roadmap further basic research is required to 
define potential biomarkers in young women. Previous work has shown HPV 16 E2 
disruption may be a suitable biomarker in women attending family planning clinics 
(Collins et al., 2009) and work by Bryant et al has suggested that methylation of HPV 
may be a biomarker for duration of HPV infection but the authors indicated a limited 
utility of methylation as a biomarker in young women (Bryant et al., 2015).  
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3.7.5.1 The HPV E2 gene was disrupted in 5.12% of samples tested. 
 
A major aim of this work was to study HPV E2 disruption as a potential 
biomarker in young women. In a population of young women (20 – 22 years old) 
attending their first routine cervical smear test with a single HPV infection (HPV 16, 
31, 33, 35 or 51) HPV E2 disruption was not a common event and was only detected 
in 5.12% of samples overall. The lowest level of HPV E2 disruption was present in 
samples with HPV 16 infections. This result does not support Hypothesis 2(a): 
Disruption of the viral E2 (and/or E1 (HPV 16 only)) gene is (A) Common in HR-HPV 
infections (HPV 16, 31, 33, 35 and 51).  
 
High levels of HPV E2 gene disruption were shown by Collins et al, when E2 
disruption was assessed by E2 tiling PCR in a cohort of young women (aged 15 to 
19 years) who had actively sought medical advice and/or treatment at a family 
planning clinic (Collins et al., 2009). These samples were collected using an Ayre’s 
spatula and placed in 10 ml of phosphate-buffered saline, stored at -80oC and then 
extracted using guanidinium thiocyanate acid. These women may have been 
exposed to behavioural risk factors for HR-HPV infection and disease such as; 
young age of sexual debut, multiple sexual partners, pregnancy and use of hormonal 
contraceptives (Brake and Lambert, 2005, Kjellberg et al., 2000, Johnson et al., 
2012a). Another study by Ramanakumar et al invited college students (mean age 23, 
range 17 to 42) to participate in their study which assessed viral integration by the 
ratio of E2:E6 gene expression (Ramanakumar et al., 2010). This study reported low 
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levels of viral gene disruption like those described in this thesis. Samples in this 
study were taken using Accelon Cervical Biosampler and extracted using QIAamp 
columns. This study does not report how samples were stored between collection 
and extraction.  
 
Samples in both of the above studies and work reported in this thesis all 
varied in sample collection, storage and extraction procedure. This may have led to 
variation in downstream HPV gene analysis. If a biomarker for HPV disease 
presence or prognosis is to be added to future cervical screening procedures the 
collection, storage and extraction of cervical material must be assessed and a SOP 
for sample collection and molecular assays must be established (BIDD 
Prognostic/Predictive Biomarkers Roadmap - stage 2). This will ensure downstream 
that a statistically robust correlation between the biomarker and clinical outcome can 
be established which ensures that the clinical outcome of the patients is improved by 
the use of the biomarker.   
 
Although HPV E2 disruption does not appear to be a common event in young 
women (as reported in this thesis) several studies have shown that with increased 
cervical histology HPV E2 disruption is a more common event (Graham and 
Herrington, 2000, Li et al., 2012, Sepetiene et al., 2011). In this study of young 
women there are few incidence of CIN II+ and no incidences of cancer, therefore 
predominant viral disruption in women with severe cytology and CIN II+ was not 
seen, rejecting Hypothesis 2 (b). This may be because this study only includes 
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women aged 20 – 22. The incidence of cervical cancer is strongly linked with age 
and in the UK the most common age of diagnosis is 25 – 29 year of age and more 
than 50% of cases are diagnosed in women under the age of 45 year of age (Cancer 
Research UK, 2017). 
 
 
3.7.5.2 Viral methylation of the E2 gene decreased with increased histology 
from no-CIN to CIN III, however this association was negligible. 
 
In this study, a low level of viral methylation of the HPV E2 gene was seen in 
samples (average methylation of less than 8%). With increasing cervical histology, 
there was a decrease in average viral methylation, although this correlation was 
negligible, therefore viral methylation failed to meet the criteria of BIDD biomarker 
discovery stage 1 and further basic research is required to define potential 
biomarkers in young women. This finding does not support Hypothesis 3: HPV 
hypermethylation is (a) Common in HR-HPV 16 infections; and (b) Detectable at 
highest levels in women with CIN II+. 
 
In cancer progression both hypo- and hyper-methylation have been reported. 
A genome wide reduction in methylation has been shown to increase genetic 
instability which can contribute to cancer progression (Cadieux et al., 2006). 
Alternatively, hypermethylation of specific promoter genes have been shown to be a 
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critical hallmark of cancer progression (Paz et al., 2003, Kulis and Esteller, 2010). 
Studies into HPV 16 genome methylation have suggested that high levels of viral 
methylation in L1, L2 and E2 are associated with a risk of higher cervical histology 
(Mirabello et al., 2012, Yang, 2013). 
 
Previous research into methylation of HPV DNA in young women has 
proposed that methylation of the HPV 16 L1/L2 gene may be another potential 
biomarker for the duration of HPV disease, specifically methylation at CpG sites 
5600 and 5609. However, like work presented in this thesis HPV 16 L1/L2 
methylation may only have limited value in young women. This research suggested 
that L1/L2 methylation may have clinical application in the triage of older women with 
HPV positive DNA (Bryant et al., 2015). Methylation of the HPV 16 E2 gene (using 
the same assays as described in this thesis) has also been recommended for further 
study as a possible biomarker to help determine treatment pathways for VIN patients 
with topical drug treatments, cidofovir and imiquimod. This cohort of women had 
higher reported methylation than reported in this study, however the demographic of 
this cohort varied greatly from that included here, specifically women included in this 
study had VIN III and an average age of 47.2 years (range 20 – 81 years) (Jones, 
2016). This shows that the methods of viral methylation reported here can be 
successfully applied and suggests that this young cohort of women is not a suitable 
cohort of women for application of this biomarker but does not rule out its application 
in other patient groups.  
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4 Chapter 4  
Gene disruption, expression and methylation of HPV 16 in 
anogenital disease 
 
Results in Chapter 3 indicated that neither disruption nor methylation of the 
HPV E2 gene were reliable biomarkers for defining anogenital disease in young 
women attending their first cervical smear. Nevertheless, HPV methylation and 
integration into the host genome can be expected to have a major impact on the 
oncogenic process and could potentially have utility in predicting progression to high-
grade cervical neoplasia in women with cervical disease. Previous work reported in 
this thesis utilised nucleic acid extracted from clinical samples which were stored in 
SurepathTM LBC media. To improve DNA/RNA quality (by reducing DNA/RNA 
degradation and sample impurities) in this chapter samples were investigated that 
had been collected in RNAprotect® media (QIAGEN Ltd, Manchester, UK) as 
described in section 2.1.2. 
 
 
 Clinical Cohort 4.1
 
Women attending a colposcopy clinic in University Hospital Llandough, Wales 
between March 2011 and April 2014 were invited to donate a cervical smear sample 
for investigation in this study. The study protocol originally aimed to obtain 15 
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samples from women with a mild, moderate and severe initial colposcopy 
impression. The study target population was extended to include samples with an 
initial cancerous colposcopy impression. Samples were obtained by taking an 
additional cervical smear with a standard cytology brush which was then transported 
to the HPV Research Group, Cardiff University. A detailed study protocol is included 
in Appendix 2. 
 
Samples were collected from 51 patients with mild (n = 11), moderate (n = 5), 
severe (n = 16) and cancerous (n = 19) initial colposcopy impression. Additional 
clinical information was made available and included any treatment for anogenital 
disease and cervical histology results (Table 4.1). Results were then categorised 
based on cervical histology result where available (90.2%) as this is the gold 
standard for assessing the presence and degree of cervical disease. In samples with 
histology reported between two categories (e.g. CIN I/CIN II or CIN II/CIN III) 
samples were categorised by the highest histology grade. Of the five samples 
categorised as ‘no reported histology’ three had no histology data reported and two 
had ungraded CIN. As these two samples could not be correctly categorised they 
were designated as not reported and were not included in any subsequent analysis. 
On average, women with cancer were older than women with negative histology or 
CIN and had the largest range of patient ages (18 to 84 years of age, average age 
49.8 years).  
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Table 4.1. Summary of clinical cohort categorised by sample histology. The 
average age of patients at the time of sampling has been shown along with the age 
range of all individuals within each category. Colposcopy impression refers to the 
initial categorisation of patients when the smear sample was taken. HR-HPV 
infections were identified using Papillocheck® and divided into HPV 16 single 
infections (HPV 16 SI), multiple infections with HPV 16 plus 1 or more other HR-HPV 
types (HPV 16 MI), other single HPV infections, excluding HPV 16 (HR-HPV SI) and 
samples with multiple HPV types, excluding HPV 16 (HR-HPV MI). 
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 HPV typing 4.2
 
HPV typing was performed using commercial DNA-array PapilloCheck® (as 
described in section 2.1.2). A single HPV type was detected in 15 samples, while 26 
samples were infected with two or more HPV types, accounting for 98 HPV 
infections in total. Samples with cancer accounted for most single infections (60%) 
and HPV 16 was the most prevalent single infection (73.3%). The most prevalent 
HPV types in samples with multiple infections were HPV 33 (12.0%), HPV 16 
(10.8%) and HPV 39 (10.8%). Samples with cancer had on average 0.88 HPV 
infections per sample; however negative, CIN I, CIN II and CIN III samples contained 
on average 2.55 HPV types per sample. A negligible negative correlation is present 
between the severity of histology and the average number of HPV infections per 
sample (rs = -0.115, p = 0.531). 
 
Ten samples tested negative for HPV using the Papillocheck® assay (Not 
reported n = 1, negative n = 3, CIN III n = 1, Cancer n = 5). To verify this result, 
‘negative’ samples were tested a second time using type specific primers for HPV 
16. This showed that 6 samples (negative n = 2, Cancer n = 4) were positive for HPV 
16 DNA. These samples were included in subsequent analysis of HPV 16 
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biomarkers but not included in this HPV typing analysis (Figures 4.1), as these 
samples may or may not contain more HR-HPV types. 
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 HPV 16 Genome Disruption 4.3
 
HPV genome disruption was used in this study as a substitute marker for HPV 
integration. Samples were considered to have a disrupted HPV genome if the E6 
gene was detectable but the E1 and/or E2 genes could not be detected by PCR 
analysis. This model is indicative of viral integration although is not a definitive 
biomarker (described in section 1.3.1). HPV genome disruption was assessed in 
HPV 16 positive samples as determined by Papillocheck® and/or type specific E6 
PCR (n = 32). The average age of samples tested for genome disruption was 40 
years old (18 to 84 years) and had varying histology (not reported n = 1, no CIN n = 
4, CIN II n = 3, CIN III n = 10 and Cancer n = 14). HPV gene disruption was seen in 
12 samples (37.5%), with CIN II (n = 2), CIN III (n = 4) and cancer (n = 6) (Figure 
4.2), although there was not a significant difference in level of integration compared 
to disease grade (X2(1) = 0.545, p = 0.46). 
 
There was very little difference in the average age of samples with and without 
viral integration, 40.1 years and 39.9 years respectively. There was a difference in 
the prevalence of viral integration when comparing samples with single (63.63% 
integration) and multiple HPV infections (45.45% integration) however this difference 
is not statistically significant (X2 = 0.64, p < 0.1).  
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Viral gene disruption was present in 66.7% of samples with CIN II (n = 2), 40% of 
samples with CIN III (n = 4) and 42.9% of samples with cancer (n = 6), (Figure 4.2). 
When patient treatment was compared, 50% of women with viral genome disruption 
had a radical hysterectomy as part of their treatment compared 10% of women with 
no genome disruption (Table 4.2).  
 
The E1 region was at least partially disrupted in all samples with genome 
disruption and four samples had no E1 gene detectable by PCR (HI-BCD-5, HI-BCD-
8, HI-BCD-31 and HI-BCD-66). HI-BCD-5, HI-BCD-8 and HI-BCD-66 had previously 
tested positive for HPV 16 by Papillocheck®, indicating the E1 gene is present, but 
may be fragmented and/or only partially present. HI-BCD-31 was the only sample to 
have no detectable E1 or E2. This sample was also HPV 16 negative when 
assessed by Papillocheck®. The HPV 16 E2 gene was disrupted in only one other 
sample, HI-BCD-29, which had CIN II and received large loop excision of the 
transformation zone (LLETZ) treatment. Both samples with E2 disruption (HI-BCD-31 
and HI-BCD-29) came from young women, aged 26 and 27 years respectively with 
mild and mild/moderate colposcopy impression. Both women were diagnosed with 
low-grade HPV disease (CIN II and CIN I/II) and treated with LLETZ. All samples 
from women with moderate, severe and cancer colposcopy impression had intact E2 
(Table 4.2). 
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Figure 4.2 HPV 16 viral disruptions in samples with no reported disease, CIN II, 
CIN III and Cancer. Samples were considered disrupted if one or more of full-length 
HPV 16 E1/E2 primers failed to amplify the target DNA with amplification of the HPV 
E6 gene (X2(1) = 0.545, p = 0.46). 
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HPV genome disruption was further investigated by using the DIPS assay to 
identify virus/host integration sites. In DIPS analysis samples are digested and 
adapters are ligated to the digested DNA. HPV specific linear PCR is followed by a 
nested PCR with primers specific from the adapter and HPV. PCR products are then 
sequenced to identify viral/host fusion sites (described in Methods section 2.4.3). 
DIPS analysis was carried out on 32 samples. HPV 16 only transcripts were 
detected in 13 samples and viral-host fusion sites were identified in 5 samples with 
CIN I (n = 1), CIN III (n = 3) and Cancer (n = 1). Findings from the DIPS analysis 
have been summarised in Table 4.3. 
 
Table 4.3 HI-BCD Samples with viral integration identified by DIPS. Samples HI-
BCD-50 showed integration at two sites in the HPV and human genome. Human 
locations noted with a * were integrated into a known common fragile site of the 
human genome.  
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HI-BCD-19 came from a 36-year-old woman who had a moderate colposcopy 
impression and histological analysis diagnosed CIN I. This sample had multiple HPV 
infections identified (HPV 16, 56, 58 and 66). The integration event was detected in 
the L1 region of the HPV genome and at locus 9q21.3 in the human genome. As 
would be expected, E1/E2 PCR did not detect this integration event.  
 
HI-BCD-8 and HI-BCD-9 both had a severe colposcopy impression and both 
were subsequently diagnosed with CIN III. HI-BCD-8 came from a 29-year-old 
woman with multiple HPV infections (HPV 16, 18, 31, 59 and 66). Viral disruption 
was detected in the E1 region of the HPV genome and integrated into chromosome 
11 at locus 11p12. HI-BCD-9 also came from a 29-year-old women with two HPV 
infections identified (HPV 16 and 18). This sample had viral genome disruption 
identified in the E1 region of HPV genome and at locus 6q15 of the human genome. 
This is a known common fragile site in the DNA, FRA6G. HI-BCD-8 had no E1 
detected by the E1/E2 PCR however HI-BCD-9 had full length E1 and E2 present. 
These results suggest that HI-BCD-8 has a fully integrated HPV 16 infection and HI-
BCD-9 is a mixed infection with both integrated and episomal HPV DNA present 
which is masking the genome disruption in the E1/E2 PCR assay. 
 
Sample HI-BCD-46 had initial cancerous colposcopy impression however the 
patient was the patient was diagnosed with CIN III by histological analysis. HI-BCD-
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46 came from a 31-year-old woman with a single HPV 16 infection. Viral disruption 
was detected by the E1/E2 PCR assays and DIPS confirmed disruption in the E1 
region of HPV and integrated into chromosome 3, locus 3q25.33. This is the location 
of common fragile site FRA3D and encodes for Interleukin-12A (IL12A), a subunit of 
Interleukin 12. 
 
Individual HI-BCD-50 had initial cancerous colposcopy impression and was 
subsequently diagnosed with invasive squamous cell carcinoma (SCC) (Figo Stage 
1b1). This sample came from a 34-year-old woman with a single HPV 16 infection. 
Two viral-host fusion sites were identified in this sample, the first was between the 
E1 gene and chromosome 9 within a common fragile site (9p21.3) and between HPV 
E2 gene and chromosome 3 (3q26.32). Histological analysis identified invasive SCC 
(FIGO stage 1b1) in HI-BCD-50. In the E1/E2 PCR analysis the E1 genome was 
disrupted however full length E2 was detected, suggesting that sample HI-BCD-50 
has a mixed infection of integrated and episomal HPV forms.  
 
 
 Viral genomic DNA methylation 4.4
 
In chapter 3, a moderate negative correlation between increasing cytology 
grade and viral methylation was observed (rs = -0.203, p = 0.004) however this work 
did not support the use of methylation as a biomarker of HPV disease in young 
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women, this may have been due to a high level of transient HPV infections in this 
young population. This subsequent work aimed to assess viral methylation as a 
biomarker for HPV disease in a population attending a colposcopy clinic, including a 
mix of ages and cervical disease.  
 
Analysis of HPV 16 DNA methylation was successfully carried out in 68% (n 
= 22/32) of HPV 16 positive samples and in 40% (n = 4/10) of samples that were 
HPV 16 negative by Papillocheck®. The average age women included in the 
methylation analysis was 39.54 years (18 to 80 years) and when comparing the age 
of patients at the time of sampling to the average level of viral methylation there is a 
trend for increased viral methylation with an increase in age, however this was not 
significant (rs = 0.413, p = 0.56) (Figure 4.3). 
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Figure 4.3. Age of participants compared to the average viral methylation 
across all 8 CpG points analysed. The blue dots each represent a patient sample 
and the black line is the linear trend of the data. (rs = 0.413, p = 0.56) 
 
 The average viral methylation detected in samples with no CIN (6.22%, n = 
3), CIN II (4.67%, n = 1), CIN III (6.41%, n = 10) and cancer (21.60%, n = 9) 
histology showed a positive correlation between the level of viral methylation and 
disease grade, although this did not reach significance (rs = 0.408, p = 0.06) (Figure 
4.4). When Figure 4.4 is considered there are two samples with higher levels of viral 
methylation compared to the cohort, HI-BCD-52 and HI-BCD-53. If these outlier 
samples are removed from the analysis, the average viral methylation in the 
cancerous colposcopy impression is reduced to 10.10% and the correlation between 
disease grade and viral methylation is reduced (rs = 0.283, p = 0.22). 
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Samples with high methylation HI-BCD-52 and HI-BCD-53 both have a single 
HPV 16 infection that was disrupted in the E1 region as identified by E1/E2 PCR 
and in both samples viral-host fusion transcripts were not identified by DIPS. Both 
women had adenocarcinoma identified by histological analysis and went on to have 
radical hysterectomies. 
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Figure 4.4 Comparison of viral DNA methylation levels in samples with (A) CIN 
III histology and (B) Cancer histology There was a positive correlation between 
the level of viral methylation and disease grade, although this did not reach 
significance (rs = 0.408, p = 0.06). 
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When viral methylation levels were compared between samples with disrupted 
genome vs. undisrupted genome there was no significant variation in the levels of 
viral methylation (X2(1) = 0.085, p = 0.770) (Figure 4.5). However when individual 
CpG sites were considered there was a significant variation in levels of viral 
methylation compared to gene disruption at three sites; CpG 3416, CpG 3435 and 
CpG 3447 (CpG 3416 X2(1) = 4.281, p = 0.039; CpG 3435 (X2(1) = 7.113, p = 
0.008); CpG 344 (X2(1) = 4.020, p = 0.045). 
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Figure 4.5 viral methylation levels were compared between samples with 
disrupted genome and intact E2 genome. (X2(1) = 0.085, p = 0.770). 
 
Across all 8 CpG sites, samples with a single HPV 16 infection had lower 
methylation compared to samples with multiple infections; however this result was 
not statistically significant (X2(2)= 1.11, p = 0.53) (Figure 4.6).  
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Figure 4.6. Trends in viral DNA methylation in samples with a single HPV16 
infection compared to samples with HPV 16 plus one or more other HR-HPV 
types. At all CpG sites samples with multiple HPV types (shown in red) had a higher 
level of viral DNA methylation compared to samples with only HPV 16 infection 
detected (shown in blue) (X2(2) = 1.11, p = 0.53). 
 
 
 Viral RNA expression 4.5
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In Chapter 3, it was not possible to assess viral RNA expression in samples 
from young women attending their first cervical smear due to sample storage in 
SurePathTM LBC Media, which meant viable viral RNA was not available for analysis. 
In this study, however, storage conditions were designed to ensure that RNA could 
be obtained. HPV E2 and E6 gene expression was assessed using qRT-PCR and 
normalised to human housekeeping genes HPRT and TBP2 (described in Methods 
section 2.5). When E2 and E6 expression levels are equivalent to zero their 
expression is comparable to housekeeping genes. When viral gene expression 
levels are quantified above or below zero, this indicates HPV gene expression is 
greater or lower than that of the house keeping genes (Tables 4.4 and 4.5). 
 
In the 32 samples analysed, 28% of samples failed to amplify any gene target. 
In addition, 25% of samples (n = 8/32) amplified the E2 gene but failed to amplify E6. 
Most samples (87%, n = 7/8) with detectable E2 but no E6 gene expression had 
cancerous colposcopy impression and 50% of samples had genome disruption in the 
E1 gene. Notably, samples HI-BCD-52 and HI-BCD-53 had high levels of viral DNA 
methylation and both amplified HPV 16 E2 gene but failed to amplify E6 (Table 4.5). 
Subsequent analysis described in this chapter includes samples which successfully 
amplified reference genes HPRT and TBP2 as well as both HPV genes; this reduced 
the sample size for analysis down to 14 samples. These 14 samples included two 
samples with no CIN detected, two samples with CIN II, six samples with CIN III and 
four samples diagnosed with Cancer. 
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Table 4.4 Summary of samples tested for HPV 16 viral gene expression with no 
CIN to CIN III. CNRQs of E2 and E6 gene expression are shown and these values 
are normalised to two reference genes HPRT and TBP2. 
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Table 4.5 Summary of samples tested for HPV 16 viral gene expression with 
Cancer. CNRQs of E2 and E6 gene expression are shown and these values are 
normalised to two reference genes HPRT and TBP2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
158 
 
The gene expression results were compared to histology and low E2 and E6 
gene expression is seen in samples with no CIN (E2 = -1.06, E6 = -2.79) and CIN II 
(E2 = -1.11, E6 = -1.23). This highest E2 and E6 levels are present in samples with 
CIN III (E2 = 1.22, E6 = 0.76) and Cancer (E2 = 0.14, E6 = 0.11). A trend can be 
seen with increased E2 and E6 gene expression in CIN III and cancer samples 
compared to no CIN and CIN II, however these results were not significant (E2 
expression, X2(3) = 4.07, p = 0.254, E6 expression, X2(3) = 5.75, p = 0.13) (Figure 
4.7). 
 
 
 
 
 
 
 
Figure 4.7 Viral E2 and E6 gene expression in samples with varying 
histological outcomes (n = 15). The CNRQs of E2 and E6 gene expression are 
shown. Values are normalised to reference genes HPRT and TBP2. (E2 expression, 
X2(3) = 4.07, p = 0.254, E6 expression, X2(3) = 5.75, p = 0.13) 
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 Discussion 4.6
 
This section will highlight the key findings from this chapter and the strength and 
limitations of this study. Each of the key findings will then be considered in greater 
details compared to the available literature. 
 
 
4.6.1 Key Findings 
 
The key findings from work presented in this chapter: 
1. Samples with cancer accounted for most single infections and HPV 16 was 
the most prevalent single infection. 
2. Viral disruption was present in 37.5% of samples; however, there was no 
significant disruption between different histology.  
3. There was a non-significant trend of increased viral methylation with increase 
in patient age and cervical histology. 
4. Overall there was no significant association between viral methyaltiuon and 
genome disruption; however there was a significant difference between 
methylation levels and gene disruption at three sites; CpG 3416, CpG 3435 
and CpG 3447. 
5. There was no significant association between HPV 16 E2 and E6 gene 
expression compared to cervical histology. 
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4.6.2 Strengths 
 
This study was designed to obtain DNA and RNA which were of a suitable 
quality for analysis. In the research presented in Chapter 3 of this thesis RNA could 
not be obtained for analysis, these samples were stored in SurePathTM which lead to 
nucleic acid degradation. To eliminate this problem samples in this study were stored 
in RNAprotect® (Raybould, 2013). RNAprotect® stabilises the RNA within the sample 
which can then be stored at room temperature during storage and transport before 
DNA and RNA extraction can be performed (QIAGEN, 2017c). This made it possible 
for HPV 16 E2 and E6 expression to be measured by qRT-PCR. 
 
In this study samples were collected from women with different cervical 
cytology and subsequent cervical histology which produced a broad range of disease 
grades to be included in this study. Women included in this study had a wide age 
range so viral biomarkers studied in chapter three could be studied in a cross-section 
of women with different ages. 
 
 
4.6.3 Limitations 
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This pilot study originally intended to collect 45 samples (15 samples with mild 
dyskaryosis, 15 with moderate dyskaryosis and 15 with severe dyskaryosis) however 
a low number of women with mild and moderate dyskaryosis were recruited onto this 
study (mild dyskaryosis – n = 11, moderate dyskaryosis – n = 5). The decision was 
taken to extend the study to include women with cervical cancer. The final cohort 
contained a small number of samples (n = 51) and consequently it was not possible 
to draw statistically significant conclusions from trends seen in the data.  
 
The small sample size also resulted in the inclusion of samples with multiple 
HPV infections in the molecular analysis of HPV 16 integration, methylation and 
gene expression. As these samples were obtained via cervical smear test, multiple 
sites of HPV infection may be sampled in each smear test, only one of which is 
driving neoplastic progression. It therefore would be advantageous in the 
assessment of potential biomarkers to only assess samples with a single HPV 
infection in order that the infection driving disease progression can be identified. 
Samples with multiple infections were excluded from analysis in chapter 3 as it 
cannot be determined which HPV type is driving cervical disease progression in 
samples with multiple HPV infections. Similarly, there are several unknown variables 
such as comorbidities, use of hormonal contraceptives, previous pregnancies etc. 
This inclusion of multiple HPV infections and unknown comorbidities must be 
considered when interpreting the results presented in this chapter.  
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4.6.4 Samples with cancer accounted for most single infections and HPV 16 
was the most prevalent single infection. 
 
This pilot data showed a greater number of multiple HPV infections in 
samples with CIN I, CIN II and CIN III when compared to samples with cancer. In 
progression from CIN I to cancer, samples with multiple HPV infections may be less 
prevalent due to clonal selection and outgrowth of a single, dominant transformed 
cell with one HPV infection (Van Tine et al., 2004). This theory is in agreement with 
other studies which demonstrate that women with CIN III+ are less likely to have 
multiple HPV infections (Lau et al., 2015, Tjalma et al., 2015).  
 
Recent work by Depuydt et al (2016) has described a method of determining 
the active HPV type driving disease in a sample with multiple HPV infections. This 
method used qRT-PCR to calculate which HPV-induced processes were ongoing. In 
samples with CIN I the results were similar regardless of single or multiple infections. 
However, in samples from CIN III+ a HPV type driving disease could clearly be 
identified. This model should be employed in further studies with multiple HPV 
infections to identify which HPV type is driving disease (Depuydt et al., 2016) 
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4.6.5 Viral disruption was present in 37.5% of samples; however there was no 
significant disruption between different histology.  
 
In this study, HPV gene disruption was identified in 37.5% of samples with 
gene disruption in 50% of cancer cases (n = 7/14). This result was lower than 
expected with other studies reporting viral integration in around 70% of cervical 
cancer cases (Pett and Coleman, 2007, The Cancer Genome Atlas Research, 
2017). Work reported elsewhere has shown a positive correlation between severity 
of histology and viral integration (Hudelist et al., 2004, Li et al., 2008, Manawapat et 
al., 2012). The lack of significant conclusions reported in this thesis may in part be 
due to the small sample size. Increasing the size of clinical cohort in future work may 
allow for significant associations to be made between disease grade and integration.  
 
Interestingly in this work HPV E1 gene was most commonly disrupted site in 
the viral genome and the E2 gene was identified in all but two HPV 16 samples. As 
described earlier (Introduction section 1.3.1) integration of HPV is a random event 
which has been shown to occur at a higher frequency in or near common fragile sites 
(Thorland et al., 2003, Jiang et al., 2015). Three of the six fusion transcripts identified 
by DIPS, in samples HI-BCD-9, HI-BCD-46 and HI-BCD-50, were integrated into 
known common fragile sites, FRA6G, FRA3D and FRA9C respectively. Also, HI-
BCD-46 was inserted into the host genome at locus 3q25.33 that encodes for 
Interleukin-12A (IL-12A), a subunit of Interleukin 12 that acts on natural killer and T 
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cells (NCBI, 2017). IL-12A has been considered as a potential marker of cervical and 
vulval cancer (Chang et al., 2015, Zhang et al., 2014). 
 
The low level of gene disruption and integration reported here may have been 
caused by a mixed infection of episomal and integrated HPV, either within the same 
lesion or multiple lesions on the cervix. In the work by The Cancer Genome Atlas 
Research Group (2017) they assessed viral integration by RNA-Seq Whole 
Transcription Sequencing which can detect viral integration events in samples which 
have mixed infections of episomal and integrated HPV (The Cancer Genome Atlas 
Research, 2017).  
 
The APOT assay or RNA-Seq could be utilised to overcome the limitations 
presented by the HPV 16 E2 tiling PCR assay and identify actively transcribed HPV-
human transcripts in samples with mixed HPV infections, however APOT requires 
high-quality RNA to provide suitable results (Klaes et al., 1999). Previous work by 
Raybould (2013) showed that due to RNA degradation APOT could not be carried 
out on these clinical samples. It was suggested that this may be due to natural 
degradation of RNA in cells at the surface of the cervix which are sampled during a 
cervical smear test (Raybould, 2013). APOT and RNA-Seq may be more suitable for 
application in RNA taken from biopsy tissue specifically preserved and extracted to 
ensure high quality and quantity of RNA can be obtained. Future research should 
consider carrying out RNA-Seq to determine if viral integration events are present 
even in a background of episomal RNA transcripts.  
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4.6.6 There is a trend observed with increased viral methylation and 
increased patient age and cervical histology and there was a significant 
difference between methylation levels and gene disruption at CpG sites 
CpG 3416, CpG 3435 and CpG 3447 
 
This work has shown a trend of increased viral methylation with an increase in 
age of the patients. Changes in host methylation has been shown to occur as people 
age (Jung and Pfeifer, 2015) and this change in global and local methylation may in 
part contribute to the methylation levels observed here. Methylation has also been 
linked with other comorbidities including obesity and smoking which can increase the 
incidence of age-associated DNA methylation (Noreen et al., 2014). Information on 
potential co-morbidities was not available for samples in this cohort and these may 
be contributing to the increase in age-associated methylation seen in this study. 
 
In this study, the highest levels of viral methylation were present in samples 
with cancer, compared to samples with no CIN, CIN II or CIN III. This agrees with 
the suggested association from Chapter 3 of this thesis and elsewhere (Mirabello et 
al., 2012) that viral methylation may be a suitable biomarker in an older population 
of women. Apart from HPV methylation, the methylation of human genes has also 
been studied as a potential biomarker for HPV disease progression. Methylation of 
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human genes p16, MGMT, FHIT, CADM1 and MAL have all been suggested as 
potential biomarkers for HPV driven cervical disease (Bierkens et al., 2013, Virmani 
et al., 2001, van Baars et al., 2016) 
 
This work has also demonstrated a significant difference between viral 
methylation levels with gene disruption at CpG 3416, CpG 3435 and CpG 3447. 
However overall there was no significant association between viral disruption and 
viral methylation when all CpG sites were considered. This result suggests that 
there is a potential clinical utility for methylation as a biomarker for HPV integration, 
although viral integration is not a prerequisite for disease presence and progression. 
Further study into the relationship between viral methylation and clinical outcome is 
required to assess methylation as a biomarker in BIDD assay development stage 2. 
This result partially supports Hypothesis 4; Disruption of viral E2 gene coincides with 
hypermethylation of viral DNA in HR-HPV 16 infections.  
 
 
4.6.7 There was no significant association between HPV 16 E2 and E6 
expression compared to cervical histology. 
 
In this study, there was an increase in both HPV 16 E2 and E6 gene expression 
with an increase in cervical histology. These results did not reach significance, 
however that may in part be due to the small sample size (n = 14). A recent study by 
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Cerasuolo et al (2017) has shown that HPV 16 E6 gene expression were 
consistently high in cervical cancer with low expression of E2 in cancer and CIN 
(Cerasuolo et al., 2017). This study used only a single reference gene, GAPDH, to 
standardise the results of the qRT-PCR analysis. MIQE Guidelines suggest that 
normalization against a single reference gene is not an acceptable form of 
normalization and the optimal number and choice of reference gene must be 
reported (Bustin et al., 2009). In this thesis reference genes were decided based on 
work carried out by geometric averaging of multiple internal control genes for a given 
set of tissues, based on high stability and expression levels in epidermal 
keratinocytes HPRT and TBP-2 were chosen as reference genes (Vandesompele et 
al., 2002, Allen et al., 2008). 
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5 Chapter 5  
A model of HPV16 neoplasia - gene expression, viral genomic 
DNA methylation and integration in differentiated epithelium 
 
A major aim of the study was to characterise molecular changes induced by 
HPV 16 neoplasia to identify useful biomarkers of disease progression. To facilitate 
this process, an in vitro system was sought to establish a model of in vivo pathology. 
To this end, a system to culture stratified epithelium (organotypic raft cultures) was 
established which could be seeded with HPV-transformed cells lines. This 
technology was used to assess the regulation of virus gene expression, cell 
proliferation and histology of HPV-transformed cells in stratified cultures. This work 
was carried out with to establish the association between histology of HPV-
transformed cell lines and molecular markers of disease. Molecular profiles could 
then be applied as part of future anogenital screening to predict disease presence 
and progression. 
 
 
 Rational for cells and organotypic raft culture 5.1
 
Cell lines used in this study were derived at Cardiff University via ring cloning 
in heterogeneous populations from patients with high grade intraepithelial neoplasia. 
(Bryant, Onions, et al. 2014). There is a direct causal relationship between HPV 16 
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infection and VIN/Vaginal Intraepithelial Neoplasia (VaIN), the precursor to 
vulval/vaginal cancer. Cell lines CU-VU-8M-16I and CU-VU-8P-16E originated from 
a biopsy taken from a 46-year-old women undergoing her first treatment for VIN 
grade III, while cell lines CU-VA-9A-16E and CU-VA-9H-16I came from a 31-year-
old woman with VaIN III (Onions 2013). As a positive control cell line W12 Ser4B 
was used to represent a high-grade cervical disease, this is a well-defined cell line 
with integrated HPV 16 genome (Doorbar et al. 1990). Human epithelial 
keratinocytes, neonate (HEKn) primary cells were used to represent a HPV negative 
culture. Information on the origin of cell lines used and culture conditions can be 
found in Methods section 2.6.  
 
Organotypic raft culture of epithelial cells provides an efficient system that 
recapitulated the full differentiation of primary human keratinocytes, thereby 
supporting the complete HPV lifecycle through to the production of virus particles. 
(Andrei et al. 2010; Delvenne et al. 2001). Differentiation is the process by which 
cells become more specialised and in a ‘normal’ epithelium the cells in the upper 
layers become elongated and unable to carry out mitosis. They provide a barrier for 
the differentiating cells in the basal layer and are slowly lost over time as they are 
replaced with new terminally differentiated cells. However in cases where 
differentiation is lost the cells continue to mitosis in the upper layers of the 
epithelium, and do not become elongated (Thiery et al., 2009). 
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In this work, the organotypic raft culture was used to produce a stratified 
epithelium to emulate the natural process of differentiation. Histology was defined as 
“in keeping with low-grade intraepithelial neoplasia” or “in keeping with high-grade 
intraepithelial neoplasia” by an independent pathologist from UHW, Cardiff, Dr Owen 
Weeks. 
 
When seeded on to raft culture w12 Ser4B cells had little differentiation and 
show features such as keratin pearls, irregularities in the cell nucleus and apoptotic 
debris. HEKn cells showed differentiation through the stratified epithelium and cells 
detaching from the top of the epithelium as would be expected in a non-transformed 
epithelium. These phenotypes match the anticipated outcome with w12 Ser4B 
showing histology consistent with high-grade intraepithelial neoplasia and HEKn 
cells displaying a differentiated phenotype as would be expected in a non-
immortalised cell line. 
 
Cell lines CU-VA-9A-16E and CU-VU-8M-16I both exhibited abnormal 
morphology like that of a low-grade intraepithelial neoplasia (Figure 5.1). CU-VA-9A-
16E (Figure 5.2 (A)) shows minimal differentiation and significant desquamation of 
the cells. Numerous apoptotic figures are also present along with prominent 
formation of keratin pearls. CU-VU-8M-16E has formed a prominent band of 
parakeritosis on the surface, suggesting this model is more like that of a condyloma 
(Figure 5.1 (D)). Parakeritosis on the surface is normally present in true mucosal 
membranes such as the vagina and the oral cavity (Ferey et al.1985). The presence 
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of the parakeritosis in cells derived from the vulva is unusual and would be expected 
in cells such as CU-VA-9A-16E or CU-VA-9H-16I that originated in the vagina. 
 
Cell lines CU-VA-9H-16I and CU-VU-8P-16E showed morphology in keeping 
with high-grade intraepithelial neoplasia. CU-VA-9H-16I shows a thick epithelium, 
which lacks maturation, however there is a slight flattening of cells on the surface of 
the raft (Figure 5.1 (B)). The cells are pleomorphic, including multinucleate cells and 
numerous apoptotic bodies. An occasional cell in mitosis was detected high up the 
epithelium. This morphology is very like that of the positive control W12 Ser4B. CU-
VU-8P-16E lacks differentiation and has similar morphology to CU-VA-9H-16I. There 
are numerous apoptotic bodies and pleomorphic cells with morphology consistent 
with a high-grade lesion (Figure 5.1 (C)). 
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Figure 5.1 H&E staining of raft sections (A) CU-VA-9A-16E (B) CU-VA-9H-16I (C) 
CU-VU-8P-16E (D) CU-VU-8M-16I (E) W12 Ser4B (F) HEKn. Features: apoptotic 
bodies (I); keratin pearls (II); multinucleated cells (IV); mitosis in the high epithelium 
(III); irregularities in the cell nucleus (IV); parakeritosis on the surface (V); apoptotic 
debris (VI). Images and pathology assessment carried out by independent 
pathologist Dr Owen Weeks. 
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This is the first time that HPV 16 positive cell lines derived from VIN and VaIN 
lesions have been grown in an organotypic raft culture. HPV genome status 
(episomal or integrated) defined in monolayer did not predict morphology of cells 
when grown in a stratified epithelium. Cell lines that originated from a single patient 
sample (CU-VA-9A-16E / CU-VA-9H-16I and CU-VU-8M-16I / CU-VU-8P-16E) both 
showed markedly different phenotypes. This work has established a suitable system 
for further analysis for the regulation of HPV and human genes to establish if cell 
lines with morphology in-keeping with a low-grade lesion have a distinct molecular 
profile compared to cell lines with morphology in-keeping with a high-grade lesion. 
 
 
 Gene expression in organotypic raft cultured cells 5.2
 
The HPV genome encodes eight proteins that are differentially expressed at 
various stages of the viral replication cycle (Introduction section 1.1). In a productive 
infection, the expression of viral proteins is tightly regulated in parallel with the host 
cell differentiation to enable efficient release of high titre virus. However, in a 
transforming viral infection, the natural progression of viral transcriptional programme 
is disrupted, viral capsid proteins are not synthesised and the expression of viral 
oncogenes enhanced (Graham, 2010). HPV can also lead to changes in host cellular 
proteins involved in tumour suppression and cellular proliferation, leading to a 
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productive infection developing into a transforming infection. Changes in the host cell 
cycle and host cell proliferation can be used as surrogate markers for HPV infection 
and transformation (Litjens et al. 2013). 
 
In this study, expression of human proteins p16 and Ki-67 were used as a 
substitute marker of HPV gene expression. Further it has been suggested that the 
Hedgehog genes are inappropriately expressed during HPV infection (Samarzija and 
Beard, 2012). Therefore SHH and GLI1 expression was investigated to assess if 
expression was altered in HPV 16 positive VIN and VaIN cells when cultured in 
stratified epithelium. The viral lifecycle was also assessed using the viral E4 protein 
as a marker of late gene expression to determine if the whole viral lifecycle is being 
completed. Histology was quantified using ImageJ, IHC Profiler and by measuring 
the proportion of the culture stained (Methods section 2.8.3) 
 
Images of IHC analysis for p16 and Ki-67 expression in organotypic raft 
cultures is shown in Figures 5.2 and 5.3. IHC results were quantified by grading the 
positive pixels in the selected raft cultures as a marker of the amount of stain the 
cells have taken; data is shown in Table 5.1 and Figure 5.4. IHC results were also 
quantified by measuring the depth of the culture that has taken in the IHC stains and 
the results of this are shown in Figure 5.5. 
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Host tumour suppressor protein p16 is instrumental in regulating the cell cycle 
and is up regulated by HPV E7 protein. In ‘normal’ epithelium, p16 expression is high 
only in the basal layer where cells are actively cycling. However, with increasing 
epithelial neoplasia, p16 expression expands to the upper layers of the epithelium. 
The positive control, w12 Ser4B had high p16 expression (86.1% high 
positive/positive pixels (HP/P pixels)) throughout the culture typical of a high-grade 
epithelial neoplasia (Figure 5.2 (A)). The negative control, HEKn had p16 expressed 
in under half of the cultures and HP/P pixels were 65.3% lower than those expressed 
in w12 Ser4B epithelium (Figure 5.2 (C)). 
 
CU-VA-9H-16I and CU-VU-8P-16E both show similar p16 expression levels 
to w12 Ser4B, with high levels of HP/P pixels throughout the culture (69.8% and 
71.2% respectively). CU-VU-M8-16I has p16 expressed in the lower 63% of the 
epithelium with 32.2% HP/P pixels but no p16 expression in the parakeratin layer on 
the surface of the culture. CU-VA-9A-16E has the lowest expression of p16 and is 
only expressed at low levels (7.3% HP/P pixels) in the lower quarter of the 
epithelium (22%) (Figure 5.3) 
 
Ki-67 is a marker of cell proliferation, in ‘normal’ epithelial cultures Ki-67 
should be expressed in the basal layer of the epithelium as these cells are actively 
proliferating. Positive control w12 Ser4B has Ki-67 expression in the lower 87% of 
the culture (16.3% HP/P pixels) indicating that cellular proliferation is occurring 
beyond the basal layer of the epithelium (Figure 5.2 (B)). The negative control, HEKn 
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had low levels of Ki-67 expression (11.8% HP/P pixels) confined to basal layer of the 
culture in keeping with normal epithelial cultures (lower 34% of the culture) (Figure 
5.2 (D)). 
 
Raft cultures CU-VA-9H-16I, CU-VU-M8-16I and CU-VU-8P-16E all showed 
similar levels of Ki-67 when the percentage spread of stain in the culture was 
measured (76%, 69% and 60% respectively) however when the number of positive 
pixels is compared only CU-VA-9H-16I has a level of HP/P pixels comparative to 
w12 Ser4B. CU-VU-M8-16I and CU-VU-8P-16E both have a similar percentage of 
HP/P pixels, measured at 4.9% and 6.8% respectively. Culture CU-VA-9A-16E has 
the lowest level of Ki-67 expression compared to all other cultures including negative 
control HEKn, (25% of culture, 1.2% HP/P pixels) (Figure 5.3). Full depth p16 
staining is present in CU-VA-9H-16I, CU-VU-8P-16E and w12 Ser4B with histology 
“in keeping with high-grade morphology”. Cultures with histology ‘in keeping with 
low-grade morphology’ CU-VA-9A-16E, CU-VU-M8-16I and HEKn had lower p16 
expression than samples with histology “in keeping with high-grade morphology” 
(22%, 63% and 47% respectively). There was a significant difference in both p16 
(X2(1) = 4.511, p = 0.034) and Ki-67 (X2(1) = 12.816, p >0.001) stain depth when cell 
lines with histology “in keeping with high-grade morphology” and cell lines with 
histology “in keeping with high-grade morphology” were compared. CU-VA-9A-16E, 
which originated from the same biopsy as CU-VA-9H-16I, had the lowest level of p16 
and Ki-67 staining of all samples tested.  
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Figure 5.2 p16 and Ki-67 IHC analysis of W12 Ser4B (positive control) and 
HEKn (negative control) raft cultures. W12 Ser4B has a high level of full thickness 
p16 and Ki-67 expression. HEKn has p16 expression throughout the culture, 
although Ki-67 expression is restricted to the basal layer of the culture. 
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Figure 5.3 p16 and Ki-67 IHC analysis of vulval and vaginal organotypic raft 
cultures. Lowest expression is seen in cultures CU-VA-9A-16E and both cultures 
CU-VA-9H-16I and CU-VU-8P-16E have high expression of p16 and Ki-67. All 
cultures have lower expression of Ki-67 compared to p16. 
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Figure 5.5 Analysis of the depth of stain in each epithelial culture. The total 
depth of the cultures and the depth of the stained culture were measured in triplicate 
and the percentage depth of stain was calculated. There was a significant difference 
in both p16 (X2(1) = 4.511, p = 0.034). and Ki-67 (X2(1)= 12.816, p > 0.001). stain 
depth when cell lines with histology “in keeping with high-grade morphology” and cell 
lines with histology “in keeping with high-grade morphology” were compared. 
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5.2.1 SHH Gene Expression 
 
Cell lines in this study were stained for SHH (Figure 5.6 and 5.8) and GLI1 
expression (Figures 5.7 and 5.8). Epithelial cultures derived from human foreskin 
keratinocytes, BU21HFK and BU21HFK (HPV18), were used as the negative and 
positive controls respectively. BU21HFK (HPV 18) had the highest SHH expression 
(176.8%) and BU21HFK has low SHH expression (19.63%) (Figure 5.9). Cell lines 
CU-VA-9H-16I and CU-VU-M8-16I both had similarly high levels of SHH expression 
(142.9% and 119.5% respectively). The lowest level of SHH expression was present 
in cell line CU-VA-9A-16E (19.63%), cultures with morphology in-keeping with high-
grade disease. CU-VA-9H-16I and CU-VU-P8-16E both have high levels of p16 
(100% and 100%) and Ki-67 (76% and 60%), however culture CU-VU-M8-16I which 
shows morphology in-keeping with low-grade disease also showed similarly high 
levels of SHH. There was a significant variation in SHH expression when cell lines 
with histology “in keeping with high-grade morphology” and cell lines with histology 
“in keeping with high-grade morphology” were compared (X2(3) = 13.205, p = 0.004). 
 
 
GLI1 expression is lower than SHH expression in all cultures and increased 
expression is not associated with increasing neoplastic morphology (X2(3) = 0.105, p 
= 0.991) (Figure 5.9). Cells that have originated from the same clinical samples 
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appear to have similar GLI1 expression regardless of differing morphology (vaginal 
sample: CU-VA-9A-16E: 42.88%, CU-VA-9H-16I: 37.17%, Vulval sample: CU-VU-
M8-16I: 62.64%, CU-VU-P8-16E: 72.17%). There results suggest that changes to 
SHH expression may be modulated by HPV, but GLI1 is not. The raft culture we 
have employed here will facilitate the further study of SHH and GLI1 expression in 
HPV infected cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
184 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 VIN and VaIN epithelial culture immunofluorescent staining for SHH 
protein. Cultures CU-VA-9H-16I, CU-VU-8P-16E and CU-VU-8M-16I all show high 
levels of SHH expression throughout the culture (142.92%, 143.19% and 119.49% 
respectively) DAPI is shown as the control staining. 
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Figure 5.7 Immunofluorescent staining for GLI1 protein in VIN and VaIN 
epithelial cultures. CU-VU-8P-16E has the highest GLI1 expression is present in 
(72.17%) however there is less variation in expression compared to SHH expression. 
DAPI is shown as the control staining. 
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Figure  5.8 Immunofluorescent staining for GLI1 protein in epithelial cultures 
BU21HFK and BU21HFK (HPV 18). 
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Figure 5.9 Analysis of SHH and GLI1 expression compared to the expression 
of DAPI staining within the cultures. There was a significant difference in SHH 
gene expression (X2(3) = 13.205, p = 0.004), but not with GLI1 expression (X2(3) = 
0.105, p = 0.991) when cell lines with histology “in keeping with high-grade 
morphology” and cell lines with histology “in keeping with high-grade morphology” 
were compared. 
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5.2.2 HPV late gene expression 
 
E4 protein is expressed late in the virus lifecycle and facilitates the release of 
newly formed virus capsids from upper layers of the epithelium [Introduction section 
1.1] (Doorbar et al. 1997). Detection of the E4 protein in the upper epithelium is a 
substitute marker for late gene expression and indicative of a complete virus 
lifecycle. E4 expression was only detected in sample CU-VA-9A-16E while all other 
samples tested were negative. The E4 expression in CU-VA-9A-16E is in the mid to 
upper suprabasal layer and is primarily cytoplasmic (Figure 5.10). CU-VA-9A-16E 
had morphology ‘in keeping with low-grade disease’ and had the lowest levels of 
p16, Ki-67 and SHH when compared to other cultures.  
 
 
 
 
 
 
 
 
Figure 5.10 Example of E4 staining in CU-VA-9A-16E. 
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 HPV Genomic DNA Methylation 5.3
 
Work in Chapter 4 showed that HPV hypermethylation is common in HR-HPV 
16 infections and the highest level of hypermethylation was present in women who 
went on to be diagnosed with CIN/ II+. This increase in hypermethylation was also 
associated with samples which had a disrupted HPV genome. Cell lines used in the 
organotypic raft culture had varying HPV genome status (integrated or episomal) and 
this work aimed to evaluate if cultures with viral gene disruption had a higher level of 
hypermethylation of the viral DNA. 
 
HPV genomic DNA methylation analysis show cultures CU-VA-9H-16I and 
CU-VU-8M-16I have hypermethylation in the E2 region of the HPV genome (49.8% 
and 78.05% average methylation respectively). In previous analyses both of these 
cell lines have reported viral integration into the human genome (Bryant et al., 2014). 
Samples with previously defined episomal HPV infections, CU-VA-9A-16E and CU-
VU-8P-16E, had low level of viral genomic DNA methylation (3.0% and 12.7% 
average methylation respectively). This result was not significant (X2(3) = -1.209, p = 
0.313) however this may, in part, be due to the small sample size. Figure 6.8 show 
the average level of methylation in eight CpGs sites of the E2 gene of HPV16 
positive rafts.  
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Figure 5.11 Average E2 viral genomic DNA methylation at 8 CpG sites for cell 
lines grown in a stratified epithelium. There was no significant variation in viral 
methylation levels. when cell lines with histology “in keeping with high-grade 
morphology” and cell lines with histology “in keeping with high-grade morphology” 
were compared (X2(1) = 1.582, p = 0.208). 
 
 
 HPV Whole transcriptome sequencing and viral integration 5.4
 
HPV whole transcriptome sequencing evaluates all the RNA present in the 
cells at a single point in time, allowing for the evaluation of HPV and human gene 
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expression. Whole transcriptome has previously been carried out on cell lines CU-
VU-8M-16I and CU-VU-8P-16E. These cell lines were grown in monolayer and 
sequenced using SOLiD RNA (Bryant et al., 2014). Here, whole transcriptome 
sequencing was employed to validate HPV gene expression and to confirm actively 
transcribed viral integration events in the epithelial culture. 
 
 
5.4.1 Quality of samples 
 
Prior to whole transcriptome analysis each sample was tested in duplicate for 
RNA quality and quantity. Quantity was assessed using Thermo Scientific 
Nanodrop® 1000 Spectrophotometer and RNA integrity was assessed using Agilent 
2100 Bioanalyzer (carried out by Central Biotechnology Services, Cardiff University). 
Samples CU-VA-9A-16E, CU-VA-9H-16I and CU-VU-8P-16E achieved a suitable 
RNA integrity number (RIN) and quantity of RNA for whole transcriptome analysis. 
However, sample CU-VU-8M-16I was excluded from further analysis as the RNA 
was at a level that could not be detected by either analysis (Table 5.2). To further 
improve results for samples CU-VA-9A-16E, CU-VA-9H-16I and CU-VU-8P-16E the 
RNA was concentrated using a RNA Clean and Concentrator-5 (Zymo Research 
Corporation, California, USA). 
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Samples CU-VA-9A-16E, CU-VA-9H-16I and CU-VU-8P-16E underwent 
transcriptome sequencing and RNA libraries were constructed by Dr P Giles and Dr 
K Ashelford, Cardiff University. The percentage of reads that mapped successfully to 
the target DNA was low for all samples but sample CU-VU-8P-16E produced a very 
low percentage of mapped reads, 22.6%. Therefore only results for HPV gene 
expression and viral integration are presented for organotypic raft cultures CU-VA-
9A-16E and CU-VA-9H-16I (61.2% and 60.9% mapping percentage respectively). 
 
 
Table 5.2 Quality and quantity of RNA used for whole transcriptome 
analysis Concentration and RNA integrity of VIN and VaIN organotypic raft 
cultures  
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5.4.2 Validation of gene expression 
 
Whole transcriptome sequencing was used to validate the HPV expression 
levels in the organotypic raft culture. HPV gene expression between samples CU-
VA-9A-16E and CU-VA-9H-16I were assessed and transcript reads were mapped to 
the HPV 16 genome (NCBI, accession no: NC_001526.2). In IGV, the reference 
HPV genome was used to define transcript locations; transcript reads that map to the 
location on the HPV 16 genome are represented by gray lines (Figure 5.12). This 
data confirms findings in section 5.2.2 which showed that cell line CU-VA-9A-16E 
was the only cell line which expressed HPV late genes. In the gene expression 
analysis, we can see cell line CU-VA-9A-16E (Figure 5.12 (A)) produces transcripts 
for all viral genes including late genes E4, L1 and L2. RNA expression of culture CU-
VA-9H-16I which has high grade morphology, a high level of E6/E7 expression but 
low level late HPV genes. 
 
 
 
 
 
 
  
194 
 
 
 
Figure 5.12 Viral gene expression of VaIN organotypic raft cultures visualised 
in IGV (A) CU-VA-9A-16E and (B) CU-VA-9H-16I. 
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5.4.3 Validation of viral integration 
 
Viral integration events were validated by the whole transcriptome sequencing 
and actively transcribed human-viral integration event were visualised using circos 
plots (Krzywinski et al., 2009). Grey lines represent paired end reads where one end 
maps to the HPV genome and the other end links to the location that it is associated 
with in the human genome. Previous work has shown cell lines CU-VA-9A-16E had 
no identifiable viral integration transcripts either by DIPS or APOT and the E2 gene 
is intact, cell lines CU-VA-9H-16I has integration defined by DIPS into 11p15.3 and 
22q12.3 and by APOT integration into 5q11.2 and 1p36.13 (Onions, 2013). Circos 
plot of CU-VA-9A-16E shows HPV/human fusions transcripts into 5 different human 
chromosomes, however these lines are all light grey and may not represent an 
actively transcribed integration event (Figure 5.13). Circos plot for CU-VA-9H-16I 
shows a very strong integration site from the HPV genome into the human 
chromosome 11, represented by a black band, and less transcribed integration 
events into chromosome 1 and 17 (Figure 5.14). This result suggested that the 
integration into chromosome 11 may be a true, transcribed integration event and this 
integration site had previously been reported in DIPS analysis. 
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Figure 5.13 Circos plot of CU-VA-9A-16E which shows HPV/human fusions 
transcripts into 5 different human chromorsomes (2, 4, 9,14 and 17). 
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Figure 5.14 Circos plot for CU-VA-9H-16I shows a very strong integration site 
from the HPV genome into the human chromosome 11, represented by a black 
band, and less transcribed integration events into chromosome 1 and 17 
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 Discussion 5.5
 
This section will highlight the key findings from this chapter and the strength and 
limitations of this study. Each of the key findings will then be considered in greater 
detail compared to the available literature and the broader implications. 
 
 
5.5.1 Key Findings 
 
1. This is the first reported organotypic raft culture of VIN and VaIN. 
2. HPV status defined in monolayer did not predict histology of cells when grown 
in a stratified epithelium.  
3. Samples with morphology in keeping with high grade disease had higher 
expression of p16 and SHH compared to samples with morphology of 
samples in keeping with low grade disease.  
4. Late gene expression E4 was only detected in CU-VA-9A-16E which had 
morphology in keeping with low grade disease. 
5. The highest levels of viral methylation were present in CU-VA-9H-16I and CU-
VU-8M-16I which both had previously defined viral integration. 
6. Whole transcriptome sequencing showed CU-VA-9A-16E expressed late 
genes compared to CU-VA-9H-16I which had high levels of E6, E7 and E1 
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and showed HPV-human transcripts in both CU-VA-9A-16E and CU-VA-9H-
16I.  
 
 
5.5.2 Strengths 
 
This is the first VIN and VaIN organotypic raft culture to be described. The use 
of the organotypic raft culture allowed for histological analysis as well as the 
molecular analysis of cultures with a mixed population of differentiated cells. All work 
in this section was carried out in triplicate to ensure the reproducibility of the 
histological and molecular results. 
 
All cellular material was fresh frozen and subsequently high quality DNA and 
RNA were obtained for molecular analysis, allowing for whole transcription 
sequencing to be carried out on three of the four raft cultures. 
 
 
5.5.3 Limitations 
 
The interpretation of the morphology of the organotypic raft cultures is a 
subjective analysis, however to overcome any technical variation each raft was 
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produced in triplicate and the same pathologist interpreted the cultures throughout to 
ensure the same criteria and standard of interpretation. The pathologist was blinded 
to the nature of the HPV infection in the raft to ensure an unbiased analysis.  
 
There is a possibility that artefacts may have been introduced into the system 
due to the production and handling of the raft cultures. This was countered using 
positive and negative controls (w12 Ser4B and HEKn). This allowed for the 
comparison of the raft cultures to a highly neoplastic control as well as a control with 
no neoplastic properties. This highlighted any artefacts that the model introduced 
when samples were analysed. 
 
 
5.5.4 This is the first reported organotypic raft culture of VIN and VaIN. 
 
Historically HPV research was dampened by the lack of a recognised model 
for the HPV lifecycle and production of HPV in the lab. This is due to the fact that 
HPV infection is species specific and there is little cross-species infection. 
Additionally unlike bacteria, viruses require a host cell in order to be grown – making 
reproduction in a laboratory difficult (Campo, 2002). Animal models have been 
pivotal in assessing the original identification of HPV as a transmissible virus 
(Rowson and Mahy, 1967, Rous and Beard, 1934) and also provided a model for 
disease progression and the interplay of host genes and papillomavirus. Although 
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animal models are still key to our understanding of HPV driven disease 
(Borzacchiello et al., 2009) the development of cellular models has increased our 
understanding of HPV related disease and are useful for testing therapeutic 
treatments against HPV.  
 
An organotypic raft culture facilitates the differentiation of cells consistent with 
a typical anogenital lesion, therefore produces a more robust model of HPV driven 
neoplasia than is possible with cells grown in a monolayer (Andrei et al., 2010, 
Anacker and Moody, 2012, Frattini et al., 1996). This model allows for the study of 
genetic and epigenetic changes due to the process of cellular differentiation and 
stratification. In the raft culture model HPV can be propagated which allows the study 
of the viral lifecycle from infection to virion production (Wang et al., 2009a, Jagu et 
al., 2013, Chow, 2015). New advances in 3D cellular in vitro cellular cultures include 
scaffold free stromal tissue resembling extracellular matrix, (De Gregorio et al., 2017, 
He et al., 2016).  
 
 
5.5.5 HPV status defined in monolayer did not predict histology of cells when 
grown in a stratified epithelium.  
 
Cell lines in this study with previously defined viral integration showed 
morphology in keeping with both a low-grade and high-grade lesion, demonstrating 
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that cellular differentiation is not solely driven by HPV genome status. This is 
consistent with claims elsewhere that whilst HPV integration is common in 
transformation, it is not a necessary step in HPV infected cells (Wentzensen and von 
Knebel, 2007, Senapati et al., 2016). The level of viral integration has been shown to 
vary between HPV types with integration being at a lower rate than in cancers driven 
by HPV 16 compared to samples with HPV 18 (Badaracco et al., 2002, Woodman et 
al., 2003). Further work should be carried out to assess if HPV status in monolayer 
can predict the histology of cells in a stratified epithelium for different HPV types. 
 
This work has shown distinct morphological changes with a marked difference 
seen in cultures originating from a single biopsy. The phenotype of integrated 
organotypic raft models, CU-VA-9H-16I and CU-CU-8M-16I, exhibit both high and 
low levels of differentiation respectively. Similarly, organotypic raft models with 
episomal DNA, CU-VU-8P-16E and CU-VA-9A-16E, displayed both high and low 
levels of differentiation. Therefore, the phenotype of the cell lines was not influenced 
by the integration status of the cell lines. 
 
 
5.5.6 Samples with morphology in keeping with high grade disease had 
higher expression of p16 and SHH compared to samples with 
morphology of samples in keeping with low grade disease.  
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Organotypic raft cultures with integrated HPV 16 infections showed both low 
and high levels of cellular differentiation and varied levels of p16, Ki-67 and SHH 
protein expression, rejecting Hypothesis 5(A) and 5(B): In vitro stratified epithelium 
models containing HPV integrated infections when compared to models of HPV 
episomal infection will display (A) a less differentiated phenotype and (B) higher p16, 
Ki-67 and SHH gene expression levels. 
 
In this research there was a significant difference in both p16 (X2(1) = 4.511, p 
= 0.034) and Ki-67 (X2(1) = 12.816, p > 0.001) stain depth when cell lines with 
histology “in keeping with high-grade morphology” and cell lines with histology “in 
keeping with low-grade morphology” were compared. p16 and Ki-67 are both 
potential biomarkers for HPV infection and as such have been introduced into 
cervical screening protocols. Previous work has suggested that Ki-67 independently 
is a poor discrete indicator of HPV disease (Agoff et al., 2003). However work 
elsewhere has suggested that Ki-67 together with p16, p53 or both may be a useful 
biomarker for use in cervical screening (Kotzev et al., 2012).  
 
The expression of SHH in all VIN/VaIN cultures in this study is consistent with 
the cell lines being transformed. This work has shown an increase in expression of 
SHH in cell lines with histology “in keeping with high-grade morphology” when 
compared to cell lines with histology “in keeping with high-grade morphology” (X2(3) 
= 13.205, p = 0.004), thus suggesting that elevated SHH expression may be a 
potential prognostic/predictive biomarker for HPV related disease worthy of 
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developing an accurate and reproducible assay to measure SHH in a clinical cohort 
(BIDD Assay Development – stage 1). CU-VU-8M-16I with low-grade morphology 
also exhibited a high level of SHH expression (119.49%). However, GLI-1 
expression was variable and (37.17% to 72.17%) and no association could be seen 
to either HPV integration status or culture morphology. Although in this study GLI-1 
was not associated with HPV status or morphology, it has been shown that GLI-1 
and other GLI proteins have an association with HPV disease outcome in head and 
neck cancer, although studies have disagreed whether this is a positive or negative 
outcome (Yan et al., 2011, Enzenhofer et al., 2016). 
 
 
5.5.7 Late gene expression of HPV 16 E4 was only detected in CU-VA-9A-16E 
which had morphology in keeping with low grade disease. 
 
Although cell lines CU-VA-9A-16E and CU-VU-8M-16I both show low-grade 
morphology only the CU-VA-9A-16E raft culture shows late HPV gene expression 
based on HPV16 E4 expression. This is the only cell line that is completing the full 
viral lifecycle leading to HPV virus particle production, this data indicates that with 
the low p16, Ki-67 and SHH expression, CU-VA-9A-16E is representative of a 
transient HPV infection, which would be naturally cleared by the immune system of 
the host. This would be a successful model for use in future work to better 
understand the host and viral biology in a normal transient infection and comparison 
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with the other line from the same host may reveal the changes that take place to 
move it from transient to progressive.  
 
It has been suggested that HPV 16 E4 may be another potential biomarker for 
disease as HPV E4 has been detected in low- and high-grade CIN but not in HPV 
negative lesions (Yajid et al., 2017), contrary to work presented in this thesis which 
only detected HPV E4 protein in CU-VA-9A-16E which had low grade morphology. It 
has also been suggested that HPV E4 and p16 detection could be used as a dual 
biomarker which could differentiate between CIN I/CIN II and CIN II+ as E4 staining 
is only present in low grade lesions (van Baars et al., 2015). This is similar to with 
work presented here for both p16 and E4 gene expression and with the use of a pan-
HPV E4 antibody (an antibody against E4 in 15 HR-HPV types) may be a suitable 
biomarker for triage of vaccinated women. 
 
 
5.5.8 The highest levels of viral methylation were present in CU-VA-9H-16I and 
CU-VU-8M-16I which both had previously defined viral integration. 
 
Higher levels of viral genomic HPV 16 DNA methylation were present in 
samples with previously defined HPV integration, agreeing with Hypothesis 5(C): In 
vitro stratified epithelium models containing HPV integrated infections when 
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compared to models of HPV episomal infection will display (C) higher levels of viral 
methylation.  
 
Integrated cell line CU-VU-8M-16I also displayed low grade morphology, 
however it had several molecular factors, (including high SHH expression, hyper 
methylation) consistent with a high-grade HPV infection. The range of organotypic 
models presented in this thesis represents a range of naturally prevalent HPV 
infections that may occur in vivo: 
i. A transient infection;  
ii. A high-grade infection; 
iii. A low-grade infection with molecular characteristics of a high-grade 
infection, perhaps representative of the transition from a low-grade to a 
high-grade infection.  
When the cell lines are divided by the observed phenotype high p16 and SHH 
expression is shown in cultures with morphology characteristic of high-grade 
neoplasia, CU-VA-9H-16I and CU-VU-8P-16E. Cultures with morphology in-keeping 
with low-grade neoplasia, CU-CU-8M-16I and CU-VA-9A-16E, had lower levels of 
p16 and SHH expression. Interestingly culture CU-VU-8M-16I had the highest level 
of viral genomic DNA hypermethylation, no HPV late gene expression and SHH 
expression consistent with cultures CU-VA-9H-16I and CU-VU-8P-16E. Therefore, 
culture CU-VU-8M-16I may represent the intermediate state between low-grade and 
high-grade neoplasia compared to culture CU-VA-9A-16E which has all the features 
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of a low-grade transient infection including late gene expression, hypomethylation of 
viral genomic DNA and low p16, Ki-67 and SHH expression. 
 
5.5.9 Whole transcriptome sequencing showed CU-VA-9A-16E expressed late 
genes compared to CU-VA-9H-16I which had high levels of E6, E7 and E1 
and showed HPV-human transcripts in both CU-VA-9A-16E and CU-VA-
9H-16I.  
 
Whole transcriptome sequencing analysis was carried out to confirm integration 
events and gene expression levels as reported in monolayer cultures (Onions, 
2016). The results confirmed that cell line CU-VA-9A-16E transcribes both early and 
late HPV genes when grown in an organotypic raft culture. There were several points 
of integration shown by whole transcriptome sequencing; however these were 
infrequent events that are believed to not be transcriptionally active. It was also 
confirmed that cell lines CU-VA-9H-16I showed a transcriptionally active integration 
event into chromosome 11 and late HPV gene expression was reduced in this 
culture compared to CU-VA-9A-16E. From these results we confirmed the gene 
expression and transcriptionally active integration events reported in the monolayer 
equivalent cultures. To further analyse which integration events are transcriptionally 
active in future work it may be of interest to look at the integration events reported by 
whole transcriptome sequencing using digital PCR to quantify these integration 
events and assess the true level of viral integration events (Sedlak et al., 2014). 
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6 Chapter 6 
General Discussion 
 
This thesis reports several key findings: 
 
1. Disruption and methylation of viral E2 gene are not suitable biomarkers for 
detecting progression to CIN II+ in young women. 
2. In population with a wide age range, viral methylation was positively 
correlated with disease grade. 
3. Models of HPV positive organotypic raft cultures from VIN and VaIN derived 
cell lines identified that: 
I. The HPV genome status in monolayer cell cultures did not predict 
subsequent histology of cells grown in a stratified epithelium. 
II. Samples with morphology in-keeping with high grade morphology have 
high expression of p16 and SHH genes compared to morphology in-
keeping with low grade disease. 
 
HPV integration and methylation were assessed in a young population and a 
mixed age population to assess whether they were associated with increased 
cervical histology. This work showed a random prevalence of low level of viral 
integration in both populations studied, which was not associated with higher grade 
disease. It has previously been reported that integration frequency is highest for HPV 
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types 16, 18 and 45 (Vinokurova et al., 2008), which is in opposition to data 
presented in chapter three, which detected the lowest level of viral integration in HPV 
16 positive samples, however this was not statistically significant. The work by 
Vinokurova et al (2008) was carried out in a mixed age population of women 
whereas work presented in chapter three focused on young women (20 – 22 years of 
age), which may account for the disparity in findings. Previous studies of viral 
integration in young women have found a disagreement in the prevalence of viral 
integration (Collins et al., 2009, Ramanakumar et al., 2010).These difference may 
have been a result of discrepancies in how the clinical samples were obtained and 
managed before molecular testing. Findings in this study support that HPV 
integration is a rare event in young women and further basic research is required to 
assess potential biomarkers for HPV related disease in this demographic. It would 
also be advantageous to consider behavioural and environmental factors that could 
be assessed in combination with molecular changes, e.g. use of hormonal 
contraceptives, pregnancy or urinary tract infections (Nelson et al, 2009, Winer et al, 
2003). These factors may highlight a subset of women for whom molecular 
biomarkers could be successfully applied to predict HPV disease. 
 
 Viral integration events are commonly seen in or near CFS of the human 
genome. Work in this thesis showed 50% of viral integration sites were in or near 
known CFS’s (6q15, 3q25.33 and 9p21.2). Recently an updated review of viral 
integration sites has been published which reported that over 1,500 integration sites 
have been published which were statistically more likely to be near CpG regions, 
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fragile sites and transcriptionally active regions (Bodelon et al., 2016). It has been 
suggested here and elsewhere that integration of HPV into the human genome may 
be related to regions of genomic instability, and could suggest that HPV may be an 
intentional mutagen of human DNA which contributes to cancer formation by 
promoting mutagenesis (Akagi et al., 2014).  
 
Methylation analysis in young women did not show any association between 
viral methylation of HPV E2 and high grade disease in young women. However, work 
described in Chapter 4 and 5 of this thesis both supported HPV methylation as a 
potential marker of high grade disease. Viral methylation has been considered as a 
potential biomarker of HPV disease. In this work, viral methylation has shown to be 
associated with an increase in HPV driven disease potentially suggesting that viral 
methylation should be further studied as a HPV biomarker, this suggestion supports 
work presented elsewhere that has shown HPV 16 L1/L2 viral methylation is a 
potential biomarker for disease duration and that E2 viral methylation has potential 
as a biomarker for predicting response to Cidofovir in the treatment of VIN (Jones, 
2016, Bryant et al., 2015). Work in this thesis showed that three CpG sites (CpG 
3416, CpG 3435 and CpG 3447) in the E2 region of HPV 16 were significantly hyper 
methylated in samples with viral genome disruption. As discussed in section 1.4.2 
viral integration is a common event in cervical cancer but not a prerequisite for 
disease. Further examination of the relationship between viral integration, 
methylation and disease progression may highlight a few individual CpG sites in the 
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human and/or HPV genome, such as CpG 3416, CpG 3435 and CpG 3447, which 
may have clinical utility. 
 
Considering the Prognostic and Predictive Biomarker Road map (Lioumi and 
Newell, 2010, Cancer Research UK, 2016) work presented in this thesis has 
reported the development and potential clinical utility of accurate and reproducible 
assays to measure viral methylation as a biomarker for HPV integration. The next 
stage in biomarker development is to refine the molecular assays, assays for HPV 
driven anogenital neoplasia must be refined to facilitate high assay performance in 
samples taken during cervical screening (BIDD Assay Development – Stage 2).  
 
This thesis considers several further biomarkers for HPV disease of which P16, 
Ki-67 and SHH showed the greatest potential as biomarkers for high-grade HPV 
disease as all of these showed significant variation between cell lines with histology 
“in keeping with high-grade morphology” and cell lines with histology “in keeping with 
low-grade morphology”. A dual stain assay has been evaluated in as a part of 
cervical screening and triage and has been shown to have comparable specificity to 
standard cervical screening (97.2% vs 95.4%, p = 0.15) with increased sensitivity 
(86.7% vs 68.5%, p<0.001) (Ikenberg et al., 2013, Petry et al., 2011). Also as the 
p16/Ki-67 dual stain is not HPV type specific but a marker of cellular changes this 
should be considered as a potential biomarker in vaccinated women. This would 
ensure monitoring of disease presence even regardless of the HPV type driving 
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disease, compared to HPV DNA testing which may only assess a small range of 
HPV types. 
 
SHH protein expression was also shown to be unregulated in organotypic raft 
cultures with morphology in-keeping with a high-grade infection. This work on SHH 
and GLI-1 protein expression presented in this thesis was carried out in collaboration 
with Dr Chris Dawson from The University of Birmingham. Work from Dr Dawson 
group has shown that the deregulation of Hedgehog protein is activated by Epstein-
Barr virus through the induction of SHH (Port et al., 2013) and has reported SHH is 
aberrantly activated in vulval cancer and 8/10 solitary VIN cases have shown over 
expression of SHH and its downstream effector GLI-1 (Dr Dawson, Personal 
Communication). It has also been shown that the inhibition of GLI-1 in cancer cell 
lines reduced the ‘stemness’ of cervical cancer cells, leading to a less-cancerous 
phenotype (Vishnoi et al., 2016). This work suggested there was an interaction 
between HPV E6 and GLI-1 which may be a useful relationship to exploit in the 
search for novel therapeutic approaches against HPV driven cancer. Work in this 
thesis also promotes further development of SHH expression as a potential 
prognostic or predictive biomarker for HPV disease. Future work is required to 
develop clinical assays for these biomarkers and to define the biomarker distribution 
in specimens from the target population (BIDD Assay Development – Stage 1). 
 
Apart from biomarkers for the prediction of disease presence or progression, 
biomarkers can also be used to predict the success of treatment of HPV infections or 
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risk of disease recurrence. Recent work in oropharyngeal SCC have shown that E6 
and E7 serum antibody level was significantly higher in patients with recurring 
disease (Spector et al., 2016). This biomarker could be implemented after 
oropharyngeal SCC treatment to monitor likelihood of disease recurrence to enhance 
patient management strategies.  
 
Work presented in this thesis must be considered within the broader context of 
the HPV vaccination programme. Cervical screening programmes must evolve to 
maintain their effectiveness in a vaccinated population, when fewer abnormalities will 
be prevalent and cytologists have the potential to become deskilled without 
appropriate new measures in place to counteract this. New molecular screening 
methods for HPV presence, which have a higher sensitivity than traditional 
cytological methods, must avoid over-treatment of women with HPV associated 
lesions to allow time for viral regression to occur naturally, wherever possible. Work 
in this thesis supports the observed natural history of HPV infection that can change 
over time with differences between transient and persistent infections detected in 
young and older women. It has been demonstrated that CIN lesions in young women 
are more likely to regress compared to older women (Moore et al., 2007, Fuchs et 
al., 2007). An optimal strategy for future cervical screening programmes may be to 
combine different detection methods to ensure that the most appropriate treatment is 
delivered dependent on the stage of infection. It may also be beneficial to have age 
specific treatment protocols to ensure that the most efficient method of screening is 
taken place depending on the women’s age. On the 1st of September 2013 CSW 
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changed the age criteria for screening women in Wales. The new protocols include 
screening women every three years from 25 to 50 years of age, then screening 
every 5 years from 50 to 64 years. More recently CSW has also changed the 
screening protocol; from April 2nd 2017 primary HPV testing has been introduced into 
the cervical screening programme in Wales (CSW, 2017). This is an initial pilot of the 
programme which is due to be rolled out across Wales by 2018/2019. Testing for 
HPV is carried out as a primary test and only if HPV is detected then cervical 
cytology is assessed. Current UK National Screening Committee have assessed the 
introduction of primary HPV screening and concluded that replacing HPV cytology 
with primary HPV DNA testing is likely to be a cost effective move (UK NSC, 2016).  
 
Several other challenges are faced in routine cervical screening programmes 
following the introduction of HPV vaccination. These include a potential reduction in 
women attending for call and recall smear testing, changes in the vaccination used 
and understanding of the long-term effectiveness of the HPV vaccination.  
 
Globally, implications must also be considered for women in low resource 
settings. Introduction and uptake of the HPV vaccine is a significant step in disease 
prevention but optimal strategies for screening in this population must be considered. 
Several studies have tried to consider novel biomarkers and screening protocols, 
which includes the use of trained sniffer dogs to detect cancerous changes 
(Guerrero-Flores et al., 2017), self-collected samples (Bansil et al., 2014) & how to 
enhance uptake rates of the vaccine in the overall population. 
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This thesis has described the first VIN and VaIN raft cultures and as expected 
has highlighted increased p16, Ki-67 and SHH expression as potential biomarkers 
for HPV disease. Future work should assess the effect of p16, Ki-67 and SHH gene 
expression on cellular morphology by assessing if knocking out p16, Ki-67 and/or 
SHH genes effect the growth of cultures CU-VA-9H-16I and CU-VU-8P-16E. These 
cultures can also be employed in future HPV drug discovery and evaluation to 
increase understanding of drug uptake, changes to human and HPV gene 
expression and changes in phenotype of the culture after exposure to drugs and/or 
radiation. Organotypic raft cultures have already been employed to assess 
compounds against Alphaherpesviruses. In this study antiviral drugs were added 
directly to lesions in the raft culture and the changes to cellular histology with various 
compounds were measured. The antiviral effect of the various compounds were then 
measured using plaque assays and qRT-PCR (Andrei, et al. 2005).  
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7 Chapter 7 
Conclusion 
 
HPV anogenital disease progression is driven by a variety of contributing 
factors. This work examined HPV methylation, HPV gene disruption and aberrations 
in host and viral gene expression and their suitability as biomarkers for HPV disease. 
This study has shown that HPV genome disruption and HPV DNA methylation are 
not suitable biomarkers for young women. However, this study showed a correlation 
between HPV methylation at three CpG sites and HPV gene disruption. More 
research is required to define if HPV methylation is a suitable biomarker which 
shows improved clinical outcome by its use in the cervical screening programme or 
to predict response to treatments. 
 
This thesis is the first to report the growth of VIN and VaIN cell lines in an 
Organotypic Raft Culture model which facilitated the growth of cells in a stratified 
epithelium. These models can also be utilised to further understand the natural 
history of VIN and VaIN by identifying phenotypic changes with related molecular 
changes. These Organotypic Raft Cultures can also be employed as a model for 
testing of potential topical treatments for VIN and VaIN.  
 
VIN and VaIN cell lines showed diverse differentiation patterns which were 
not associated with viral integration status as defined in monolayer. This work 
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supports that integration is unlikely to be an appropriate biomarker in predicting 
disease progression. The increased expression of p16, Ki-67 and SHH in cell lines 
with high-grade histology supports the further investigation of these biomarkers in 
cervical screening as a potential prognostic biomarkers  
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9 Appendix 1 
Prognostic/Predictive Biomarkers (BM) Roadmap 
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10 Appendix 2 
Study Protocols 
 
Samples from two studies were used in this study:  
 
Study 1: Young women attending their first cervical smear 
Study 2: HI-BCD Study Cohort 
 
The Study protocols for each of these studies are included in this appendix.  
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 Study 1: Young women attending their first cervical smear 10.1
 
Base HPV 2009: Characterisation of HPV infection in cervical smears from young 
women attending first cervical screening prior to implementation of HPV vaccination  
 
Protocol Summary 
Acronym: Base HPV 2009 (Baseline HPV Prevalence in women aged 20-22 yrs 
2009) 
Principle Clinical Investigator: Professor Alison Fiander 
Other Investigators: Dr Sam Hibbitts, Dr Richard Peevor, Jo Jones, Dr Ned Powell, 
Dr Amanda Tristram, Dr Hilary Fielder, Dr Anne Hauke, Dr Nick Dallimore, Helen 
Beer, Jane McRea, Bryan Rose, Dr Malcolm Adams. 
Study Site: HPV Research Laboratory, School of Medicine, Cardiff University and 
Cervical Screening Wales (Velindre NHS Trust). 
Aim: The aim of the study is to assess and characterise the current HPV burden 
prior to the implementation of prophylactic HPV vaccination in Wales. This cohort will 
serve as a ‘control’ group to compare with vaccinated cohorts both as part of the 
catch up campaign and the main target group for vaccination. 
 
Objectives Primary: 
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 To determine baseline Human Papillomavirus (HPV) genotype specific 
prevalence in women aged 20-22 years attending first cervical screening in 
Wales, prior to the introduction of an HPV vaccination programme.  
Objectives Secondary 
 To correlate HPV type-specific infection with cytology and histology where 
available.  
 To correlate HPV type-specific infection with age.  
 To correlate HPV type-specific infection with social deprivation score 
according to the Welsh Index of Multiple Deprivation (WIMD) 
Objectives Tertiary: 
 Development of ‘bio-bank’ to investigate potential prognostic biomarkers. 
Methodology: This is a pseudo-anonymous prospective cohort study design 
Number of Subjects: 250 samples per week up to 10,000 per annum 
Inclusion Criteria:  
 All women attending for their first routine cervical smear (20-22 yrs) within 
Cervical Screening Wales (CSW) in 2009. 
 Samples from women who have an inadequate first routine cervical smear 
(20-22yrs) and are re-called for a repeat smear. 
Exclusion Criteria:  
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 Women attending for any other routine cervical smear Inadequate Cytology 
result  
 No information available for age, cytology or social deprivation score 
 
 
Baseline HPV Prevalence in women aged 20-22 yrs 2009 (Base HPV 2009) 
 
Characterisation of HPV infection in cervical smears from young women attending 
first cervical screening prior to implementation of HPV vaccination  
 
Contents 
1.0 Lay Summary 
2.0 Introduction  
2.1 Human Papillomavirus 
2.2 Cervical Screening 
2.3 HPV vaccination 
2.4 Objectives 
2.5 Rationale 
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3.0 Investigational Plan 
3.1 Overall Study Design 
3.2 Study Population 
3.3 Inclusion and Exclusion Criteria 
3.4 Sample Collection 
3.5 Interventions 
3.6 Blinding 
3.7 Study Plan 
3.8 Endpoints 
4.0 Sample Management 
4.1 Cytological analysis 
4.2 HPV Testing 
5.0 Data Management 
5.1 Statistical Methods 
5.2 Sample Size and Power Calculations 
6.0 References 
7.0 Project Management 
8.0 Ethical Considerations  
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8.1 Administrative Procedures  
8.2 Monitoring Procedures 
8.3 Recording of Data and Retention of Documents 
 
Lay Summary 
 
Human Papillomavirus (HPV) is the underlying cause of cervical cancer and is found 
in 99.7% (Munoz, 2000),(Jacobs et al., 1997) of invasive cervical carcinomas. The 
introduction of a national HPV vaccination programme in 12-13 year old girls has 
been announced and is due to commence in Autumn 2008. A catch up campaign 
vaccinating 16 to 18 year olds will begin in Autumn 2009 and 15-17 year olds in 
Autumn 2010. The catch up programme will result in vaccinated women attending 
screening from 2011 (Welsh Assembly, 2007). 
 
Vaccination will inevitably change the type-specific prevalence of HPV in the 
community and reduce the incidence of pre-invasive and invasive disease of the 
cervix (Villa et al., 2005, Harper et al., 2004).  
 
This project is designed to assess and characterise the current HPV burden prior to 
the implementation of prophylactic HPV vaccination in Wales. This cohort will serve 
as a ‘control’ group to compare with vaccinated cohorts both as part of the catch up 
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campaign and the main target group for vaccination. Only a narrow window of 
opportunity exists in which to do this study, since delay may see ad hoc HPV 
vaccination outside of a National programme leading to contamination of the pre-
vaccination cohort.  
 
Introduction 
 
2.1 Human papillomavirus 
The Human Papillomavirus (HPV) plays a central aetiological role in cervical 
carcinogenesis, such that it is recognised as a necessary, if not a sufficient cause of 
cervical cancer (Bosch et al., 2002). HPV infection is very common with a 75% 
lifetime risk (Koutsky, 1997). It is particularly common in young women following 
onset of sexual activity (Hibbitts et al., 2006),(Peto et al., 2004a). The majority of 
infections are, however, transient and asymptomatic with less than 5% of those 
infected developing anogenital neoplasia. 
 
2.2 Cervical screening 
Cervical screening identifies women at increased risk of developing cervical cancer 
and is estimated to save around 5,000 lives per year in the UK (Peto et al., 2004c). 
Screening is currently based on cervical cytology identifying dyskaryotic cells 
indicating the need for further assessment and possibly treatment of cervical 
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intraepithelial neoplasia (CIN) to prevent potential progression to invasive disease. 
However, cytological screening is not infallible with up to half of the 1,000 women 
who die annually in the UK of cervical cancer having participated in Cervical 
Screening Programmes.  
 
It is anticipated that HPV testing will be introduced into cervical screening, especially 
following implementation of prophylactic HPV vaccination. HPV testing has higher 
sensitivity for high-grade disease compared to cytology but since HPV infection is so 
common, this is at the expense of lowered specificity.  
 
2.3 HPV vaccination 
HPV vaccination represents a major public health breakthrough, which could 
potentially prevent 70-75% of cervical cancers in women vaccinated before contact 
with the virus, i.e. before sexual debut. Infection with HPV usually occurs decades 
before the development of cervical cancer and therefore the impact of HPV vaccines 
will take time to become apparent. Surrogate endpoints such as persistent type-
specific HPV infection or high-grade intraepithelial neoplasia have been employed in 
phase III trials with near 100% efficacy for the vaccines in per protocol populations 
(Villa et al., 2005, Harper et al., 2004).  
 
Monitoring and surveillance of HPV vaccine implementation and impact upon 
disease will be essential for the evaluation of this public health intervention. Changes 
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in HPV prevalence following vaccination may offer an early opportunity to assess 
impact of prophylactic vaccination especially where cervical screening programmes 
commence from the age of 20 years. A degree of cross protection against similar 
HPV types has been found, with the bivalent vaccine showing 60% efficacy for 
preventing 6-month persistent infections with HPV 45, 36% for HPV 31 and 32% for 
HPV 52. The 12-month efficacy against persistent infections for any non-vaccine 
oncogenic types was 27% (Paavonen et al., 2007). The possibility of type 
replacement has been raised following lowered prevalence of HPV 16 and 18 (also 
HPV 6 and 11 in the case of the quadrivalent) in the vaccinated population.  
 
UK implementation of prophylactic vaccination will commence in September 2008, 
although acceptability, uptake and hence effectiveness in a community setting is at 
present unknown. Experience in Australia suggests uptake maybe in the region of 
80% (S. Garland, personal communication).  
 
A previous HPV prevalence study in women (20-65 years) attending cervical 
screening in South East Wales suggests an unusual pattern of HPV types, which 
may have implications for the effectiveness of prophylactic vaccination in Wales 
(Hibbitts et al., 2006). The current proposal is to characterise HPV type specific 
prevalence on an ‘All Wales’ basis amongst young women attending for their first 
cervical screen aged 20-22 years. This cohort represents a control or comparison 
group for subsequent vaccinated cohorts when they undergo first cervical screening 
upon reaching 20 years of age.  
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The two vaccines commercially available, Cervarix and Gardasil, are active against 
High Risk (HR) HPV types 16 and 18. Gardasil has additional protection against the 
Low Risk (LR) HPV types, 6 and 11. In June 2008, the Government announced that 
Cervarix™ had been chosen for the first 3 years of implementation within the UK. 
We should see a type specific reduction in HPV infection in vaccinated women and 
the magnitude of this reduction will give an indication of the efficacy of the 
vaccination programme and address both type replacement and cross protection. It 
is possible that transient cervical contamination by HPV may still occur but would not 
result in dyskaryosis. Linking HPV and subsequent cytology +/- histology will indicate 
clinically significant infections resulting in cervical dysplasia and neoplasia. 
 
Ultimately, reduced prevalence of HPV infection and cervical intraepithelial neoplasia 
in the vaccinated population will affect the health economics of the screening 
programme and it is likely that change will be required. HPV testing is now 
commercially available, with ongoing clinical trials evaluating whether cervical 
screening can be improved by HPV testing and how best to incorporate HPV testing 
into the screening programme.  
 
HPV testing has been shown to be more sensitive than cervical cytology for high-
grade disease but less specific due to high prevalence of HPV infection within 
populations, especially in women less than 30 years of age. Additional ‘prognostic’ 
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biomarkers are being investigated to improve specificity for disease or the potential 
to progress to disease for example P16INK4, MCM, TOP2A, viral integration, 
methylation, mRNA, etc. Storage of samples from this cohort will allow subsequent 
investigation of selected biomarkers to detect underlying high-grade disease or the 
potential to progress to high-grade disease when linked to future cytology and 
histology collected as part of the Cervical Screening Wales programme.  
 
2.4 Objectives 
The aim of the study is to assess and characterise the current HPV burden prior to 
the implementation of prophylactic HPV vaccination in Wales. This cohort will serve 
as a ‘control’ group to compare with vaccinated cohorts both as part of the catch up 
campaign and the main target group for vaccination. Only a narrow window of 
opportunity exists in which to do this study, since delay may see ad hoc HPV 
vaccination outside of a National programme leading to contamination of the pre-
vaccination cohort.  
 
Primary 
 To determine baseline HPV genotype specific prevalence in women aged 20-
22 years attending first cervical screening in Wales, prior to the introduction of 
an HPV vaccination programme.  
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Secondary 
 To correlate HPV type-specific infection with cytology and histology where 
available.  
 To correlate HPV type-specific infection with age.  
 To correlate HPV type-specific infection with social deprivation score (SDS) 
according to the Welsh Index of Multiple Deprivation (WIMD) 
 
Tertiary 
 Development of ‘bio-bank’ to investigate potential prognostic biomarkers. 
 
2.5 Rationale 
Monitoring and surveillance of HPV infection following implementation of HPV 
vaccination, together with the impact upon cervical neoplasia will be essential for the 
evaluation of this major public health intervention. Changes in HPV prevalence 
following vaccination may offer an early opportunity to assess impact of prophylactic 
vaccination, especially where cervical screening programmes commence from the 
age of 20 years.  
 
The organisation base in Wales is well positioned to carry out this early evaluation of 
HPV vaccination where cervical screening starts at 20 yrs; 5 years earlier than in 
England. In addition, within Wales data on HPV immunisation uptake, the incidence 
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of cervical cancer and pre-invasive disease are all collated by divisions of the same 
NHS Trust, thus facilitating a collaborative approach. 
 
Subject to additional funding and regulatory approvals, the present cohort will be 
used in future work in comparison with vaccinated cohorts.  Initially this will involve 
catch up cohorts (2011) and subsequently the target age group: girls aged 12-13 
years as they reach the age of 20 years and attend first cervical screening (2015).  
This will allow us to address the issue of type replacement, comparison of HPV 
assays and assessment of biomarkers. 
 
This work will form part of a comprehensive framework programme evaluating the 
HPV vaccination programme coordinated in collaboration with a working steering 
group that includes Cardiff University, Cervical Screening Wales (CSW), National 
Public Health Services, and the Health Protection Division of the Welsh Assembly 
Government. 
 
3.0 Investigational Plan 
3.1 Overall Study Design 
This is a pseudo-anonymous prospective cohort study design. The primary outcome 
will establish a baseline HPV genotype specific prevalence in women aged 20-22 
years attending first cervical screening in Wales, prior to the introduction of 
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prophylactic HPV vaccination for subsequent comparison with vaccinated cohorts of 
women. The analysis will be performed on residual liquid based cytology samples 
and the HPV typing result will not alter patient management. 
 
3.2 Study Population 
Approximately 27,000 20-22 year-old women are eligible and invited for first cervical 
screening in Wales annually. Screening uptake is approximately 39% in this age 
group and it is therefore estimated that ~15,000 residual Liquid Based Cytology (LBC 
SurePath) samples will be collected from this ‘All Wales’ unvaccinated cohort with 
information on current cytology result, age and social deprivation score (Welsh Index 
of Multiple Deprivation). Cytological and histological follow-up data will be collected 
on over the next two rounds (minimum 6 years) of screening. 
 
3.3 Inclusion and Exclusion Criteria 
All samples collected from women attending for their first routine cervical screen (20-
22 yrs) at each of the Cervical Screening Laboratories in Wales will be flagged and 
included in the study and samples from women who have an inadequate first routine 
cervical smear (20-22yrs) and are then recalled for a repeat smear. Women 
attending for any other routine cervical smear will be excluded and those women 
with an inadequate cytology result or no information available for age, cytology or 
social deprivation score. 
 
  
295 
 
Data analysis will be performed on all samples that comply with the following 
-globin PCR positive; complete information available on age, 
cytology result and SDS; within the target age group 20-22 years; first routine 
cervical smear. 
 
3.4 Sample Collection 
Sample collection will be initiated in March 2009 for a period of 18 months. LBC 
samples will be processed and analysed by the local cervical screening laboratories 
in Wales according to the guidelines of the British Society of Clinical Cytology 
(BSCC), standard operating procedures [12] and CSW guidelines. The residual 
samples will be anonymised by the originating laboratory prior to being forwarded to 
the HPV Research laboratory, School of Medicine, Cardiff University at room 
temperature. Two hundred and fifty samples per week will be processed (HR /LR 
HPV genotype) with completion of the full 15,000 within 18 months i.e. March 2009 - 
Sept 2010.  
 
3.5 Interventions 
This study is designed to evaluate baseline HPV prevalence in women attending for 
their first cervical smear in a real life setting and no additional samples will be taken 
from the participants. One additional test (HPV genotyping) will be carried out on a 
sample that has already been taken.  
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3.6 Blinding 
All patient identifiable information will be removed from the residual liquid based 
cytology samples within the originating Cervical Screening Laboratory leaving only 
the lab ID on the specimen pot. Samples will be batched on a weekly basis and then 
forwarded to HPV Research Laboratory, School of Medicine, Cardiff University for 
HPV typing.  
 
Each cytology lab will fax/ email the HPV lab when samples are dispatched giving 
the lab ID numbers and the originating cytology lab ID. The HPV lab will confirm 
receipt of the specified samples and assign a unique Study ID code. The Project 
manager will compile an excel datasheet that links the date of sample receipt by 
HPV lab, originating cytology lab, lab number and the HPV lab allocated study code 
from 00001 onwards. This information will be transferred back to the Cervical 
Screening Administration computer database to enable sample linkage with age, 
cytology result and social deprivation score (SDS). 
 
CSW will have not have access to any HPV typing results and therefore this will not 
alter patient management and Cardiff University will not have access to any patient 
identifiable information (pseudo-anonymised). 
 
3.7 Study Plan 
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October 2008-December 2008  
Project sponsorship from Cardiff University will be established with application for the 
appropriate ethical and regulatory approvals. 
 
Jan 2009-Feb 2009 
Research Assistants appointed within the HPV Research laboratory, School of 
Medicine, Cardiff University.  
 
March 2009 
Sample collection initiated from all local cervical screening laboratories in Wales. 
 
Work Process for each specimen: 
Cervical cytology preformed according to the guidelines of the British Society of 
Clinical Cytology (BSCC) standard operating procedures and CSW Protocols [12] in 
the normal manner. 
Flagging of targeted specimens defined as ‘LBC smears from women attending for 
their first cervical screen 20-22yr’ using date of birth and removal of all patient 
identifiable information within the originating Cervical Screening Laboratories in 
Wales. 
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Each cytology lab will fax/ email the HPV lab, Cardiff University, when samples are 
dispatched giving the lab ID numbers and the originating cytology lab ID. 
Weekly collection of the targeted residual LBC specimen pots on an ‘All-Wales’ basis 
with subsequent transportation to the HPV Research Laboratory, Cardiff University. 
The HPV lab will confirm receipt of the specified samples and assign a unique Study 
ID code. The Project manager will compile an excel datasheet that links the date of 
sample receipt by HPV lab, originating cytology lab, lab number and the HPV lab 
allocated study code from 00001 onwards. 
This data will be transferred back to the Cervical Screening Administration computer 
database to enable subsequent sample linkage with age, cytology result and social 
deprivation score (SDS) (pseudo-anonymisation). 
HPV testing following the laboratory standard operating procedures. Login receipt 
(hard copy and electronic copy of LBC samples and preparation of cell pellets from 
LBC material). 
Extraction of DNA from cell pellets and quantification of extraction efficiency with 
PCR for the house-keeping gene b-globin. 
HPV genotyping of samples using PCR-enzyme immunoassy with the GP5+/GP6+ 
primers [8]. 
Once the results of the HPV typing are available, data analysis will be performed for 
the primary outcome and secondary outcomes.  
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The samples collected at the end of the 18 months will form a sample bio-bank for 
future studies into potential biomarkers of disease progression. 
 
3.8 Endpoints 
Primary  
Baseline HPV type specific prevalence in women attending for their first routine 
cervical smear prior to the introduction of the HPV vaccination programme. 
Secondary  
Correlation of HPV type-specific prevalence with cytology, age and SDS in women 
attending for their first cervical smear prior to the introduction of the HPV vaccination 
programme (2009). 
Tertiary  
Establish a sample bio-bank that will be available for future studies into potential 
prognostic biomarkers of disease progression. 
 
4.0 Sample Management 
Each LBC sample will be processed within the originating Cervical Screening 
laboratory according to the British Society of Clinical Cytology (BSCC) standard 
operating procedures [12] and CSW guidelines. Each sample will be given a unique 
study number and entered into a database with cytology result, age and social 
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deprivation score. Samples will be HPV genotyped according to standard operating 
procedures within the HPV Research Laboratory, Cardiff University. In brief 
specimens will be centrifuged and aliquoted before storage at -80ºC. HR and LR 
HPV typing using the PCR-EIA methodology reported by Jacobs et al (Jacobs et al., 
1997) will be performed on all samples with full HR genotyping on HR positive 
specimens. To control for extraction efficiency each DNA sample will be screened for 
b-globin by PCR. HR genotyping will occur with 10% re-analysis of samples for 
quality control/assurance purposes. 
  
4.1 Cytological analysis 
Cervical samples are collected using a plastic broom device and placed into a vial of 
preservative fluid (SurePath CytoRich). The head of the device is detached and left 
in the vial which is then capped and transported to the cytology laboratory. The vials 
are then vortexed to re-suspend the cell pellet and an aliquot is placed into a 
centrifuge vial using the PrepMate device. The aliquot is treated through a density 
gradient centrifugation process to remove unwanted material and a concentrated 
pellet of cervical cells is produced. The pellet is then re-suspended and the 
PrepStain slide processor transfers an aliquot to a settling chamber mounted on a 
microscope slide. Cells sediment onto the slide to form a thin layer and the excess 
fluid and cells are discarded. The slides are routinely stained as part of the 
automated process. The cytology slides will be analysed in the normal manner, 
according to Cervical Screening Wales policy.  They will undergo primary screening, 
checking and referral for consultant reporting as required. This will be completed 
  
301 
 
within four weeks. Residual samples are kept normally until a report has been issued 
with storage at room temperature. Flagged samples for use in this study will be 
separated from all specimens in each of the participating laboratories. 
  
4.2 HPV Testing 
HPV testing will be performed in the HPV Research Laboratory, Dept Obstetrics & 
Gynaecology, School of Medicine, Cardiff University following laboratory procedures. 
 
In brief, the residual cell pellets will be washed and re-suspended in 1ml 10mM Tris 
pH 7.4 with DNA extraction using recombinant Proteinase K and subsequent PCR 
for the human b-globin gene to determine extraction efficiency as previously 
described [8].  
 
The GP5/GP6+ HPV PCR-ELISA method of Jacobs et al [2] (Jacobs MV 1997)will 
be performed on all specimens in a 96-well format with minor modifications. Samples 
will be processed in batches of 96 to increase throughput and a two tier method 
applied:  
An initial PCR-ELISA with a cocktail of HR or LR type specific probes  
A second PCR-ELISA of all HR positive samples with genotyping using 14 individual 
HR HPV probes: HPV 16; 18; 31; 33; 35; 39; 45; 51; 52; 56; 58; 59; 66 and 68.  
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The initial ‘HR/LR’ and sub-typing PCR reaction will be performed in a final volume of 
25µl and 100µl respectively. PCR cycling conditions were 94°C 4 mins, 40 cycles of 
94°C 30 sec, 40°C 90 sec, 72°C 60 sec followed by 72°C 4 mins. Positive (CaSki) 
and negative (water) DNA extraction, PCR and ELISA controls will be included for 
every 94 samples. 
 
4.3 Data Analysis 
Results will be analysed in an Excel worksheet. Raw data from each ELISA reading 
at each time point is pasted into a specific position in the datasheet and results are 
given as positive (1) or negative (0). The negative extraction control included in 
every 96-well plate serves as the background reading for which all the other results 
are compared. A positive result is equivalent to 3 times background.  
 
4.3  Quality Controls and Assurance 
Positive (CaSki) and negative (water) DNA extraction, PCR and ELISA controls are 
included for every 94 samples for the GP5-GP6+ HPV PCR-EIA. Re-analysis of 10% 
of all samples processed will be evaluated for quality assessment purposes.  
 
5.0 Data Management 
A hard and electronic (password protected) copy of raw HPV typing data will be 
maintained and kept in a central location (School of Medicine, Cardiff University 
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Office 6FT 157 main building, Heath Park).  A central (password protected) database 
of results linking unique study number, age, cytology, SDS and HPV typing result will 
be maintained with a weekly back-up system of data on to an external hard drive.  
 
5.1 Statistical Methods 
Statistical analysis will be performed within Cardiff University on samples that comply 
-globin PCR positive; complete information 
available on age, cytology result and SDS; within the target age group 20-22 years; 
and first cervical smear. Social deprivation will be estimated by linking postcodes to 
the Welsh Index of Multiple Deprivation (WIMD) which describes levels of deprivation 
across Wales with higher scores indicating greater deprivation (WIMD, 2005). The 
overall deprivation scores in Wales range from 78.9 to 1.4. Geographical units are 
termed Lower Layer Super Output Areas (LSOA) and they are graded according to 
SDS as follows: 10% most deprived (41.91-78.9 SDS); 10% to 20% most deprived 
(32.71-41.9 SDS); 20% to 30% most deprived (26.31-32.70 SDS); 30% to 50% most 
deprived (17.91-26.30 SDS); 50% least deprived LSOA in Wales (1.4-17.9 SDS). 
The Chi-square test will be used to calculate a P value and 95% Confidence 
Intervals (CI) will be calculated where appropriate. All HR HPV positive cases will be 
differentiated into those with a single HR type and those with multiple HR types. 
 
Sample Size and Power Calculations 
All sample size calculation are based on the following assumptions:  
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Approximately 27,000 20-22 year-old women are eligible and invited for first cervical 
screening in Wales annually.   
Screening uptake is approximately 39% in this age group  
It is therefore estimated that ~15,000 residual LBC samples will be collected from 
this ‘All Wales’ cohort 1st March 2009 –1st Sept 2010 with information on current 
cytology result, age and social deprivation score (Welsh Index of Multiple 
Deprivation).   
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7.0 Project Management 
Principal Investigator: Prof Alison Fiander  
With recognised expertise in HPV infection, the novel management of HPV 
associated neoplasia and clinical practice in the field of Gynaecological Oncology 
and Colposcopy Prof Alison Fiander will provide the central management for this 
project and assist in the interpretation of results as applicable to clinical practice.   
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Cytology Laboratory Coordinator: Jane McRea  
Mrs Jane McRea is the Laboratory Manager for the Cytology Department, CSW at 
Llandough. She will develop the generic standard operating procedure for flagging, 
isolating and anonymising all required specimens and develop local amendments in 
collaboration with laboratory managers at each participating site in Wales or on the 
England/Wales border.  Mrs McRea will be the central manager for the cytology 
laboratories involved in this study and ensure all specimens are identified and then 
transported to the HPV laboratory, School of Medicine, Cardiff University. 
 
Scientific Project Manager: Dr Sam Hibbitts   
Dr Hibbitts is the Scientific Manager for the HPV Laboratory, School of Medicine 
Cardiff University.  She has demonstrated her abilities in handling large scale cross-
sectional HPV genotyping studies (n=10,000) (Hibbitts et al, 2006) and will be 
responsible for coordinating the scientific study protocol and data management.  This 
will include: maintenance; training and adherence to SOPs for sample login; sample 
storage; DNA extraction; PCR; ELISA; and quality control procedures.  
 
Laboratory Technical Staff to be appointed: 1 x FTE and 1 x 21hr  
250 samples are required to be processed in the HPV laboratory per week for a 12-
month period.  Two dedicated laboratory technical assistants will be appointed.  One 
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part-time (21hrs) research assistant will be responsible for sample login, initial 
sample processing and storage.  The full time technician will perform the DNA 
extraction, PCR and HPV typing ELISA. 
 
Management and Coordinator for record linkage: Helen Beer  
Helen Beer is the Information Analyst/ Manager for Screening Services within 
Cervical Screening Wales. She will oversee the management of the pseudo-
anonymisation process required to confirm eligibility of all flagged specimens for 
inclusion into this study and linkage of samples with age, cytology and social 
deprivation score. 
8.0 Ethical Considerations 
Residual LBC samples will be anonymised but linked to age (years and completed 
months), cytology and social deprivation score.  Anonymity will allow complete 
collection of samples in the cohort since individual consent will not be required.  
Patient identifiable information will be removed by the originating laboratory prior to 
their being forwarded to the HPV laboratory in the School of Medicine, Cardiff 
University.  Each sample will be given a unique study number and entered into a 
database with cytology result, age and social deprivation score.  The unique study 
number will enable future linkage with screening records over the next 2 rounds of 
screening (ie minimum 6 years).  The HPV laboratory will not have access to patient 
identifiable information and CSW will not have access to individual HPV results, 
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thereby maintaining anonymity.  Cervical Screening Wales will identify repeat 
samples from the same woman, thus avoiding confounding of HPV prevalence.  
 
Approval will be sought for longitudinal follow up of cytology and histology over the 
next two rounds of cervical screening (minimum of 6 years) in order to correlate HPV 
type-specific prevalence and potential prognostic biomarkers for the development of 
high-grade cytology and/or histology. 
 
8.1 Administrative Procedures 
All potential women eligible for participation in this study will be identified by the 
originating laboratory i.e. ‘first smear test and aged 20-22 yrs’ and residual samples 
will be flagged for collection following routine cytological analysis. The Cervical 
Screening Administration Department (CSAD) computer database will confirm the 
eligibility of each sample (coordinated by the Information Analyst/ Manager). Patient 
identifiable information will be removed (anonymisation) by the originating laboratory 
and a unique study number will be assigned by the HPV Research Laboratory, 
School of Medicine, Cardiff University. 
 
8.2 Monitoring Procedures 
Mrs McRea will be the central coordinator for the cytology laboratories involved in 
this study and ensure specimens identification and transportation to the HPV 
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laboratory, School of Medicine, Cardiff University. Dr Hibbitts will oversee the project 
management of the HPV genotyping and ensure compliance with SOP and quality 
assurance of HPV typing results. 
 
8.3 Recording of Data and Retention of Documents 
A hard and electronic copy of HPV typing raw data will be maintained and kept in a 
central location (School of Medicine, Cardiff University Office 6FT 157 main building, 
Heath Park).  A central database of results linking unique study number, age, 
cytology, SDS and HPV typing result will be maintained with a weekly back-up 
system of data on to an external hard drive. No patient identifiable data will be held 
by the HPV Research Laboratory, School of Medicine, Cardiff University.  
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 Study 2: HI-BCD Study Cohort 10.2
 
Protocol Summary 
Acronym: HI BCD (HPV Integration as a Biomarker for Cervical Disease) 
 
Principle Investigator: Sam Hibbitts, Senior Lecturer in Gynaecological Oncology, 
Cardiff University 
 
Co-Investigators: Amanda Tristram, Senior Lecturer in Gynaecological Oncology, 
Cardiff University; Sue Ashman, Research Nurse Colposcopist, Cardiff University; 
Joanne Jones, Senior Technician in Gynaecological Oncology, Cardiff University; 
Helen Beer, Senior Information Manager and Research Specialist, Cervical 
Screening Wales 
 
Study Advisors: Anne Hauke, Regional Programme Coordinator, Cervical Screening 
Wales; Bryan Rose, All Wales Programme Manager, Cervical Screening Wales; 
Dave Nuttall, Head of Laboratory Services, Cervical Screening Wales 
 
Participating Institutions; Cardiff University; Cardiff and Vale University Health Board; 
Public Health Wales, Screening Division. 
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Aim: To pilot methods investigating Human Papillomavirus molecular biology and 
host cell biology to determine: if HPV viral integration can predict high-grade cervical 
abnormality in women with cytological abnormality the effectiveness of 
transformation zone (TZ) sampling by objectively demonstrating the presence and 
quantity of endocervical cells from the upper margin of the TZ. If there is a 
correlation between the presence and absence of host cell adhesion molecules and 
HPV infection and viral integration in cervical cells  
 
Number of Subjects: 60 
 
Study Design : Pilot, cohort, observational study. 
 
Inclusion Criteria: Women referred to colposcopy following an abnormal cytology 
report 
 
Exclusion Criteria: Women unable to give informed written consent. 
 
Study Interventions: HPV testing, biomarker assays for viral integration on an 
additional smear taken during colposcopy. 
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Primary endpoint: Histologically proven high-grade disease at first colposcopy visit 
where biopsy taken. 
 
Secondary endpoint : Histologically proven high-grade disease during subsequent 
visits (up to 4 years). 
 
Contents 
 
1.0 Lay Summary 
 
2.0 Introduction  
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6.2  Study Advisors 
7.0 Administrative Procedures 
7.1 Changes to the Protocol 
7.2 Recording of Data and Retention of Documents 
7.3 Publication of Results 
8.0 Ethical Considerations and Consent 
9.0 References 
 
1.0 Lay Summary 
This is a study to see if carrying out new tests on cervical screening samples could 
safely reduce the number of women referred to hospital following an abnormal smear 
result.  Taking part in the study will involve having one additional smear taken but will 
not affect patient treatment.  Identifiable personal details will be removed from the 
samples before they are tested. The result of the tests will only be used by the study 
team to evaluate the new tests for viral integration and host biology markers. The 
result will not be included in the women’s hospital or screening records.  The women 
will be invited to take part if they have been referred tothe colposcopy clinic following 
an abnormal smear.  If they consent to being included in the study, a smear will be 
taken and tested for human Papillomavirus (HPV) before colposcopy.  
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HPV is a very common virus that is responsible for cervical cancer. HPV types 16 
and 18 are considered to be high risk and, together with type 45, are the three 
commonest HPV types in cervical cancer, causing about 80% of cervical cancers. 
HPV 16, HPV 18 and HPV 45-positive samples will be tested further to examine how 
far the virus has integrated into the cervix. The results of these tests will be 
compared with available smear and biopsy results from consenting women at 
subsequent visits (up to 4 years). These results will be provided by Cervical 
Screening Wales part of the Screening Division, Public Health Wales. Results will be 
interpreted with the support of a data analyst. 
 
2.0 Introduction  
2.1 Cervical Screening 
UK national cervical screening programmes have been estimated to prevent 80% of 
deaths from cervical cancer(Peto et al., 2004c).  The premise of the screening 
programmes is that women at risk of having cervical intraepithelial neoplasia (CIN) 
can be identified by cytological analysis of a cervical smear.  Women are then 
referred to colposcopy for diagnostic biopsy.  Those identified at colposcopy as 
having high-grade CIN (CIN2+) are then offered treatment in order to prevent future 
development of cervical cancer. 
 
In Wales, women are referred for colposcopy as a result of the following cytological 
abnormalities: 
  
317 
 
 
 Persistent low-grade: either two consecutive samples with mild dyskaryosis or 
three with borderline nuclear change.   
 One test reported as borderline nuclear change in endocervical cells 
 One test reported as moderate dyskaryosis 
 One test reported as severe dyskaryosis 
 One test reported as possible invasion 
 One test reported as glandular neoplasia 
 One test reported as borderline change in endometrial cells 
 One test reported as query high grade 
 One test reported as other glandular cells 
 Three tests reported as abnormal at any grade in a 10 year period 
 
Whilst there is a high incidence of CIN2+ in biopsies taken following a moderate or 
severe cytology result (78% and 92% respectively), only approximately 24% of 
women with persistent low-grade cytology will have biopsy-assessed high-grade 
disease and require treatment(Wales, 2007). Therefore,approximately 50% of all 
women who are referred will have high-grade disease and require treatment.  This 
means that many women are being referred that do not require hospital treatment.  It 
is known that referral for colposcopy itself generates anxiety in women(Jones et al., 
1996).  Reducing the number of women referred would, in a high proportion of 
cases, spare women the unnecessary concern that they might have cervical cancer. 
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Moreover, this would permit valuable resources to be focused specifically only on 
those women that need them.   
 
In this study we aim to investigate viral integration as a potential prognostic marker in 
women referred to colposcopy.  Many women with low-grade cytological 
abnormalities are referred for colposcopy but do not have disease. Nevertheless, 
samples from women with all grades of cytological abnormality will be taken to 
evaluate integration status in relation to grade of abnormality. It may be possible to 
identify whether assays able to detect viral integration in low-grade smears are able 
to predict high-grade disease.   
 
2.2 Human Papillomavirus 
High risk Human Papilloma Virus (HPV) plays a central aetiological role in ano-
genital neoplasia(Walboomers et al., 1999).  Such is the strength of the association 
that there are increasing calls to incorporate oncogenic HPV testing into Cervical 
Screening or even to replace cervical cytology with a test for the virus(Cuzick et al., 
2006, Cuzick et al., 2003). Consequently, many large randomized controlled trials 
are in progress to determine the most efficient and effective algorithm for detection of 
high-grade cervical intraepithelial neoplasia (CIN 2+) in primary screening (Davies et 
al., 2006, Mayrand et al., 2006). There is also evidence that testing for oncogenic 
HPV is a sensitive and cost effective measure in follow up of women treated for CIN 
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(Arbyn et al., 2005) and in triage of women with equivocal cytology (borderline and 
mild dyskaryosis) (Kulasingam et al., 2006, Moss et al., 2006, Solomon et al., 2001). 
 
However HPV infection is common, with an 80% lifetime risk of infection. The 
majority of infections are transient and asymptomatic with less than 5% of individuals 
infected developing CIN. Because of the discrepancy between those infected and 
those developing disease, it is necessary to determine prognostic markers in order to 
identify women at risk of developing disease, thereby allowing valuable resources to 
be focussed on those most at risk.  Regulation of HPV oncogene expression has 
emerged as a critical factor and this is intimately linked to the differentiation state of 
the host cell, and in undifferentiated cells, oncogene expression is repressed by 
modulation of chromatin structure by factors including CDP and YY1 (Stunkel and 
Bernard, 1999). Factors reported to effect expression include integration of the HPV 
genome into host cell DNA (Tan et al., 1994). 
 
2.3 Viral Integration 
Episomal HPV genomes exist during the normal viral life cycle and are maintained in 
basal cells of the squamous epithelium at approximately 50-100 copies per cell 
(Stanley et al., 1989b). Within HPV episomes the expression of viral oncogenes is 
highly regulated. E6 and E7 induce the unscheduled re-entry into the S-phase of the 
cell cycle and activate the host replication machinery in order to allow amplification of 
the viral genomes before virion synthesis(Cheng et al., 1995). Although viral 
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oncogenes E6 and E7 are actively produced within episomes they appear not to be 
functionally carcinogenic. This is because these events take place in cells that are 
ultimately lost from the cervical squamous epithelium as a result of the constant 
renewal process that occurs in this area. For cervical neoplastic progression to occur 
the viral oncogenes need to become expressed and maintained throughout the 
cervical epithelium. 
 
Most cervical carcinomas have deregulated viral oncogene expression and their 
tumour cells contain truncated viral genomes integrated into the host genome. In 
vitro, viral integration increases cell proliferation (Wentzensen et al., 2004, Jeon et 
al., 1995) even though integration is not a normal part of the HPV life cycle and 
causes the deletion of viral genes that are essential for production of infectious 
virions. Numerous studies have characterised viral integrants and although many 
variants have been found, some consistent features have been defined. A 
predominant finding is the loss of the viral E2 gene. E2 recognises and binds to the 
origin of replication of the viral promoter and controls the decreased expression of 
E6 and E7. The loss of E2 is the first stage in transformation with subsequent 
increased expression of the viral oncogenes responsible for disruption in function of 
key cellular proteins (p53 and Rb).  
 
A positive HR HPV result alone has a poor positive predictive value (PPV) due to the 
high number of transient infections. This project aims to establish whether viral 
integration can increase the PPV for detection of high-grade cervical disease in 
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women with cytological abnormalities. This is a pilot, prospective, cohort study and 
testing reflects the setting in which the biomarkers might be used if introduced into 
clinical practice.  
 
 
2.4 Aims and Objectives 
To pilot methods investigating Human Papillomavirus molecular biology and host 
Cell biology to investigate if HPV viral integration can predict high grade cervical 
abnormality in women with cytological abnormalities.  
 
Primary Outcomes: 
Comparison of three viral integration methods for identification and prediction of 
high-grade disease. 
To correlate results from the integration assays with histology obtained from this 
cohort at subsequent visits (up to 4 years) to validate long-term positive predictive 
value (PPV). 
 
2.5 Rationale 
This pilot, cohort, observational study has been designed to examine the the virus 
molecular biology. Benefits for patient management of demonstrating viral integration 
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following a HPV-positive result in a clinical cohort of patients attending colposcopy 
will be investigated. 
 
3.0 Investigational Plan 
3.1 Overall Study Design 
This is a cohort study to investigate viral integration as a biomarker in a group of 
women referred for colposcopy with follow up of their screening results over the next 
round of screening (up to 4 years). The primary outcome will be whether viral 
integration following a HPV positive result can predict histological high-grade disease 
on biopsy. The analysis will not be undertaken until after the woman has attended 
colposcopy and consented and will not alter her management. 
 
3.2 Discussion of Design 
The design of the study has been chosen to reflect as closely as possible the setting 
in which the test might be used if introduced into clinical practice.  As the efficacy 
has not been assessed in this setting before, it was considered appropriate for the 
study to be a pilot and observational, rather than interventional. 
 
3.3 Study Population 
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The study population consists of those women attending colposcopy at a single site 
within Cardiff and Vale University Health Board.  The sample will be a convenience 
sample, taken from women who give written informed consent. 
 
3.4 Inclusion and Exclusion Criteria 
Inclusion Criteria 
 Women referred to colposcopy due to abnormal cytology  
 Women undergoing treatment for high-grade CIN 
Exclusion Criteria 
 Women who are unable to give informed written consent. 
 
3.5 Recruitment 
Women will be invited to take part in the study when they attend for colposcopy. This 
study will include 15 patients with mild dyskaryosis, 15 with moderate dyskaryosis, 
15 with severe dyskaryosis and 15 with cervical cancer. Approximately 20 women 
per month are expected to be eligible for the study within the single site.  
Recruitment is expected to be completed within nine months. 
 
3.6 Interventions 
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This study is designed to evaluate viral integration in a real life setting: for this, one 
additional sample will be taken from the participants.  Up to three additional methods 
for viral integration will be carried out on the sample taken. 
 
3.7 Study Plan 
Women will be informed of their smear test result and colposcopy referral according 
to Cervical Screening Wales (CSW) standard operating procedures (CSAD Quality 
Manual April 2011). 
 
The colposcopy administration at Llandough Hospital will send the study information 
to women referred from CSAD with abnormal cytology along with their colposcopy 
appointment. This ensures women receive the study information in advance, giving 
them time to read and absorb the information. This study is a pilot and will only 
include 15 patients with mild dyskaryosis, 15 with moderate dyskaryosis, 15 with 
severe dyskaryosis and 15 with cervical cancer. 
 
After confirming eligibility criteria, women will be given the opportunity to discuss the 
study and ask any questions when they attend the colposcopy clinic.  Written 
informed consent will be obtained at this time. 
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Women will also be asked to consent to allow the results of cervical cytology and 
histology for one round of screening (up to 4 years from the date of the study 
sample) after entry to be made available for the study.  These data will be retrieved 
by Cervical Screening Wales. 
 
A cervical sample will be taken into sample transport medium optimal for DNA/RNA 
recovery, according to standard operating procedures, from all women who give 
written consent. The samples will be pseudo-anonymised in clinic: all patient 
identifiers will be removed and a unique study code allocated for transportation to the 
HPV Laboratory at Cardiff University.  Once received in the lab the samples will be 
recorded electronically in an EXCEL worksheet linking study ID for linkage through 
the Informatics Team within Screening Division. 
 
Colposcopy will be undertaken according to normal practice as set out in the current 
version of CSW’s Quality Manual Version. When 60 eligible women have consented 
to the study, the HPV Research Team will notify CSAD to close recruitment. HPV 
testing and analysis of viral integration will be performed by the HPV Research 
Laboratories, Department of Obstetrics and Gynaecology at Cardiff University. 
 
3.9 Endpoints 
 Primary endpoint will be high-grade disease on histology at first colposcopy 
visit where biopsy taken. 
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 Secondary endpoints will be detection of viral integration. 
 
Histological analysis will be carried out according to usual practice at each centre. 
Histological analysis is already subject to quality assurance as part of CSW 
standards and will not be repeated.  This will ensure that participation in the trial will 
not change patient management and that it reflects true clinical practice.  High-grade 
disease will be defined as the presence of CIN2+.  The exact grade will be recorded 
and may be used in analysis of false negative samples.  
 
4.0 Sample Management 
4.1 Cytology 
Samples will be taken from women with written informed consent within the Cardiff 
and Vale NHS Trust Colposcopy Clinics following standard operating procedures. 
The samples will be sealed and transported to the HPV Research Laboratories, 
Department of Obstetrics &Gynaecology, Cardiff University. 
 
4.2 HPV Testing 
Samples received by Cardiff University will be logged electronically and processed 
according to the standard operating procedures. 
All specimens will be tested for HPV DNA using 2 methods: 
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The research based PCR-EIA method of Walboomers(Jacobs et al., 1997). Each 
sample will be divided into high-risk (HR) and low-risk (LR) HPV infection using a 
cocktail of type-specific probes and then HR HPV-positive samples will be sub-typed 
using type-specific probes.  
The commercial Greiner Bio-one, PapilloCheck® HPV-Screen DNA-chip: detects 24 
different HPV types (18 HR and 6 LR) in DNA-preparations from human cervical 
smears. The HPV types which can be detected and differentiated by PapilloCheck 
are HPV 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 43, 44/55, 45, 51, 52, 53, 56, 58, 59, 
66, 68, 70, 73 and 81.  
 
4.3 HPV Viral Integration 
HPV 16, HPV 18 and HPV45 positive samples will be assessed using validated viral 
integration assays. There are a number of methods currently employed to detect HR-
HPV integrants in the human genome.  Amplification of Papillomavirus Oncogene 
Transcripts (APOT) detects transcripts of integrated HPV, Restriction Site PCR (RS-
PCR), Southern blot and Detection of Integrated Papillomavirus Sequences (DIPS) 
detect integrated HPV DNA regardless of its transcriptional status. The methods 
used to detect HPV integration are important because a transcriptionally active 
integrant may contribute more to the malignant phenotype.  However, integrants that 
are not transcribed may also contribute to malignant progression by regulating or 
disrupting the expression of genes that contribute to cervical malignant progression. 
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DNA and RNA based methods to detect HR HPV integration have been validated 
through a PhD studentship funded by the Welsh Office of Research and 
Development.  
 
5.0 Data Management 
5.1 Statistical Methods 
This pilot study aims to investigate the potential of viral integration as a biomarker in 
predicting high-grade cervical abnormality in women referred to colposcopy. 
 
5.2 Sample Size  
The project will test 60 samples for HPV status and HPV 16, HPV 18 and HPV 45 
positive cases will be investigated further for viral integration status.  It is expected 
that approximately 60% of women in this group will be HPV positive and 60% of 
these cases will be HPV 16, HPV 18 or HPV 45 positive (n=22)(Jones et al., 2009).  
 
Data Analysis and Dissemination 
Using the unique study code CSW will identify the relevant screening data. The HPV 
Research Laboratories will link all results with a unique study code. The results of 
the histology, HPV testing and viral integration will be correlated for the primary 
outcome.  Subsequent analysis will be performed over the follow-up period as data 
becomes available (up to 4 years). Findings will be disseminated through peer-
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review publication. Favourable primary outcome will provide support for further 
funding proposals on increased sample size with prospective cohort studies and 
randomized control trials that aim to reduce cervical cancer mortality through 
decreased incidence with early detection of CIN2+. 
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6.0 Project Management 
6.1 Investigators 
Principal Investigator: Dr Sam Hibbitts 
Dr Hibbitts is a Senior Lecturer in Gynaecological oncology and the Scientific 
Manager for the HPV Research Laboratory, School of Medicine, Cardiff University. 
She has demonstrated her abilities in handling large scale cross-sectional HPV 
genotyping studies (n=10,000) (Hibbitts et al, 2008) and will be responsible for 
coordinating the scientific study protocol and data management.  Dr Hibbitts is the 
supervisor for a PhD studentship focusing on HPV viral integration. 
 
Dr Amanda Tristram 
Dr Tristram is a Senior Lecturer in Gynaecological Oncology and the clinical lead for 
the HPV Research Laboratory. Dr Tristram has experience in designing trials, 
obtaining regulatory approval and funding, recruiting patients, analysing results as 
well as publishing research and presenting it at International meetings.  
 
Sue Ashman 
Miss Ashman is a qualified nurse colposcopist and has previous experience in phase 
I and II clinical trials. Miss Ashman coordinates studies within the department of 
Obstetrics &Gynaecology and is experienced in study recruitment, organising clinics 
and taking informed consent.  Miss Ashman has also been responsible for the 
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maintenance of study documentation and the preparation of protocols and patient 
specific documentation for clinical trials.  Miss Ashman will be the primary link 
between the colposcopy clinic and the HPV laboratory.  
 
Miss Helen Beer 
Miss Beer is a Senior Information Manager and Research Specialist for Screening 
Division and has expertise in the linkage and statistical analysis of identifiable data 
for all screening programmes in Wales, concentrating on the cervical screening 
programme. Miss Beer has been involved in the evaluation of new technologies into 
the cervical screening programme, such as Liquid Based Cytology and Computer 
Assisted Screening.  
 
6.2 Study Advisors 
Dr Anne Hauke 
Dr Hauke is the Regional Programme Coordinator for South East Wales, Cervical 
Screening Wales. 
Mr Bryan Rose 
Mr Rose is the All Wales Programme Manager for Cervical Screening Wales. 
Mr Dave Nuttall 
MrNuttall is the Head of Laboratory Services for Cervical Screening Wales. 
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7.0 Administrative Procedures 
7.1 Changes to the Protocol 
Any amendments to the protocol will be notified to relevant regulatory bodies. 
  
7.2 Recording of Data and Retention of Documents 
The research team will act to preserve patient confidentiality and will not disclose or 
reproduce any information by which patients could be identified.   
 
7.3 Publication of Results 
The results of the study will be submitted for publication in a peer reviewed journal 
and presented at national and international conferences.  
 
8.0 Ethical Considerations and Consent 
Women participating in this study will provide one extra sample however, the study 
will not influence their clinical management.  They will be asked to permit study 
specific testing on the extra sample and to allow the study team access to results 
relating to their cervical smears and colposcopy for four years.  The women will be 
sent information in advance and will be invited to consent during their visit to the 
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colposcopy clinic, having had an opportunity to discuss the study with an 
appropriately trained health professional. 
 
The purpose of the extra testing is to evaluate a potential screening test.  The results 
of the HPV viral integration tests will not change clinical management for the women 
and we will not inform women of the results of their study tests. 
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11 Appendix 3 
PCR Primers 
 
This appendix includes the details for all the PCR primers used in this thesis.  
 
 Beta-Globin PCR 11.1
 
Table Apx 3.1 Beta-globin PCR primers 
Primer Name F/R Sequence Product Size 
BGPCO3 F ACACAACTGTGTTCACTAGC 110 
BGPC05 R GAAACCCAAGAGTCTTCTCT 110 
 
 
 E2 Tiling PCR 11.2
 
Table Apx 3.2 HPV 16 E2 tiling PCR Primers  
Primer 
name 
F/R Sequence Product size  
PCR1 F  AGGACGTGGTCCAGATTAAG 419 
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R TCAAACTGCACTTCCACTGT 
PCR2 
F  
R 
TAACTGCACCAACAGGATGT 
GCCAAGTGCTGCCTAATAAT 
341 
PCR3 
F  
R 
ATCTGTGTTTAGCAGCAACG 
TAAATGCAGTGAGGATTGGA 
224 
PCR4 
F  
R 
ACAGTGCTCCAATCCTCACT 
TCACGTTGCCATTCACTATC 
244 
PCR5 
F  
R 
GGCATTGGACAGGACATAAT 
CAAAAGCACACAAAGCAAAG 
207 
E6 PCR 
F  
R 
GAACAGCAATACAACAAACC 
GATCTGCAACAAGACATACA 
161 
 
 
Table Apx 3.3 HPV 31 E2 tiling PCR Primers  
Primer Name F/R Sequence Product 
Size 
31E2_F_11 
31E2_R_01 
F 
R 
AGCAGACTGGTGGTTTTTACATTTCCA 
TGGCCTTTGATACTGACAACGCTGG 
352 
  
340 
 
31E2_F_03 
31E2_R_03 
F 
R 
CCAGGTGGTGCCAGCGTTGT 
TGTTTGCTGCATTGTCCAGTCCT 
124 
31E2_F_04 
31E2_R_04 
F 
R 
AGGACTGGACAATGCAGCAAACA 
TGCCCTTCCACAACAGTACATTGGC 
184 
31E2_F_06 
31E2_R_06 
F 
R 
GGCCAATGTACTGTTGTGGAAGGGC 
CGCCGCACACCTTCACTGGT 
287 
31E2_F_08 
31E2_R_08 
F 
R 
AAAACCTGCGCCTTGGGCACC 
GACACTGTCCACGGAGTCGCC 
135 
31E2_F_09 
31E2_R_09 
F 
R 
TGTTGCGAGGCGACTCCGTG 
TCCTGTTGACACTGATACTGTGTTAGGTA 
323 
31E2_F_10 
31E2_R_10 
F 
R 
ACCTAACACAGTATCAGTGTCAACAGGA 
ACCGACACAGACAGCACAAGTGG 
160 
 
 
Table Apx 3.4 HPV 33 E2 tiling PCR Primers  
Primer 
Name 
F/R Sequence Product 
Size 
33E2_F_02 F AGCACGTTTAAATGCAGTGCAGGA  178 
  
341 
 
33E2_R_02 R TGCTAACAAAGAAGGCACCACCTG   
33E2_F_03 
33E2_R_03 
F 
R 
CACCAGGTGGTGCCTTCTTTGTT 
GGTGGTTCACAAAGCCACACCTCT 
 155 
  
33E2_F_04 
33E2_R_04 
F 
R 
AGGTGTGGCTTTGTGAACCACC 
CCTGACCACCCACATGTACTTCCCA 
 276 
  
33E2_F_05 
33E2_R_05 
F 
R 
TGGGAAGTACATGTGGGTGGTCAGG 
GTCCAAGGCGGGGTCTGCAC 
 204 
  
33E2_F_06 
33E2_R_06 
F 
R 
ACCGACCACCACAAGCAGCG 
ACTGGTCCAATGCCAGGTGGATGA 
 281 
  
33E2_F_09 
33E2_R_07 
F 
R 
GTGCAGACCCCGCCTTGGAC 
AGCAGCACATATTGGCTTGTGATGT 
 358 
  
33E2_F_08 
33E2_R_08 
F 
R 
TCCCATTTGATGAAAATGGTAACCCAGTG 
ACCTGGTGGCATAAATGTGAAAATCCCA 
 290 
  
33E2_F_E62 
33E2_R_E62 
F 
R 
TGCACGACTATGTTTCAAGACACTGAGG 
TGCATTCCACGCACTGTAGTTCA 
109 
  
 
 
Table Apx 3.5 HPV 35 E2 tiling PCR Primers  
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Primer Name F/
R 
Sequence Produc
t Size 
HPV35_F_01 
HPV35_R_01 
F 
R 
TCCTTTTTCTCAAGGACGTGGTGCAG 
GGCCTGCGTTGGAACCACTTG 
250 
HPV35_F_02 
HPV35_R_02 
F 
R 
ACCACCAAGTGGTTCCAACGC 
TGCAGTGTCCAGTCCTCTGTGCT 
121 
HPV35_F_03 
HPV35_R_03 
F 
R 
GCCAAAGCAATGCAAGCAATTGAAC 
TGTTTCTACACCCTGATGCACATAATAAATAC
C 
300 
HPV35_F_04 
HPV35_R_04 
F 
R 
ACTGTGGAAGCACAATTTGATGGTGA 
GCTGTGTAGCAATTTCAGCAGTGG 
295 
HPV35_F_05 
HPV35_R_10 
F 
R 
AGTGCATGTGGGTGGTCAGGT 
CGCACTCGCTTGGTGGGGTT 
289 
216 
HPV35_F_11 
HPV35_R_06 
F 
R 
CGAGGGGGTACCGAGCTCCC 
TGAAGCATCTTGATACAATGCTTTATATTTAC
CCA 
225 
 
HPV35_F_07 
HPV35_R_07 
F 
R 
AAAAGGTGATGCAAATACATTAAAGTGTTCAA
GA 
GCTGAGTATAATGACACAGATAGCAATAGCG 
341 
  
343 
 
HPV35_E6_F02 
HPV35_E6_R02 
F 
R 
ACATGTCAAAAACCGCTGTGTCCA 
ACATACACCGACCTGTCCACCGT 
100 
 
 
Table Apx 3.6 HPV 51 E2 tiling PCR Primers  
Primer Name F/R Sequence Produc
t length 
E2_Forward_01 
E2_Reverse_06 
F 
R 
TGGAGACCCTATGCCACCGTT 
TGCTTGGGAGCCACACACCA 
 322 
  
E2_Forward_03 
E2_Reverse_03 
F 
R 
ACCTGCAGCGACGCGTTATCC 
TGCACTTTGGTGCCCTCCAG 
 234 
  
E2_Forward_04 
E2_Reverse_04 
F 
R 
AGCACTAACACTGGAGGGCACC 
TGTTTCCCGTTGATGTGCACTGT 
210 
  
E2_Forward_05 
E2_Reverse_05 
F 
R 
TCCTCAACCTGGCATTGGACCAG 
GCAGCACATATTGGCTTGTGACAGT 
 198 
  
E2_Forward_07 
E2_Reverse_07 
F 
R 
ATGGGGCACAACAGTGGGAGGT 
CCCACGCAGGTGGTAAGGGGA 
 154 
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E2_Forward_08 
E2_Reverse_08 
F 
R 
ATGTTATGAACTATGGTGTGTGGCTCCCAA 
CATACATATAGACCTCCCACTGTTGTGCCC 
 275 
  
E2_Forward_09 
E2_Reverse_09 
F 
R 
TCCATTTGATAACAATGGGAATGCTGTGT 
TCGTAAGTTTCTTTCCCGTGCTGC 
 269 
  
E6_Forward_03 
E6_Reverse_04 
F 
R 
ACGTTATAGCAGGTCTGTGTATGGTACT 
ATTGCCCCGTCCAACGTCCC 
 176 
  
 
 
 E1 tiling PCR 11.3
 
Table Apx 3.7 HPV 16 E1 tiling PCR primers 
Primer Name F/R Sequence Product Size 
HPV16 E1 1F F CTAGGAATTGTGTGCCCATCTG 1096 
HPV16 E1 1R R CTTTCTATCCATTCTGGCGTGTCT 
HPV16 E1 2F F GATAGAGCCTCCAAAATTGCGT 995 
HPV16 E1 2R R ACGTTGGCAAAGAGTCTCCATC 
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 DIPS PCR 11.4
 
 
Table Apx 3.8 HPV 16 DIPS PCR adapter primers  
Name Sequence 
DIPS_AL
1 
GGGCCATCAGTCAGCAGTCGTAGCCCGGATCCAGACTTA
CACGTTG 
DIPS_AS 
Taq 
PO4-cgcaacgtgtaagtctg-NH2 
DIPS_AS 
SauAI 
PO4-gatccaacgtgtaagtctg-NH2 
DIPS_AP
1 
GGCCATCAGTCAGCAGTCGTAG 
 
 
Table Apx 3.9 HPV 16 DIPS PCR Primers  
Name Sequence 
DIPS_PCR1_16F1 ACAAAGCACACACGTAGACATTCG 
DIPS_PCR1_16F2 AGTAATAAATCAACGTGTTGCGATTG 
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DIPS_PCR1_16F3 TTTGGTTACAACCATTAGCAGATGC 
DIPS_PCR1_16F4 GTGCCAACACTGGCTGTATCAAAG 
DIPS_PCR1_16F5 TACCAATTCTACTGTACCTAATGCCAG 
DIPS_PCR1_16F6 ACTTATTGGGGTCAGGTAAATGTATTC 
DIPS_PCR1_16F7 AGTAGATATGGCAGCACATAATGAC 
DIPS_PCR1_16F8 GTTGGCAAGCAGTGCAGGTCAG 
DIPS_PCR2_16F1 CGTACTTTGGAAGACCTGTTAATGG 
DIPS_PCR2_16F2 GGACTTACACCCAGTATAGCTGACAG 
DIPS_PCR2_16F3 AATAGGTATGTTAGATGATGCTACAG 
DIPS_PCR2_16F4 ACAAGCAATTGAACTGCAACTAACG 
DIPS_PCR2_16F5 GAGGTTAATGCTGGCCTATGTAAAG 
DIPS_PCR2_16F6 CCCTGTATTGTAATCCTGATACTTTAGG 
DIPS_PCR2_16F7 TGCGTGTAGTATCAACAACAGTAAC 
DIPS_PCR2_16F8 TTAAACCATAGTTGCTGACATAGAAC 
 
 
 qRT-PCR  11.5
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Table Apx 3.10 HPV 16 HPRT qRT-PCR Primers 
HPRT 
Sense Primer TGACACTGGCAAAACAATGCA 
Antisense Primer GGTCCTTTTCACCAGCAAGCT 
Amplified DNA 4982 bp* (NT 133627546-133632438 of Chr 6) 
Amplified RNA 94 bp (NT** 496-589 of M31642.1) 
Reference Allen et al, 2008 
 
 
Table Apx 3.11 HPV 16 TBP2 qRT-PCR Primers  
TATA binding protein, 2nd pair of primers (TBP2) 
Sense Primer TCAAACCCAGAATTGTTCTCCTTAT 
Antisense Primer CCTGAATCCCTTTAGAATAGGGTAGA 
Amplified DNA 803 bp (NT 170880539-170881341 of chr 6) 
Amplified RNA 122 bp (NT 1128-1224 of M55654.1) 
Reference Minner and Poumay 2008 
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Table Apx 3.12 HPV 16 E6 qRT-PCR Primers  
E6 Primer 
Sense Primer CTGCAATGTTTCAGGACCCA 
Antisense Primer TCATGTATAGTTGTTTGCAGCTCTGT 
Amplified DNA/RNA 80 bp(NT 99-178 of NC001526.1***) 
 
 
Table Apx 3.13 HPV 16 E2 qRT-PCR Primers  
E2 Primer 
Sense Primer AACGAAGTATCCTCTCCTGAAATTATTAG 
Antisense Primer CCAAGGCGACGGCTTTG 
Amplified DNA/RNA 82 bp (nt 3362-3426 of NC001526.1) 
 
 
 Methylation 11.6
 
Table Apx 3.14 HPV 16 methylation PCR primers  
Forward Primer GTGAAATTATTAGGTAGTATTTGG 
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Reverse Primer *BTN-CAACAACTTAATAATATAACAAAAA 
Sequencing Primer GTGAAATTATTAGGTAGTA 
Sequenced CpGs nt 3411 3414 3416 3432 3435 3447 3461 3472 
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12 Appendix 4 
Presentation of Work in Thesis 
 
Work in this thesis has previously been presented at the following events:  
 
NCRI Conference Nov 2012 – Poster Presentation 
UK HPV Conference Nov 2012 – Oral Presentation 
WMA Winter Meeting Nov 2012 – Oral Presentation 
Cardiff University Speaking of Science May 2013 - Oral Presentation 
UK DNA Tumor Virus Meeting Jul 2013 - Oral Presentation 
Cardiff University Medic Post Graduate Research Day Nov 2013 - Oral Presentation 
MITReG Winter Symposium Dec 2013 - Oral Presentation 
 
 
 
 
